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ABSTRACT 
 
ASSOCIATION BETWEEN OBESITY AND THERAPEUTIC GOAL ATTAINMENT 
IN PATIENTS WITH CONCOMITANT HYPERTENSION AND DYSLIPIDEMIA  
 
 
 
 
By 
Ishveen Kaur Chopra 
August 2012 
 
Thesis supervised by Dr. Khalid M. Kamal 
Objective: A retrospective study was conducted to examine variations in therapeutic 
{blood pressure (BP) and lipid} goal attainment and medication utilization pattern in 
patients with concomitant hypertension and dyslipidemia, specifically comparing obese 
versus non-obese patients. 
Methods: GE Centricity EMR database (2004-2011) was utilized.  9,086 patients 
diagnosed with concomitant hypertension and dyslipidemia were evaluated.  According 
to NHLBI guidelines, overweight is defined as a BMI of 25-29.9 kg/m
2
 and obesity as a 
BMI ≥ 30 kg/m2.  Goal attainment and treatment pattern for BP and lipid levels were 
assessed based on JNC 7 and NCEP ATP III guidelines, respectively. 
  v 
Results:  Patients who were obese had higher baseline BP, lipid levels, were more likely 
to be prescribed antihypertensives and antilipemic agents, and were less likely to attain 
BP and dual BP/LDL-C goals. 
Conclusions:  Substantial proportion of patients with concomitant hypertension and 
dyslipidemia failed to attain BP and lipid goals, specifically in patients who were obese. 
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CHAPTER ONE 
INTRODUCTION 
 
Obesity 
Obesity has become a major public health concern in the United States (US), with 
about 97 million adults being either overweight or obese.
1
  It is a complex, multifactorial 
chronic condition that involves the integration of social, cultural, behavioral, 
psychological, metabolic, and genetic factors.
1   
It is an independent risk factor for high 
blood pressure (BP), high blood cholesterol, type 2 diabetes, coronary heart disease 
(CHD), stroke, gallbladder disease, osteoarthritis, sleep apnea and respiratory problems, 
and cancer (e.g., endometrial, breast, prostate, and colon cancers).  It negatively impacts 
overall health-related quality of life (HRQoL) and is associated with an increase in all-
cause mortality.
1, 2
   
 
Definition and measurement 
Obesity generally  refers to excess body fat/adiposity, a characteristic that is 
difficult to measure directly.
1, 3
  Currently, there is no precise clinical definition of 
obesity based on the degree of adiposity; it is defined based on the body mass index 
(BMI), which is calculated as weight in kilograms divided by height in meters squared 
[weight (kg)/height (m
2
)].
1,3
  According to the clinical guidelines developed by the 
National Heart, Lung, and Blood Institute (NHLBI), overweight is defined as BMI 
between 25 to 29.9 kg/m
2
 and obesity as BMI ≥ 30 kg/m2.1  BMI is an appropriate 
measure used for evaluating obesity-related morbidity and mortality.  In addition, BMI 
  2 
measurements are simple, inexpensive, and reliable and provide a standardized definition 
for purposes of national surveillance and international comparisons.
4
 
For clinical purposes, patient assessment should include evaluation of BMI, waist 
circumference, and their overall medical risk.  The measurement of waist circumference 
assesses the risks associated with obesity or overweight.  BMI provides an acceptable 
approximation of total body fat, but is unable to capture the variations in the percentage 
of body mass (degree of adiposity), i.e. it does not distinguish fat mass from lean mass.
5
  
Thus, in some instances, a BMI value might overestimate the body fat in muscular 
patients, such as athletes, and in other instances might underestimate the body fat in 
patients with less muscle mass or edema, such as the elderly.  The NHLBI panel 
recommends using BMI for classification of individuals who are overweight and obese 
and to estimate their relative risk of disease compared to those with normal weight.  
Whereas, waist circumference should be used for adult patients with BMI  between 25 
and 34.9 kg/m
2
 and should be used in conjunction with BMI to identify increased disease 
risks.
1,5
 
 
Epidemiology 
The prevalence of obesity in adults (≥ 20 years) has increased significantly, 
becoming the second leading cause of preventable death in the US.  According to the 
2007-2008 National Health and Nutrition Examination Survey (NHANES), 
approximately 34.2% adults were overweight, 33.8% were obese, and 5.7% were 
extremely obese (BMI ≥ 30 kg/m2).6  Societal, economic, and cultural  factors have a 
major contribution in increasing obesity rates.  For instance,  change in environment and 
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technological advancements have resulted in a sedentary lifestyle and change in food 
habits (increased consumption of processed food)  have resulted in an increased intake of 
calories, sugars, and fats.
6
  Data from the 2007-2008 NHANES suggested an estimated 
age-adjusted obesity prevalence of 34% compared to 23% in NHANES III (1988-1994).  
In 2010, there were 12 states with obesity prevalence of 30% or more compared to no 
state with 30% or more obesity prevalence in 2000.
8
 
There is a significant variation in obesity prevalence in adults based on age, 
gender, and race/ethnicity, according to data from the 2007-2008 NHANES.
7
  The 
likelihood of being obese is the highest in the age group of 40-59 years.  The age-
adjusted obesity prevalence is higher among women (35.5%) than men (32.2%).  
However, the prevalence of combined obesity and overweight is higher among men 
(72.3%) compared to women (64.1%).  There has been no significant change in the 
prevalence of obesity in women over a 10 year period (1999-2009), however, there has 
been an increase in prevalence among men.  Regarding  race/ethnicity, non-Hispanic 
blacks have the highest prevalence of obesity (44.1%)  followed by Mexican-Americans 
(39.3%), all Hispanics (37.9%), and non-Hispanic whites (32.6%).
8
  Moreover, the 
prevalence of obesity varied from 18.6% to 34.4% among states, with higher prevalence 
in the South (29.4%) and in the Midwest (28.7%) compared to the Northeast (24.9%) and 
the West (24.1%), based on the 2009 Behavioral Risk Factor Surveillance System 
(BRFSS) survey.
8
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Socioeconomic burden 
Obesity substantially increases the risk of morbidity from conditions such as 
hypertension, type 2 diabetes, hypercholesterolemia, CHD, stroke, asthma, arthritis, and 
cancer, thereby increasing the direct medical spending on diagnosis and treatment of 
these conditions.  The estimated annual medical costs associated with adult obesity in the 
US is as high as $147 billion, accounting for about 10% of all US healthcare (medical) 
spending.
9
  In 2006, the per capita medical spending for people who were obese was 
$1,429 (42%) greater than that for people with normal weight.  Across all payers, the 
increase in obesity-related costs ranged from 27% (non-patient services) to 80% 
(prescription drugs) from 1998-2006.
9
  The obesity-related annual direct costs for 
children are estimated at $14.3 billion and these costs are expected to increase further 
since these overweight and obese children and adolescents will transition to obese 
adults.
10
 
In addition to the direct medical costs, obesity has an overall impact on the 
indirect costs (productivity loss due to absenteeism, presenteeism, and disability).  
Studies suggest that there is a positive correlation between obesity and measures of 
absenteeism.  For example, Serxner et al. observed that employees considered at-risk for 
obesity were 1.23 times more likely to be in high-absenteeism group compared to 
individuals with normal-weight.
11
  Similarly, workers who were obese tend to have a 
higher total lost productive time (LPT) compared to workers with normal-weight, and 
this was largely due to the presence of co-occurring conditions in workers who were 
obese.  Furthermore, two-thirds of the total cost of LPT was attributable to presenteeism 
and one-third to absenteeism.
10
  Besides absenteeism and presenteeism, obesity also 
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results in increased disability payments and disability insurance premiums, premature 
mortality and/or reduction in quality adjusted life years (QALYs).  Thus, overall indirect 
costs are substantial, accounting for about $66 billion annually.
10
 
 
Hypertension 
Hypertension is usually referred as elevated systolic blood pressure (SBP) or 
diastolic blood pressure (DBP).  According to the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC7) guidelines, hypertension is defined as SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg.12  
It is a major risk factor for cardiovascular disease (CVD) and is usually associated with 
considerable morbidity and mortality.  Hypertension increases the risk of developing 
coronary artery disease (CAD), congestive heart failure, stroke, and kidney disease.
12
  
Although hypertension is common and has substantial risk associated with it, proper 
diagnosis and treatments have shown to reduce the risk. 
 
Epidemiology 
Hypertension is one of the most prevalent conditions in the US with 
approximately 76.4 million individuals aged 20 years and older having high blood BP.
13
  
The prevalence of hypertension has increased from 24% to 32% from 1988-1994 to 
2005-2008.  Hypertension has been indicated as a primary or contributing cause of 
mortality, with high BP associated mortality being 347,689 in 2008.  The overall 
mortality rate associated with hypertension in 2007 was 18.3 per 100,000, an increase of 
9% from 1997.
13
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The variations in hypertension rates have been assessed based on age, sex, and 
race/ethnicity.
8,13
  The prevalence of hypertension is the highest among individuals aged 
≥ 65 years, with 75% of women and 65% of men having high BP (2003 to 2006).  The 
prevalence is higher in men than women until 45 years of age, but increases in women 
above 65 years of age.    It is more common among women taking oral contraceptives, 
especially among obese and older women.  The prevalence is the highest among African-
Americans with an increase from 35.8% (1988-1994) to 41.4% (1999-2002).
8
  Moreover, 
the mortality is also higher among African-Americans, with mortality rate in females and 
males  being 38.6% and 50.3%, respectively. 
 
Socioeconomic burden 
 In 2010, the direct medical costs associated with hypertension were estimated to 
be $69.9 billion.  With increase in the aging population and rising obesity rates, 
hypertension has shown the greatest increase in medical costs and these costs are 
projected to be about $200.3 billion dollars by 2030.
15
  The direct medical costs 
associated with hypertension include hospitalizations for related cardiovascular events, 
renal disease, and ambulatory care visits.  The costs associated with hypertension 
including healthcare services, medication, and indirect costs (e.g., missed days of work) 
account for about $76.6 billion.
14
  The office visits are 40% higher for hypertensive 
patients aged ≥ 60 years compared to individuals aged 45-54 years.  According to the 
2006 American Hospital Association report, hypertension-related productivity loss was 
estimated to be 181 work days lost per 1,000 workers.  Variations were observed based 
on the region and state; Southeast had the highest productivity loss, at 200 missed days 
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per 1,000 employees and California had the highest workplace absenteeism followed by 
Texas, Florida, New York, and Illinois.  In addition, productivity loss due to presenteeism 
has also been reported; the estimated average annual cost of presenteeism per employee 
with hypertension is $247.  Furthermore, presence of CVD and stroke along with 
hypertension doubles the medical cost of hypertension management. 
16
  Hypertension is a 
modifiable risk factor, making it a valuable target for controlling future total costs of 
CVD. 
 
Hypertension management 
In patients with hypertension, the primary goal is to control and treat SBP so as to 
achieve target levels (defined on page 62), with an overall goal of reducing morbidity and 
mortality associated with cardiovascular, cerebrovascular, and renal conditions.  The JNC 
7 guidelines provide recommendations for accurate measurement of BP, classification 
and staging, and treatment strategies.
12
  The treatment strategies comprise of both non-
pharmacological and pharmacological treatments.  Behavioral and lifestyle modifications 
are recommended for patients with prehypertension and hypertension.  Besides lifestyle 
modifications, antihypertensive medications are indicated for patients with stage 1 or 2 
hypertension.  The choice for drug therapy includes single-drug therapy, fixed-dose 
combination therapy, or two drugs in combination and is based on hypertension stage, 
risk factors, target organ damage, and any compelling indications. 
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Dyslipidemia 
Dyslipidemia generally refers to the number of lipid disorders. 80% of the lipid 
disorders have been linked to diet and lifestyle.
17
  Dyslipidemia consists of different 
categories including elevated low-density lipoprotein cholesterol (LDL-C), low high-
density lipoprotein cholesterol (HDL-C), excess lipoprotein, hypertriglyceridemia, 
atherogenic dyslipidemia, and mixed lipid disorders.  Dyslipidemia is also a risk factor 
for CHD, a major cause of death in the US.
17 
 
 
Epidemiology 
An estimated 90 million adults in the US have one or more type of lipid disorder, 
out of which 71 million have high LDL-C.
8, 14
  According to data from the (combined) 
2005-2006 and 2007-2008 NHANES, approximately 33.5 million adults (≥ 20 years) 
have total serum cholesterol levels ≥ 240 mg/dL, with a prevalence of 16.2%.  The 
prevalence of high LDL-C was 33.5% in 2005-2008.
14
  
The 2007-2008 NHANES shows that the prevalence of lipid levels varies with 
age, sex, and race/ethnicity.
14
  The prevalence of total serum cholesterol is higher among 
women compared to that of men, whereas the prevalence of  elevated LDL-C and low 
HDL-C is higher among women compared to that of men.  In males, the prevalence of 
total cholesterol is the highest among Mexican-Americans (50.1%) followed by non-
Hispanic whites (41.2%) and blacks (37.0%).   Similarly, in females, the prevalence of 
total cholesterol is the highest among Mexican-Americans (46.5%) followed by non-
Hispanic whites (47.0%) and blacks (41.2%).  The prevalence of elevated LDL-C is the 
highest among Mexican-American men (41.9%) and the lowest among non-Hispanic 
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black women (27.7%).  Similarly, the prevalence for low HDL-C levels is the highest 
among Mexican-American men (31.7%) and the lowest among non-Hispanic black 
women (6.6%).  The prevalence of high LDL-C increases with age, being the highest for 
individuals ≥ 65 years (58.2%), followed by 41.2% for the age group of 40-64 years and 
the lowest in the age group 20-39 years (11.7%).  Although high LDL-C levels can be 
managed and controlled successfully, yet one-third of the population have uncontrolled 
LDL-C levels. 
 
Socioeconomic burden 
Most of the total costs, including direct and indirect costs, associated with CVD 
and stroke are related to dyslipidemia and were estimated to be more than $400 billion in 
2006.  The direct costs attributed to dyslipidemia account for about two-thirds of the total 
costs.
17
 
  
Dyslipidemia management 
The Third Report of the National Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III, or ATP III) focuses on Framingham risk assessment and 
treatment strategy for reduction of lipid levels.
18
  Controlling elevated LDL-C levels has 
been recommended as the primary target for therapy and the treatment focuses on both 
lifestyle modifications and use of lipid-lowering medications.  The guidelines 
recommend that the intensity of risk-reduction therapy should be adjusted according to a 
person‘s absolute risk.  The risk assessment requires measurement of LDL-C as a part of 
  10 
lipoprotein analysis and assessing the risk determinants, including presence or absence of 
CHD, other clinical forms of atherosclerotic disease, and other major risk factors 
(cigarette smoking, hypertension, low HDL cholesterol, family history of premature 
CHD, and age-men ≥ 45 years; women ≥ 55 years). 
 
Concomitant hypertension and dyslipidemia 
Hypertension and dyslipidemia are the most prevalent and modifiable risk factors 
for CVD, and they often co-exist.
19  
According to NHANES III (1988-1994), 30 million 
US adults have concomitant hypertension and dyslipidemia, with an estimated prevalence 
of about 15%.  Among patients with hypertension, 64% also have dyslipidemia, and 
among patients with dyslipidemia, hypertension is present in 47% of the patients.
20
 
Studies have shown that patients with presence of concomitant hypertension and 
dyslipidemia have a greater than additive risk of CVD compared to either condition 
alone.
21
  Moreover, simultaneous presence of these conditions accelerates the course of 
atherosclerosis and the progression to cardiovascular morbidity and mortality.  Both of 
these conditions cause endothelial dysfunction, which impairs endothelium-dependent 
arterial relaxation, promoting plaque formation, and development of clinical 
atherosclerotic disease that ultimately results in clinical sequelae of CVD such as 
myocardial infarction or stroke (Figure 1).
19, 22
 
 
 
 
 
 
 
 
  
1
1
 
 
Figure 1: Interaction of hypertension and dyslipidemia in endothelial dysfunction in cardiovascular disease. 
  
COX: cyclooxygenase; NO: nitric oxide 
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According to the NCEP ATP III guidelines, concomitant hypertension and 
dyslipidemia requires aggressive treatment, especially in persons with known CHD.  The 
treatment involves lifestyle modifications and the use of both antihypertensive and lipid-
lowering medications.  The clinical choice of specific antihypertensive medication is 
based on the JNC 7 guidelines and requires consideration of benefits and effects of the 
therapy on quality of life (QoL), concomitant diseases, and costs.  Selection of lipid-
lowering drugs is based on recommendations of the NCEP ATP III guidelines.
18
 
 
Concomitant obesity, hypertension, and dyslipidemia 
Patients with high BMI are at an increased risk for hypertension and dyslipidemia, 
and conversely, a majority of patients with these metabolic conditions are either 
overweight or obese.
23, 24
  Based on the 1999-2002 NHANES, an increase in prevalence 
of hypertension and dyslipidemia is associated with an increase in BMI.  The prevalence 
of hypertension was the highest among morbidly obese individuals (51%).  However, in 
the case of dyslipidemia, there was increase in prevalence as BMI increased up to 30 
kg/m
2
; there was no increase in prevalence for any further increase in BMI.
23
 
In addition, the distribution of BMI levels among individuals with hypertension or 
dyslipidemia was analyzed using the 1999-2002 NHANES.  The prevalence of obesity 
was higher among patients with hypertension; approximately 85% of patients were either 
overweight or obese, and among these, 55% of patients were only obese.  Similar trends 
were observed with dyslipidemia, in which high prevalence of obesity was observed in 
patients with one or more lipid disorders.  Among patients with dyslipidemia, 84% of 
patients were either overweight or obese out of which 52% of the patients were obese.
23
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Besides increased risk of morbidity in obese patients with hypertension and 
dyslipidemia, obesity substantially increases the deleterious effect of dyslipidemia and 
hypertension on medical expenditures and lost productivity.  Sullivan et al.
25 
showed that 
medical expenditures for hypertension or dyslipidemia were approximately 1.5 times 
higher for patients who were obese compared to that of normal-weight individuals.  
Regarding productivity loss, the number of missed work days was 3 times higher in 
individuals who were obese compared to that of normal-weight individuals with 
hypertension.  Similarly, the number of missed work days was 1.5 times higher in 
individuals who were obese compared to that of normal-weight individuals with 
dyslipidemia. 
 
 
PROBLEM STATEMENT 
Obesity is associated with increased morbidity and mortality and has become a 
major public health concern, especially since 33.7% of the US adults are reported to be 
obese (BMI ≥ 30 kg/m2).7  Most of the obesity-related morbidity  is linked to 
cardiovascular risk factors such as hypertension; the addition of dyslipidemia further adds 
to the incidence of CVD.
19
  Cardiovascular diseases are the leading cause of morbidity 
and mortality in the US; an estimated 82.6 million US adults have one or more type of 
CVD and 16.3 million adults have CHD, the most common heart disease in the US.
13
  As 
discussed earlier, the prevalence of hypertension and dyslipidemia substantially increases 
with an increase in BMI, suggesting an increased incidence of concomitant hypertension 
and dyslipidemia, and thus an increased burden on the healthcare system.
24
  Obesity 
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accounts for about 36% increase in costs for both inpatient and ambulatory care as well 
as increased utilization of physician and hospital services, specifically for patients with 
diabetes, hypertension, dyslipidemia or CVD.  In addition, patients who are obese utilize 
more medications than individuals with normal-weight, and account for about 77% more 
in annual medication costs.
9
  Another study evaluating the costs of treating major obesity-
related disorders demonstrated that about 65%-70% of the cost is attributed to obesity-
related cardiovascular risk factors or CVD.
9, 10
  Additionally, in middle-aged men, 
treatment of the five major obesity-related conditions (stroke, CHD, diabetes, 
hypertension, and high cholesterol levels)  accounts for about $9,000 to $17,000  more 
compared to that of adults with normal-weight.
10
  Thus, the concomitant presence of 
obesity, high BP, and dyslipidemia adds to the complexity, morbidity, and cost of long-
term management of CVD.
19
 
In order to reduce the cardiovascular risk, current guidelines for the treatment of 
obesity emphasize lifestyle modifications and control of associated risk factors such as 
hypertension and dyslipidemia, to decrease the obesity-related morbidity and mortality.
26  
Guidelines for the treatment of hypertension and dyslipidemia have been established in 
terms of risk assessment, recommended treatment patterns, and therapeutic goal 
attainment.  The JNC7
12 
and the NCEP ATP III
18
 guidelines have established optimum 
BP and lipid targets, respectively, for reducing cardiovascular risk.  Presence of both 
hypertension and dyslipidemia has additive risk of developing CVD, and thus, even 
relatively small reductions in both BP and LDL-C levels can result in large reductions in 
the risk for cardiovascular events.
18, 20
  However, most of the patients fail to attain their 
therapeutic goal; more than 50% of patients with hypertension  have failed to achieve 
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their BP goal 
27-29 
and about 50% of the patients with dyslipidemia have failed to attain 
lipid goals
30-32
.  The attainment of therapeutic goals has only been evaluated in patients 
with hypertension, dyslipidemia, diabetes, or CVD.  Knowing that obesity results in 
cluster of medical conditions (high BP, high blood cholesterol, high triglycerides, and 
insulin resistance), attainment of recommended BP and lipid levels has not been 
examined in this population. 
Current guidelines also emphasize the concomitant management of multiple risk 
factors such as hypertension and dyslipidemia.  One study has examined BP and lipid 
goal attainment in patients with concomitant hypertension and dyslipidemia.
 34
  However, 
studies have not evaluated attainment of guideline recommended BP and lipid targets and 
medication utilization patterns in obese versus non-obese patients with concomitant 
hypertension and dyslipidemia.  The CHD risk associated with overweight and obesity 
appears to be mediated through the major risk factors, such as hypertension and 
dyslipidemia, suggesting importance of controlling BP and lipid levels in these 
individuals.  Studies have also suggested that more aggressive treatment including 
medications and interventions is required for obese patients compared to non-obese 
patients 
75, 76
.  Thus, this study is designed to evaluate prevalence, medication utilization 
pattern, and therapeutic goal attainment in patients with concomitant hypertension and 
dyslipidemia stratified by BMI. 
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CONCEPTUAL FRAMEWORK 
The objective of this study is to evaluate variations in therapeutic goal attainment 
and medication utilization pattern in obese versus non-obese patients and having 
concomitant hypertension and dyslipidemia, using retrospective data obtained from GE 
centricity primary care electronic medical records (EMR) database.  The database 
contains data from 2004-2011 with 155,483 active patients receiving care from 42 
primary care providers in Southwestern Pennsylvania.  The EMR database includes data 
from patient records including demographics and clinical diagnoses, prescribed 
medications, procedures, and laboratory test results.  The study will evaluate the 
characteristics of obese patients not attaining required BP and lipid levels.  The pattern of 
anti-hypertensive and lipid-lowering medication utilization will be identified in this 
population. 
 
 
OVERALL HYPOTHESIS 
The overall hypothesis of the study is that there is no variation in the attainment 
of blood pressure and lipid goals and medication utilization pattern in obese versus non-
obese patients having concomitant hypertension and dyslipidemia. 
 
 
STUDY OBJECTIVES 
The specific objectives of the study are: 
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1. To examine distribution of patient-related factors, and clinical factors in patients 
with concomitant hypertension and dyslipidemia stratified by BMI. 
2. To examine variation in blood pressure and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia stratified by BMI. 
3. To examine variations in antihypertensive and antilipemic medication utilization 
pattern based on JNC7 and NCEP ATP III guidelines, respectively in patients 
with concomitant hypertension and dyslipidemia stratified by BMI. 
4. To examine predictors of BP or/and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia. 
 
 
SIGNIFICANCE OF THE STUDY 
As discussed earlier, obesity is an independent risk factor for both hypertension 
and dyslipidemia and its concomitant presence might negatively impact the appropriate 
control of cardiovascular risk factors.  The guidelines for management of hypertension 
and dyslipidemia are well established, but more than 50% of patients are not attaining 
recommended BP and lipid goals.  This study will help in understanding variations in 
medication utilization pattern and therapeutic (BP and lipid) goal attainment in obese 
patients with concomitant hypertension and dyslipidemia in a real-world medical 
practice.   
This study utilizes EMR database that contains clinical information useful for 
assessing the effect of obesity on achieving BP and lipid goals as well as evaluating 
cardiovascular risk profile of the patient population.  These study results can be useful in 
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the following aspects.  First, this information will help healthcare providers in making 
clinical decisions on intensity of preventive interventions (whether dietary advice should 
be strict and specific, when to provide suggestions for physical activity and when it 
should be intensified or individualized, and when and which medications should be 
prescribed) based on overall predicted risk.  Second, for treatment to be effective patients 
should be aware of their risk status, and need and benefits of a multifactorial 
(combination of medications and lifestyle modification) approach to treatment.  This can 
be achieved by healthcare professionals (physicians and pharmacists) by implementing 
interventions such as motivational interviewing, behavior modification techniques, or 
using a patient-centered approach. A patient-centered approach entails individualized 
planning and delivery of services, consideration of patient values and culture, a medical 
home, and an interdisciplinary team care.   Third, the patients with high cardiovascular 
risk identified in the study can be monitored by the physicians using this EMR database 
for improving health status of these patients. 
The study results can also have long-term implications.  Identifying patients with 
multiple cardiovascular risk factors and proper management of risk factors in this 
population can reduce long-term obesity-related morbidity in these patients, thereby 
alleviating the associated healthcare burden (hospitalizations, medication costs, outpatient 
care, and physician visits).  In addition, assessing cardiovascular risk and appropriate 
control of modifiable cardiovascular risk factors in obese patients is also important from 
employer and payer perspective.  Obesity-related conditions have been implicated to have 
higher employer costs resulting from lost productivity and the increased cost of health 
and disability insurance.  Spending on obesity-related conditions accounted for about 
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8.5% of Medicare spending, 11.8% of Medicaid spending, and 12.9% of private-payer 
spending (results from 2006 MEPS data).
9
  Timely and appropriate management of these 
risk factors can reduce these costs. 
Current guidelines also recommend aggressive treatment strategies for individuals 
having multiple risk factors.  Assessing medication prescribing pattern will provide 
insight into the following aspects: whether patients at high risk are prescribed 
medications, variations in number of medications prescribed to obese versus non-obese 
patients, type of medication prescribed, and effect of medications on attaining therapeutic 
goals attainment.  This information helps in identifying two specific groups of patients: 
those who are not prescribed adequate medications and those who are prescribed 
adequate medications but are not attaining goals.  Healthcare professionals can use this 
information in designing appropriate interventions with primary focus on improving 
medication adherence in patients with multiple risk factors. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
Obesity is highly prevalent in US population and is an independent risk factor for 
high BP, high blood cholesterol, type 2 diabetes, and CHD.
1, 2
  Presence of multiple risk 
factors (hypertension, dyslipidemia, and diabetes) in obese patients negatively affects 
therapeutic (BP and lipid goal attainment) thereby increasing cardiovascular risk. 
 
Objectives 
The objective of the review was to identify studies assessing variations in BP or 
lipid goal attainment in obese population, specifically in the US population.  In addition, 
studies assessing BP and lipid goal attainment in patients with other cardiovascular risk 
factors (hypertension, dyslipidemia, and diabetes) or CVD were also evaluated. 
 
Methods 
Search strategy 
Following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines
35
, a systematic literature search was conducted among 
peer-reviewed journals from January 2000 to March 2012 across four electronic 
databases including Pubmed, PsychInfo, Embase, and Cinahl (Figure 2). 
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Figure 2: Schematic presentation of methodology used and selection criteria
a
. 
 
 
 
aSearch and selection criteria conducted in accordance with PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) statement criteria35 
 
 
676 articles identified 
through database search 
(Pubmed, PsychInfo, 
Embase, Cinahl) 
Articles excluded 
175 duplicate articles 
501 articles were screened 
 
Articles excluded 
 6 studies were clinical trials 
 34 non-English studies 
 86 studies were on patients < 18 years of age 
 301 studies were not relevant to topic  
74 full text articles were 
reviewed 
 
Articles excluded 
 2 studies focused on general population 
 32 studies did not focus on variations in BP 
or lipid goal attainment 
 4 studies not conducted in US population 
 13 studies were not relevant to BP or lipid 
goal attainment 
23 studies included for evaluation 
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The search strategy included the following keywords or their combinations: hypertension, 
dyslipidemia, hyperlipidemia, hypercholesterolemia, diabetes, obesity, metabolic 
syndrome, coronary heart disease, cardiovascular, cardiovascular risk factors, 
cardiovascular conditions, blood pressure, low density lipoprotein, lipid, cholesterol, 
goal attainment, and goal achievement.  The search was conducted to identify studies 
evaluating variations in the attainment of therapeutic goals in population having 
cardiovascular risk factor(s) or CVD(s).  For the purpose of the review, the term 
therapeutic goal was referred to BP and lipid (LDL-C, HDL-C, triglyceride, and 
cholesterol) goals.  The major cardiovascular risk factors were referred to health 
conditions that increase the risk of CVD.  These include hypertension, dyslipidemia, 
diabetes, metabolic syndrome, and obesity.  The CVDs were defined as the group of 
diseases that involve heart or blood vessels, which usually refer to cardiovascular system 
or atherosclerosis. 
 
Inclusion and exclusion criteria 
The studies were included in the review if they evaluated variations (e.g., patient-, 
provider-, clinical-, or treatment-related) in attaining BP or lipid goals.  The search was 
limited to studies in English language and those conducted in the US population.  The 
inclusion of articles was limited to population with cardiovascular risk factors or any 
cardiovascular condition; studies on population with health conditions not related to 
cardiovascular system were excluded.  In addition, included studies focused on patient 
population receiving pharmacological treatment; studies focusing on any non-
pharmacological interventions or with no indication of pharmacological treatment were 
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excluded.  Studies evaluating the effect of specific pharmacological drug on BP or lipid 
goals were also excluded.  Randomized clinical studies focusing on treatment for 
elevated BP or lipid levels and review studies evaluating BP or lipid goal attainments 
were excluded.  Also excluded from the review were conference abstracts, dissertations, 
commentaries, editorials, or summary reports. 
 
Data extraction 
For the studies evaluating therapeutic goal attainment, the following information 
was collected: sample size, socio-demographic variables (age, race/ethnicity, and 
employment status), type of cardiovascular risk factor or CVD, therapeutic goal (BP, 
lipid level) evaluated, guidelines used for assessing therapeutic goals, setting/data source, 
different characteristics (e.g., patient-, provider-, clinical-, and treatment-related) 
resulting in variations, and disparities observed in  therapeutic goal attainment.  In 
addition, information on medication utilization pattern including type of medication class 
and number of medications, if any, as assessed by these studies was also collected. 
 
Results 
Therapeutic goal attainment in patients with cardiovascular risk factors or CVD 
Based on the literature search methodology, 23 studies were identified that 
assessed variations in attainment of BP or lipid goals in patients with cardiovascular risk-
factors or cardiovascular conditions.  Tables 1-3 provide summary of the studies 
including information regarding sample size, setting/data source, cardiovascular risk 
factor or CVD present, factors evaluated, guidelines used, variations observed, and 
medication utilization pattern. 
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Studies primarily focused on patient population with either cardiovascular risk 
factors such as hypertension, dyslipidemia, and diabetes or cardiovascular conditions 
such as CAD (Figure 3).  Current guidelines including JNC 7 for BP goal attainment and 
NCEP ATP III guidelines for lipid goal attainment were utilized by most of the studies.  
Moreover, the studies utilized different patient setting or data sources.  Most of the 
studies obtained data from the claims database, patient chart reviews, or electronic 
medical records (EMR).  Five studies utilized data collected from surveys such as 
NHANES, NCEP Evaluation Project Utilizing Novel E-technology (NEPTUNE II), and 
survey conducted on patients in West Virginia Breast and Cervical Cancer Screening 
Program.  However, the clinical data for survey studies was obtained from screening and 
laboratory results. 
Variations in BP goal and lipid goal attainment were observed in patient-, 
clinical-, provider- and medication-related factors (Figure 4).  For the purpose of review, 
the results from the 23 studies are summarized into three categories.  These include 
studies focusing on BP goal attainment, lipid goal attainment, and both BP and lipid goal 
attainment. 
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Figure 3: Evaluating studies based on population type assessed by the included 
studies. 
 
CAD: Coronary artery disease; CHD: Coronary heart disease; CKD: Chronic kidney disease; CV: 
Cardiovascular 
 
Figure 4: Evaluating studies based on factors assessed by the included studies. 
 
Patient-related factors (age, gender, race), clinical factors (co-morbidities, lipid levels, hypertension stage, 
BMI), provider-related factors (provider type), and medication-related factors (medication type, number of 
prescribed medications). 
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Attainment of BP goals 
Nine studies evaluated variations in BP goal attainment in patients with 
hypertension, diabetes, or stroke
36-44 
(Table 1).  BP goal was evaluated based on the JNC 
7 guidelines.  However, Choe et al. (2007)
39
 evaluated studies based on BP goals 
recommended by JNC 7 and randomized clinical trial studies.  Lower rates of BP control 
were observed among older patients (≥ 65 years of age), women, and African-American 
patients.  However, Choe et al. (2007)
39
 showed that BP goal attainment was higher 
among older patients with diabetes and Shelley et al. (2011)
43
 showed that BP control 
rates were higher among women compared to men. 
Regarding clinical factors, presence of complicated hypertension, isolated systolic 
hypertension, stage 2 hypertension, and BMI ≥ 30 resulted in lower rates of BP goal 
attainment.  In addition, patients with co-morbidities including heart failure, chronic 
kidney disease, stroke, and ischemic heart disease were less likely to achieve BP targets.  
Similarly, presence of diabetes as co-morbidity in hypertensive patients was also 
associated with less likelihood of attaining BP.  Presence of co-morbidities was not 
associated with BP goal attainment in stroke survivors.  Choe et al. (2007)
39
 also 
observed the effect of elevated LDL-C on BP goal attainment in patients with diabetes; 
attainment of LDL-C goals was important for controlling BP. 
BP goal attainment varied with type and number of medications; patients on 
angiotensin-converting enzyme inhibitors (ACEI) compared to other antihypertensive 
medications (angiotensin receptor blockers (ARBs), thiazide diuretics) were more likely 
to attain recommended BP goals.  Andros et al. showed that patients with diabetes 
receiving no antihypertensive medication were more likely to attain BP goals.  However, 
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Choe et al. (2007)
39
 showed that patients on antihypertensive therapy were more likely to 
attain BP goals.  Use of more than one antihypertensive drug reduced the likelihood of 
BP goal attainment.  Duggirala et al. (2005)
40
 showed that ≥ 1 annual visit to 
subspecialist physician was important for attaining BP goal in patients with diabetes. 
 
  
2
8
 
Table 1: Studies evaluating variations in attainment of blood pressure goals 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Andros et 
al. 
(2006)36 
Patients 
aged ≥ 18 
years. Type 
1 DM (N = 
1,011); 
Type 2 DM 
(N = 3,644) 
Retrospective review of 
pharmacy claims and 
medical records; 
conducted in October 
2003. Patients enrolled 
in 30 health plans, were 
part of a MCO located 
in sites in the Southeast, 
southwest, mid-
Atlantic, Midwest, 
Northeast, North 
central, Western US 
Diabetes  Type of anti-
hypertensive 
medication 
class 
 
JNC 7 Overall 26.3% of patients 
receiving antihypertensive 
therapy were at BP goal. 
BP goal attainment was 
higher among patients 
receiving no therapy 
(43.4%), followed by 
patients receiving ACEI 
(30.7%) compared to other 
drug classes (e.g., ARB, 
ACEI+ARB, diuretics) 
Majority of patients 
were on ACEI, 
especially lisinopril. 
ACEIs, ACEI/diuretic, 
diuretic were top 3 
drug regimens for 
diabetes and 
uncontrolled 
hypertension. 
Biskupiak 
et al. 
(2010) 37 
Patient‘s 
age: 18-64 
years (N = 
61,355) 
and ≥ 65 
years (N = 
47,796) 
Retrospective cohort 
study using GE 
centricity EMR 
database (comprised of 
more than 70 
consortium membera 
institutions located in 
more than 40 US 
states); study period 
ranged from January 1, 
2004 –December 31, 
2007 
Hypertension 
 
Socio-
demographic, 
clinical (BMI, 
hypertension 
stage, co-
morbidities) 
JNC 7 Age ≥ 65 years, African-
American race, BMI ≥ 30, 
presence of complicated 
hypertension contributed to 
a lower likelihood of BP 
goal achievement. 
ACEI: most 
commonly prescribed 
medication class in 
both elderly and non-
elderly patients 
followed by diuretics 
and ARBs. 
ACEI/diuretic was 
most commonly seen 
combination followed 
by ARB/diuretic. 
Elderly patients were 
more likely to have 
more than 1 
medication. 
Bisognano 
et al. 
(2007) 38 
Patients 
aged ≥ 60 
years; N = 
388 
Retrospective review of 
medical charts for 
patients treated at 
geriatric clinic; period 
January 1,1998-
December 31, 1998. 
Hypertension Age, gender, 
co-morbidities, 
number of 
visits, 
medication 
type 
JNC 7 BP goal was not achieved 
among patients with 
isolated systolic 
hypertension, diabetes, and 
heart failure and treatment 
with thiazide diuretics. 
Not reported 
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Table 1 (continued) 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Choe et al. 
(2007) 39 
Patients 
aged ≥ 18 
years; N = 
362 
Retrospective, cross-
sectional study; data 
collected from patient‘s 
chart and EMR, for 
years 2002, 2003 and 
2004.  
Diabetes Demographic, 
clinical, 
medication 
type, number 
of medications 
JNC 7 and 
RCTs 
Overall 65% of patients 
attained BP goals. Patients 
who attained BP goals 
were more likely to be 
older, having achieved 
LDL-C goal, did not have 
higher BMI, were at least 
on 1 antihypertensive. 
ACEI was the most 
commonly used 
antihypertensive 
agent. Among the 
patients treated, 35% 
were on monotherapy 
and 65% were on 
combination therapy. 
Duggirala 
et al. 
(2005) 40 
Patients 
aged ≥ 18 
years; N = 
1,231 
Retrospective study 
utilizing data from 
patients‘ medical 
records outpatient 
medical care delivered 
in the Division of 
Primary Care Internal 
Medicine or in the 
Department of Family 
Practice at the Mayo 
Clinic (Rochester, MN) 
from January 1, 2000-
December 31, 2002. 
Diabetes and 
hypertension 
Demographic, 
clinical, patient 
lifestyle, type 
of medications, 
physician-
related. 
 
JNC 7 Lower rates of BP control 
observed in older patients, 
with isolated systolic 
hypertension, uncontrolled 
BP at inception, using oral 
hypoglycemic drugs, using 
3 or more antihypertensive 
drugs. Use of nitrates, 
history of CHD, at least 1 
annual visit to subspecialist 
increased likelihood of BP 
goal attainment. 
Not reported 
Gu et al. 
(2008) 41 
Patients 
aged ≥ 18 
years. 
N = 5,410 
NHANES (1999-2004), 
a cross-sectional survey 
comprising of 
nationally 
representative sample 
of civilian non-
institutionalized US 
population. 
Hypertension Socio-
demographic,  
co-morbidities, 
type of anti-
hypertensive 
drug class 
JNC 7 BP control rates were 
lower in women, older age 
groups, non-Hispanic 
whites, and those with co-
morbidities such as kidney 
disease, stroke, or ischemic 
heart disease. Among β-
blockers and diuretics, 
control rate was higher 
among men. 
Use of diuretics and 
ARBs was higher 
among women. Men 
were more likely to 
use ACEI. About 30% 
of patients used 2 
antihypertensives. Use 
of 3 or more 
antihypertensives was 
lower among elderly 
people. 
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Table 1 (continued) 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Kesarwani 
et al. 
(2009) 42 
Patients 
aged ≥ 20 
years; 
N = 438 
NHANES (1999-2004), 
a cross-sectional survey 
comprising of 
nationally 
representative sample 
of civilian non-
institutionalized US 
population. 
Stoke 
survivors 
Age, gender, 
co-morbidities 
JNC 7 Overall, 46.5% of patients 
achieved BP goal. Men 
were more likely to attain 
BP goals compared to 
women. No differences 
were seen regarding 
presence of co-morbidities. 
Not reported 
Shelley et 
al. (2011) 
43 
Patients 
aged ≥ 18 
years; N = 
2,712 
EMR for all adult, non-
obstetric patients seen 
in any four FQHCs 
affiliated with Open 
door Medical Centers 
located in New York; 
from June 2007-
October 2008 
Hypertension Socio-
demographic, 
medications 
(number), 
presence of 
diabetes, BMI 
JNC 7 BP control rates were 
lower among men, in 
blacks compared to whites 
and Hispanics, patients 
prescribed more than one 
medication, having 
diabetes, having higher 
BMI. 
Not reported 
Weycker 
et al. 
(2008) 44 
Patients 
aged ≥ 18 
years; N = 
10,345 
GEMS EMR database; 
initiated 
antihypertensive 
therapy between July 1, 
2003- December 31, 
2004 
Hypertension Co-
morbidities, 
hypertension 
stage 
JNC 7 BP control rates were 
lower among patients with 
stage 2 hypertension, 
patients with diabetes or 
chronic kidney disease, or 
with other cardiovascular 
risk-factors 
Not reported 
aConsortium members: variety of practice types, ranging from solo practitioners to community clinics, academic medical centers, and large integrated delivery 
networks 
 
ACEI: Angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; BMI: Body mass Index; BP: Blood pressure; CHD: Coronary heart 
disease; CVD: Cardiovascular disease; DM: Diabetes mellitus; EMR: Electronic medical records; FQHCs: Federally qualified community health centers; GEMS: 
General Electric Medical System; JNC 7:  Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure; LDL-C: Low-density lipoprotein cholesterol; MCO: Managed Care Organization; NHANES: National Health and Nutrition Examination Survey; RCT: 
Randomized clinical trial; US: United States 
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Attainment of lipid goals 
Nine studies evaluated lipid goal attainment in patients with dyslipidemia, 
diabetes, CAD, CHD, chronic kidney disease, or at high-risk of CVD
45-53
 (Table 2).  
Lipid goal was evaluated based on NCEP ATP III guidelines.  However, Mosca et al. 
(2005)
49
 used American Heart Association (AHA)-evidence based guidelines, Putzer et 
al. (2004)
51
 used American Diabetes Association (ADA) guidelines, and Stadler et al. 
(2010)
52
 used National Kidney Foundation/Kidney Disease Outcomes Quality Initiative 
(K/DOQI) guidelines.  Most of the studies have evaluated LDL-C goals.  In addition to 
LDL-C goals, HDL-C or triglyceride goals were also evaluated by Mosca et al. (2005)
49
, 
Nichols et al. (2009)
50
, Putzer et al. (2004)
51
, and Virani et al. (2011)
53
. 
LDL-C goal attainment rates were lower among women and African-Americans.  
Massing et al. (2004)
48
 evaluated variations specific to gender and race; highest rates of 
goal attainment were observed among Caucasian men and lowest rates were observed 
among African-American men.  However, varied results were obtained for age.  
Kauffman et al. (2010)
47 
observed lower rates of goal attainment among patients < 65 
years of age in patients with CAD.  Cone et al. (2011)
46
 results showed that LDL-C goal 
attainment increased until 70 years of age and then decreased.  Stadler et al. (2010)
52
 
assessed patients with chronic kidney disease and observed increased likelihood of LDL-
C goal attainment with increasing age. 
Regarding clinical-factors, presence of obesity or increasing BMI resulted in 
lower rates of LDL-C goal attainment.  Presence of CHD risk > 20% and co-morbidities 
including hyper-triglyceridemia, diabetes, and CHD reduced the likelihood of LDL-C 
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goal attainment.  However, increase in chronic disease score or increase in severity of 
illness has been associated with higher rates of LDL-C goal attainment. 
Treatment-related variations such as use of statins, especially high efficacy statins 
are important for LDL-C goal attainment.  In addition, Cone et al. (2011)
46
 showed that 
higher doses of simvastatin or lovastatin were useful in increasing rates of LDL-C goal 
attainment.  Higher rates of LDL-C goal attainment were also observed among patients 
who were treated by subspecialist (Clark et al., 2005
45
) and patients with higher number 
of primary care visits (Virani et al., 2011
53
). 
Variations were also observed for HDL-C and triglyceride goals.  Putzer et al. 
(2004)
51
 showed that HDL-C goal attainment was higher among women, blacks, and 
patients with low BMI and with elevated triglyceride levels.  Virani et al. (2011)
53
 
observed lower rates of triglyceride goals among African-Americans, but higher rates 
were observed among men, 65-74 years age group, patients with CHD, diabetes, obesity, 
increased severity of illness, and higher number of primary care visits. 
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Table 2: Studies evaluating variations in attainment of lipid goals 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Clark et al. 
 (2005) 45 
Patient‘s 
age = 20 – 
75 years; N 
= 4,885 
Data  were collected 
from NEPTUNE II, a 
national survey of 
dyslipidemia 
management; data 
collected between May 
and September 2003 
Dyslipidemia Socio-
demographic, 
clinical, 
therapy type, 
provider type 
NCEP ATP 
III 
LDL-C control rates were lower 
among African-Americans, 
women, patients having obesity, 
hypertriglyceridemia, and 
diabetes mellitus. Use of high-
efficacy statin, treatment by 
subspecialist increases 
likelihood of treatment success. 
Not reported 
Cone et al. 
(2011) 46 
Patients on 
statin 
therapy 
N = 5,191 
Retrospective cohort 
study using New 
Mexico Veterans 
Affairs Health Care 
System‘s outcome 
database was studied, 
for period between 
1998 and 2008 
CAD or 
diabetes 
Socio-
demographic, 
BMI, 
medication 
type 
NCEP ATP 
III 
The likelihood of LDL-C goal 
increased with age until 70 
years and started to decrease. 
LDL-C control rates were 
higher among men, higher 
dosage of simvastatin or 
lovastatin. 
Not reported 
Kauffman 
et al. 
(2010) 47 
Patients 
aged ≥ 18 
years; N = 
7,427 
Retrospective study 
using Kaiser 
Permanente Colorado 
healthcare system. 
Patients enrolled in 
CPCRS for at least 1 
year before April 1, 
2008. 
CAD Socio-
demographic, 
clinical, lipid 
lowering 
medication 
type 
NCEP ATP 
III 
Lower LDL-C control rates 
were observed in who were < 
65 years of age, were female, 
had dyslipidemia, and used non-
statin medication, previous CK 
between 861 and 2000 IU/mL. 
Not reported 
Massing et 
al. 
 (2004) 48 
Patients 
aged ≥ 21 
years; N = 
23,123 
Medical record data 
collected from QAP II 
(patients from January 
1995-March 1998) 
database, includes data 
from 1,171 physicians 
at 238 medical 
practices in 23 US 
states. 
CAD  Patient‘s race, 
gender 
NCEP ATP 
III 
LDL-C goal attainment was 
higher among Caucasian men 
and was lowest among African-
American men. 
Not reported 
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Table 2 (continued) 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Putzer et al.  
(2004) 51 
N = 239 Patients were identified 
using computerized 
scheduling/billing 
database (includes patient 
visit data for university 
primary care clinic in 
Tampa, FL) for period 
March 1999-March 2001. 
Diabetes Socio-
demographic, 
smoking status, 
BMI, 
medication type,  
ADA Overall 42%, 47%, and 70% 
patients attained HDL-C, LDL-C, 
and triglyceride goals, respectively. 
LDL-C goal was met among men, 
patients taking lipid lowering drug, 
and patients with hypertension. 
HDL-C goal was met among 
women, blacks, patients with lower 
BMI and triglyceride.  
Not reported 
Nichols et 
al.  
(2009) 50 
Patients 
aged ≥ 35 
years; N = 
5,158 
Retrospective study 
using medical record 
data from Kaiser 
Permanente 
Northwest. Study 
period: July 2004-June 
2006. 
Dyslipidemia Socio-
demographic, 
clinical, lipid 
lowering 
medication 
type 
NCEP ATP 
III 
Patients with CHD, diabetes, or 
CHD risk > 20% were less 
likely to attain LDL-C goals. 
Attainment of LDL-C, HDL-C, 
and triglyceride goals was 
higher among men. 
Not reported 
Putzer et 
al.  
(2004) 51 
N = 239 Patients were 
identified using 
computerized 
scheduling/billing 
database (includes 
patient visit data for 
university primary care 
clinic in Tampa, FL) 
for period March 
1999-March 2001. 
Diabetes Socio-
demographic, 
smoking 
status, BMI, 
medication 
type,  
ADA Overall 42%, 47%, and 70% 
patients attained HDL-C, LDL-
C, and triglyceride goals, 
respectively. LDL-C goal was 
met among men, patients taking 
lipid lowering drug, and 
patients with hypertension. 
HDL-C goal was met among 
women, blacks, patients with 
lower BMI and triglyceride.  
Not reported 
Stadler et 
al.  
(2010) 52 
Patients 
aged ≥ 18 
years; N = 
4541 
Cross-sectional study 
utilizing data 
maintained by Kaiser 
Permanente Colorado. 
Study period: January 
1, 2002-Dcember 31, 
2005. 
Chronic 
kidney 
disease 
Demographic, 
BMI, smoking 
status, co-
morbidities, 
medication 
type, renal 
factors  
K/DOQI 
guidelines 
LDL-C goal attainment was 
observed among men, patients 
with increasing age, increasing 
chronic disease score, history of 
diabetes, and statins 
Not reported 
  
3
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Table 2 (continued) 
Study Patient 
population 
Setting/data source CVD/CVD 
risk factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Virani et 
al.  
(2011) 53 
N = 21,801 Retrospective study 
utilizing VA Health 
Care System in the 
Midwest region 
(includes 3 states). 
Study period: October 
1, 2007-September 30, 
2008. 
CHD Socio-
demographic, 
clinical, 
provider, 
facility 
characteristics 
NCEP ATP 
III 
LDL-C and triglyceride goal 
attainment was higher among 
patients age group 65-74 years, 
having diabetes, obesity, higher 
number of primary care visits, 
and increase in severity of 
illness. Lower control rates 
were observed among African-
Americans. 
Use of statins was 
highest among these 
patients, especially 
simvastatin. 
AHA: American heart Association; ADA: American Diabetes Association; CHD: Coronary heart disease; CPCRS: Clinical pharmacy Cardiac Risk Service; 
EMR: Electronic medical records; GEMS: General Electric Medical System; HMO: health maintenance organization; K/DOQI: National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative; LDL-C: Low-density lipoprotein cholesterol; MCO: Managed care organization; NCEP ATP III: National 
Cholesterol Education Program Adult Treatment Panel III; NEPTUNE: NCEP Evaluation project Utilizing Novel E-technology; QAP: Quality Assurance 
Program; US: United States; VA: Veteran Affairs 
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Attainment of BP and lipid goals 
Five studies evaluated both BP and lipid goals in patients with hypertension, 
hypercholesterolemia, CAD, diabetes, and dyslipidemia
33, 54-57 
(Table 3).  JNC 7 (for BP) 
and NCEP ATP III (for lipid) were the most commonly used guidelines, but Johnson et 
al. (2006)
33
 assessed patients based on JNC 6 and NCEP ATP II guidelines.  The studies 
included in this review evaluated individual cardiovascular risk factors, but study by 
Johnson et al. (2006)
 33
 focused on concomitant cardiovascular risk factors (hypertension 
and dyslipidemia).  Each study focused on different population and different factors.  
These studies vary widely based on the factors evaluated, thereby making it difficult to 
identify consistent results. 
 
  
3
7
 
Table 3: Studies evaluating variations in attainment of both blood pressure and lipid goals 
Study Patient 
population 
Setting/data source CVD/CVD risk 
factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Ahluwalia 
et al. 
(2010) 54 
Uninsured, 
low-
income, 
rural 
women 
aged 40-64 
years; N = 
733 
Cross-sectional 
study in which data  
were collected by 
survey and 
screening. Patients 
were recruited from 
WV-BCCSP clinic. 
Data collected from 
middle of 2004-
early 2007. 
Hypertension or 
hypercholesterolemia  
Socio-
demographic, 
smoking 
status, BMI, 
lifestyle, 
family history 
of CHD 
JNC 7 
(BP) and 
NCEP 
ATP III 
(Lipid) 
BP and total 
cholesterol levels were 
not met in women 
without a regular 
physician, lack of 
physical activity, less 
than 12 years of 
education. 
Not reported 
Federman 
et al. 
(2005) 55 
Patients 
age: 23-95 
years; N = 
19,660 
Retrospective study 
conducted using 
EMR maintained by 
VA Connecticut 
Health Care System  
CAD or diabetes or 
hypertension 
Provider type JNC 7 
(BP) and 
NCEP 
ATP III 
(Lipid) 
No difference seen 
among provider type 
for LDL-C control, but 
BP goal attainment 
was higher among 
attending physicians 
compared to residents. 
Not reported 
Johnson et 
al.  
(2006) 33 
N = 41,050 Retrospective study 
conducted using 
computerized data 
from South-central 
VA; period from 
October 1, 1998-
September 30, 2001. 
Concomitant 
hypertension and 
dyslipidemia 
Presence of 
diabetes 
JNC 6 
(BP) and 
NCEP 
ATP II 
(Lipid) 
BP goal attainment 
was higher among 
asymptomatic patients 
without diabetes. LDL-
C goals were met 
among patients with 
concomitant diabetes 
and hypertension.  
Use of 
antihypertensives 
and antilipemic 
medications was 
higher among 
patients with 
concomitant 
hypertension, 
dyslipidemia, and 
diabetes.  
McDonald 
et al. 
(2009) 56 
Patients 
aged ≥ 65 
years; N = 
3,810 
NHANES (1999-
2004), a cross-
sectional survey 
comprising of 
nationally 
representative 
sample of civilian 
non-institutionalized 
US population. 
Hypertension or 
dyslipidemia 
Socio-
demographic, 
doctor visits 
per year, 
presence of 
usual health 
care provider 
JNC 7 
(BP) and 
NCEP 
ATP III 
(Lipid) 
BP control rate was 
lower among women. 
Patients with 2 or more 
doctor visits were more 
likely to attain LDL-C 
goal. 
Not reported 
  
3
8
 
Table 3 (Continued) 
Study Patient 
population 
Setting/data source CVD/CVD risk 
factor  
Factors 
evaluated 
Guideline Study findings Medication 
utilization pattern 
Welch et 
al.  
(2007) 57 
Patients 
aged ≥ 18 
years; N = 
8,450 
Retrospective study 
utilizing outpatient 
electronic medical 
records for veterans 
obtained from 
patients visits to 
Atlanta VAMC. 
Study period: 
October 1, 2001-
September 30, 2003. 
Hypertension  Cardiovascular  
risk factors  
JNC 7 
(BP) and 
NCEP 
ATP III 
(Lipid) 
Overall, 37% achieved 
BP goal, 45% achieved 
total cholesterol/HDL-
C ratio < 6, 14.3% 
achieved both BP and 
lipid goals. Patients 
with ≥ 3 cardiovascular 
risk factors were less 
likely to achieve dual 
goals. 
ACEI were 
prescribed 
commonly. Use of 
antihypertensive 
agents lipid 
lowering 
medications was 
higher among 
patients with ≥ 3 
cardiovascular risk 
factors.  
ACEI: Angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CHF: Congestive heart failure; BP: Blood pressure; DM: diabetes 
mellitus; HDL-C: High density lipoprotein cholesterol; JNC 7:  Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure; NCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III; NHANES: National Health 
and Nutrition Examination Survey; VA: Veteran Affairs; VAMC: Veterans Affairs Medical Center; WV-BCCSP: West Virginia Breast and Cervical 
Cancer Screening Program 
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Medication utilization pattern in patients with cardiovascular risk factors or 
cardiovascular conditions 
Besides evaluating variations in therapeutic goal attainment, eight studies also 
examined medication utilization pattern (Tables 1-3).  Use of both antihypertensive 
agents and antilipemic agents was more common among patients with ≥ 3 cardiovascular 
risk factors or presence of concomitant conditions.  Regarding antihypertensive therapy, 
ACEI were the most commonly used antihypertensive medication class, followed by 
ARBs and thiazide diuretics.  In addition, Andros et al. (2006)
36
 showed that lisinopril 
was the most commonly used ACEI.  Among combination therapy, ACEI/diuretic was 
used by majority of patients.  Gu et al. (2008)
41
 showed that the use of ACEI was more 
common among men whereas the use of ARBs and diuretics was primarily seen in 
women.  Use of more than one antihypertensive medication was seen among elderly 
patients.  For achieving recommended LDL-C goals, statins are preferred choice of 
therapy, especially simvastatin (Virani et al., 2011
53
).  Mosca et al. (2005)
49
 showed that 
fibrate or niacin therapy is primarily used for attaining recommended HDL-C and 
triglyceride levels. 
 
Discussion 
Studies conducted in a range of settings reflect variations in attainment of BP or 
lipid goals.  A wide variety of studies were included in this review making it difficult to 
quantitatively compare all the information to identify specific factors that affect 
therapeutic goal attainment.  Even among the studies assessing patients with similar 
cardiovascular risk factor or CVD, several factors (e.g., patient population, setting, year 
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of study, medication type, and factors evaluated) preclude a direct comparison of the 
included studies.  Despite these limitations, some consistent differences in therapeutic 
goal attainment were identified.  For example, in patients with diabetes or hypertension, 
factors resulting in lower BP goals included older age, female gender, African-American 
race, and presence of co-morbidities (e.g., heart failure, chronic kidney disease, and 
stroke). 
Studies evaluated BP or lipid goals in patients with cardiovascular risk factors 
including hypertension, dyslipidemia, and diabetes.  Obesity is highly prevalent and is an 
independent risk factor for high BP, high blood cholesterol, type 2 diabetes, and CHD
1, 2
; 
studies exploring the effect of obesity on therapeutic goal attainment and underlying 
variations might be helpful in recognizing patient population at-risk of CVD.  Moreover, 
there is lack of studies assessing variations in therapeutic goal attainment in patients with 
multiple cardiovascular risk factors.  Current guidelines emphasize control of 
concomitant risk factors
12, 18
.  Hypertension and dyslipidemia are the most prevalent 
cardiovascular risk factors and studies have shown that concomitant presence of these 
factors further adds to the risk of CVD
18, 20
.  Johnson et al. (2006)
33
 assessed patients with 
concomitant hypertension and dyslipidemia, but their study evaluated the effect of 
presence or absence of diabetes.  Also, they did not explore medication utilization pattern 
in these patients.  Studies exploring patient-, clinical-, and treatment-related variations in 
these concomitant factors are needed.  LDL-C is primarily recommended for assessing 
goal attainment, but including other lipids (HDL-C, total cholesterol, and triglycerides) 
for goal assessment might be useful in further reducing cardiovascular risk.  In addition, 
medication utilization pattern was evaluated by very few studies. 
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The present study aims to retrospectively determine patient- related and clinical 
variations in therapeutic (BP and lipid) goal attainment in patients with concomitant 
hypertension and dyslipidemia.  The study cohort will be stratified based on BMI to 
explore the role of obesity in therapeutic goal attainment.  In addition, medication 
utilization pattern will be analyzed for this cohort.  GE Centricity electronic medical 
records (EMR) will be used for assessing variations in therapeutic goal attainment and 
medication utilization pattern. 
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CHAPTER THREE 
METHODOLOGY 
 
Obesity is highly prevalent in US population and is an independent risk factor for 
high BP, high blood cholesterol, type 2 diabetes, and CHD.
1, 2
  Presence of multiple risk 
factors (hypertension and dyslipidemia) in obese patients negatively affects the 
therapeutic (BP and lipid) goal attainment, thereby increasing cardiovascular risk.  Thus, 
the overall objective of this study was to evaluate variations in therapeutic (BP and lipid) 
goal attainment and medication utilization pattern in obese versus non-obese patients 
having concomitant hypertension and dyslipidemia. 
This chapter includes information on data source, patient selection criteria, study 
variables, data extraction, and statistical analyses. 
 
Data source 
Retrospective cohort study was conducted utilizing the GE Centricity Electronic 
Medical Records (EMR) database of a primary care physician group.  This study was 
approved by Duquesne University Institutional Review Board. 
 
Electronic Medical Records (EMR) 
EMR generally refers to standardized electronic databases for healthcare, 
developed, maintained, and/or provided by clinicians and providers in direct patient care.  
The EMR systems contain information on all clinical, administrative, and laboratory 
encounters between a patient and provider.
58, 59
  Currently, these EMR systems are 
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available at some of the large, integrated healthcare providers in the US, such as Kaiser 
Permanente, Harvard Pilgrim Health System, and the Department of Veterans Affairs 
(VA).  The current government program, American Recovery and Reinvestment Act 
(ARRA) of 2009, enacted by President Obama in 2009 includes the Health Information 
Technology Extension Program with $19 billion in grants and loans for adopting certified 
EMR technology.
58, 60
 
EMR systems have the potential to provide clinical data required for research and 
with technological advancement, it has become a valuable source for outcomes research.  
EMR offers various potential benefits in research by providing access to a fully 
integrated system with both clinical and healthcare utilization data.  These EMR systems 
provide access to a more diverse patient population.  In addition, it provides access to 
readily available, in-depth, more accurate, and complete data.
60
 
 
GE Centricity EMR Database 
This study utilized GE Centricity EMR database used by physician group. .  The 
database contains data from 2004-2011 with 155,483 active patients receiving care from 
42 primary care providers in Southwestern Pennsylvania.  The EMR dataset comprises of 
longitudinal patient data that includes patient demographics and clinical diagnoses, 
prescribed medications, procedures, and laboratory test results. 
 
Database organization 
GE centricity EMR database uses an Oracle
®
 relational database.
61
  A database is 
a collection of tables which contain related information.  A table in a relational database 
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is organized in rows and columns.  Column, also known as field, represents a specific 
type of data stored in the table.  For example, PERSON table includes columns such as 
person‘s ID, sex, race, etc.  Each row (also known as record) represents a set of related 
data about a single object.  For example, each row in PERSON table represents 
demographic information for each person.  In APPOINTMENTS table, each person can 
have multiple appointments, where each row contains information for one specific 
appointment.
61
  Figure 5 represents organization of data in EMR database. 
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Figure 5: GE Centricity EMR database organization. 
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Patient population 
The patients aged ≥18 years diagnosed with concomitant hypertension and 
dyslipidemia and having ‗active‘ status (patients with one or more visit(s) to the 
physician) were selected.  Identification of cases with concomitant hypertension and 
dyslipidemia was based on the combination of information.  Patients were classified as 
having hypertension if they met any of the following three criteria: (1) diagnosis of 
hypertension; or (2) or at least 1 elevated BP (≥140mmHg systolic or ≥90mmHg diastolic 
for patients not having any CVD, renal disease or diabetes and ≥130mmHg systolic or 
≥80mmHg diastolic for patients with heart disease, renal disease or diabetes) followed by 
1 antihypertensive prescription; or (3) at least 2 consecutive (1-3 months interval)
12, 62
 
elevated BP measurements.  Patients were classified as having dyslipidemia if they met 
any of the following three criteria: (1) diagnosis of dyslipidemia; or (2) at least 1 
prescription of antilipemic drug; or (3) at least 1 elevated fasting LDL-C level (LDL-C 
level evaluated based on the CHD risk factors, discussed in detail in therapeutic goal 
attainment {refer Table 7}).  In addition, hypertension or dyslipidemia cases were 
confirmed if they had at least one more of the above mentioned diagnosis criteria post-
index date (defined on page 48) (hypertension or dyslipidemia).  International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 
were used for diagnosis of hypertension (ICD-9: 401.xx) and dyslipidemia (ICD-9: 272.0, 
272.1, 272.2, 272.4).  Patients having both hypertension and dyslipidemia were then 
selected.  The study cohort included patients with BMI reported at index date, at least 1 
elevated LDL-C and BP measurement reported within 2 years prior to or at index date, 
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and at least 1 elevated LDL-C and BP measurement reported between 3 and 24 months 
post-index.  Figure 6 represents the selection criteria for study cohort. 
 48 
 
Figure 6: Selection criteria for study cohort. 
 
 
 
BMI: Body mass index; BP: Blood pressure; EMR: electronic medical records; LDL: Low-density 
lipoprotein 
 
Patient population in EMR database (N = 166,795) 
Cases with ‘active’ status (N = 155,843) 
Patients with hypertension 
(N= 30,549) 
Patients with dyslipidemia 
(N = 25,255) 
Patients with concomitant hypertension and dyslipidemia (N = 19,200) 
Patients with age ≥18 years at index date were selected (N = 19,190) 
Patients with BMI reported at index date (N = 18,376) 
Patients with at least 1 LDL and BP measurements reported ≤24 months of index 
date (N = 14,447) 
Patients with at least 1 LDL and BP measurements reported between 3 months 
and 24 months post-index (N = 9,086) 
Patients with 1elevated LDL and BP measurement at index (N = 11,572) 
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Index date 
For longitudinal measurement, the index date was identified.  Hypertension index 
date was defined as the date at which any one of the above mentioned hypertension 
diagnosis criteria occurred at an earlier date.  Similarly, dyslipidemia index date was 
defined as the date at which any one of the above mentioned dyslipidemia diagnosis 
criteria occurred at an earlier date.  For concomitant hypertension and dyslipidemia, latter 
of the two cohort dates (hypertension or dyslipidemia) index was used.  The latter date 
helps in identifying patients with diagnosis of both conditions.  The overall description of 
index date is shown in Figure 7. 
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Figure 7: Index date for concomitant hypertension and dyslipidemia. 
 
 
 
BP: Blood pressure; DYS: Dyslipidemia; HTN: Hypertension; LDL: Low-density lipoprotein 
 
 
Concomitant HTN and DYS index date: Latter of the two (HTN or 
DYS) index dates 
HTN index date: Date at which any one 
of the 3 HTN diagnosis criteria (diagnosis 
of HTN, at least 2 consecutive elevated BP 
reading or 1 elevated BP followed by 1 
anti-HTN medication) occurred earlier for 
each patient 
DYS index date: Date at which any 
one of the 3 DYS diagnosis criteria 
(diagnosis of DYS, at least 1 elevated 
LDL or at least 1 antilipemic 
medication) occurred earlier for each 
patient 
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Data extraction 
The data is available in Microsoft SQL server 2005 management studio express.  
The data files exist as tables containing information for patient demographics, clinical 
diagnoses, prescribed medications, procedures, and laboratory test results.  The data were 
extracted using Microsoft SQL.  Specific tables and columns were identified and linked 
using unique ID.  The related information in one table column was linked to information 
in another table column using Person ID (PID) as the primary key.  PID is a unique 
identification for each person or contact in the PERSON table.  The PID is used in most 
of the tables and is used to identify the information related to a specific person.  Figure 8 
represents some of the tables containing related information that were linked using PID. 
Selection criteria were used to extract only the required information.  Besides 
PID, other IDs in EMR database that were used include PVID (for each healthcare 
provider), HDID (heading ID for identifying information related to patient observations, 
laboratory results, etc.), and MID (medication ID for identifying information for specific 
medication).  The required data were exported in Microsoft Excel (Excel).  For statistical 
analyses, the data in Excel were imported into Statistical Package for Social Sciences 
(SPSS version 20.0). 
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Figure 8: Representation of linking pattern for tables in database. 
 
 
PID: Person ID; it used to link all tables containing information related to each patient. 
Other IDs such as ApptID (appointment ID), MID (medication ID), INSID (insurance ID), OBSID 
(observation ID), order ID, PRID (Problem ID) are used to link tables with related information.  For 
example, to have more information regarding insurance company, we can use INSID to link it to the table 
containing required information. 
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Study Variables 
 
Patient-related variables 
Patient-related variables included age, gender, race, marital status, insurance type, 
and area of residence.  Information was obtained from PERSON table (contains 
demographic information).  All of these variables were recorded at baseline. 
 
Age at index date 
It was calculated from the date of birth of each patient.  The index date was used 
as a reference for calculating age.  Age was categorized as: 18-44 years, 45-55 years, 56-
64 years, 65-74 years, and ≥75 years. 
 
Gender 
The gender variable was used as the indicator of sex. 
 
Race 
For the purpose of analysis, the variable race was categorized as Caucasians, 
African-Americans, other minority classes, and undetermined (race was not reported). 
 
Marital status 
In the EMR database, marital status is categorized as married, single, divorced, 
widowed, separated, and others.  For the purpose of analysis, marital status was grouped 
into four categories: married, single, divorced/widowed/separated, and undetermined 
(marital status was not reported). 
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Primary payer  
EMR data contains information for type of insurance for each patient.  This 
variable was categorized into five categories: Medicare, Medicaid, private insurance, 
self-pay, and other. 
 
Area of residence 
The EMR contains information on patient location which includes zip codes, city, 
and state.  Using this available information, patient location was categorized into 
different counties.  Further, counties were grouped into two categories: urban and rural.  
This urban/rural classification was used as the indicator of patient location. 
 
Clinical variables 
Clinical variables included BMI, co-morbidities, smoking status, diastolic and 
systolic BP, hypertension stage, LDL-C levels, HDL-C levels, total cholesterol levels, 
and triglyceride levels.  Information on co-morbidities was obtained from PROBLEM 
table (contains information on diseases along with ICD-9-CM codes).  Physical 
examination and laboratory results were obtained from OBS table.  BMI, co-morbidities, 
and smoking status were assessed at baseline.  BP and lipid levels were assessed both at 
baseline and follow-up for the purpose of evaluating therapeutic goal attainment. 
 
BMI 
To evaluate the effect of obesity on BP and lipid goal attainment, patients with 
concomitant hypertension and dyslipidemia were categorized into three cohorts based on 
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the patient‘s BMI (calculated as weight (kg)/[height (m)]2): ≤24.9 kg/m2 (includes both 
underweight and normal-weight individuals), 25.0-29.9 kg/m
2
 (overweight), and ≥30.0 
kg/m
2
 (obese)
18
. 
 
Smoking status 
Cigarette smoking is one of the CHD risk factor.  This variable consists of three 
categories: non-smoker, former smoker, and current smoker. 
 
Co-morbidities 
Presence of cardiovascular co-morbidities affects both BP and lipid levels as well 
as therapeutic goal attainment.  Co-morbidities were identified based on the ICD-9-CM 
codes and are shown in Table 4.  The type of co-morbidity and the number of co-
morbidities were analyzed.  For the purpose of analysis, the number of comorbidities 
were grouped into four categories: 0, 1, 2, ≥3 co-morbidities. 
 
 56 
 
Table 4: Co-morbid conditions and their ICD-9-CM codes 
Co-morbid conditions ICD-9-CM codes 
Diabetes mellitus (Type II) 250.xx 
Heart failure 428.xx 
Myocardial infarction 410.xx, 411.0x, 411.8x, 412.xx 
Angina pectoris 411.1x, 413.xx 
Peripheral vascular disease 440.xx, 441.4x, 441.9x, 443.xx, 444.xx 
Coronary artery disease 414.0x, 414.8x, 414.9x, 429.2x 
Cerebrovascular disease 430.xx-434.xx, 435.9x, 436.xx-438.xx 
Kidney disease 403.xx, 585.xx 
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Hypertension- and dyslipidemia-related variables 
For baseline measurements, the lipid (LDL-C, HDL-C, total cholesterol, and 
triglyceride), and BP (both systolic and diastolic) measurements 2 years prior to or at 
index date were selected.  If a patient had more than one measurement, then the 
measurements closest to index date were included for analysis.  For post-index period, 
the lipid and BP measurements between 3-24 months of post-index were selected.  If a 
patient had more than one measurement, then their last lipid or BP measurement during 
the evaluation period was included for analysis.  The selection of baseline and post-index 
BP and lipid measurements are shown in Figure 9. 
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Figure 9: Selection of baseline and post-index BP and lipid measurements. 
 
 
 
BP: Blood pressure 
 
2004-2011 
Index date 
(Diagnosis of concomitant 
hypertension & dyslipidemia) 
24 months 
3-24 months 
Baseline: BP or lipid value 
closest to index  
Post-index: Last BP or 
lipid value during follow-
up period  
 
Pre-index Post-index 
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Based on the JNC 7 guidelines, diastolic and systolic BP measurements are 
grouped into four categories, collectively referred as hypertension stage as shown in 
Table 5.
17
  The patients included in study had elevated BP, thus for purpose of analysis 
only three categories were used: prehypertension, stage 1 hypertension, and stage 2 
hypertension. 
Similarly, based on the NCEP ATP III guidelines, lipid (LDL-C, HDL-C, total 
cholesterol, and triglyceride) measurements are also grouped into different categories as 
shown in Table 6.
18
  For the purpose of analysis LDL-C was grouped into three 
categories: Near optimal/above optimal (100-129 mg/dL), borderline high (130-159 
mg/dL), and high/very high (≥160 mg/dL).  HDL-C was grouped into two categories: low 
(<40 mg/dL) and high (≥40 mg/dL); total cholesterol categories included optimum (<200 
mg/dL), borderline high (200-239 mg/dL), and high (≥240 mg/dL); triglyceride 
categories included optimum (<150 mg/dL), borderline high (150-199 mg/dL), and high 
(≥200 mg/dL). 
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Table 5: Classification for hypertension stage
17
 
SBP (mmHg) DBP (mmHg) Categories 
< 120 and < 80 Normal 
120-139 or 80-89 Prehypertension 
140-159 or 90-99 Stage 1 hypertension 
≥ 160 or ≥ 100 Stage 2 hypertension 
DBP: Diastolic blood pressure; SBP: Systolic blood pressure 
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Table 6: Classification of LDL-C, HDL-C, total cholesterol, and triglyceride levels
18
 
Lipid level (mg/dL) Categories 
LDL cholesterol 
<100 Optimal (Desirable) 
100-129 Near optimal/above optimal 
130-159 Borderline high 
160-189 High 
≥190 Very high 
Serum HDL cholesterol 
<40 Low 
≥40 High (Desirable) 
Total cholesterol 
<200 Normal (Desirable) 
200-239 Borderline high 
≥240 High 
Serum triglyceride level 
<150 Normal (Desirable) 
150-199 Borderline-high  
200-499 High triglycerides 
>500 Very high triglycerides 
HDL: High-density lipoprotein; LDL: Low-density lipoprotein 
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Therapeutic goal attainment 
Therapeutic goal attainment is the outcome variable and comprises of three 
different aspects: (1) inadequate attainment of BP goals; (2) inadequate attainment of 
lipid goals; (3) inadequate attainment of both BP and LDL-C goals. 
BP goals were evaluated based on JNC 7 guidelines and were defined as either 
systolic/diastolic BP <140/90 mm Hg or <130/80 for patients with diabetes or chronic 
kidney disease.
17
 
Lipid goals were evaluated based on NCEP ATP III guidelines.  LDL-C is 
considered the primary target for evaluating lipid goals.  Table 7 shows the required 
LDL-C goals based on presence or absence of CHD and other clinical forms of 
atherosclerotic disease, and the CHD risk factors.  CHD risk factors include hypertension, 
family history of CHD, HDL-C <40 mg/dL, cigarette smoking, age (≥45 for men, ≥55 for 
women).
18
 
For other lipid levels (non-LDL-C), patients were considered at goal if they 
achieved post-index HDL-C ≥40 mg/dL, total cholesterol <200 mg/dL and triglycerides 
<150 (Refer Table 6). 
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Table 7: LDL-C goal classification
18
 
LDL-C goal CHD risk factor 
<100 mg/dL Presence of CHD or CHD risk equivalent (diabetes, peripheral arterial 
disease, abdominal aortic aneurysm, and symptomatic carotid artery 
disease) 
<130 mg/dL ≥ 2 CHD risk factors 
<160 mg/dL 0-1 CHD risk factor 
CHD: Coronary heart disease 
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Medication-related variables 
The medication-related information was obtained from MEDICATE table of the 
GE Centricity EMR database.  These variables were assessed at both baseline and follow-
up. 
 
Antihypertensive medications  
According to the JNC 7 guidelines, the commonly used antihypertensives 
medication classes include beta-blockers (BBs), alpha blockers, alpha and beta blockers, 
calcium channel blockers (CCBs), thiazide diuretics, other diuretics (potassium-sparing 
and loop diuretics), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II 
receptor blockers (ARBs), other antihypertensives (centrally acting and vasodilators).  
Combination drugs include ACEIs and CCBs, ACEIs and diuretics, ARBs and diuretics, 
BBs and diuretics, and diuretic and diuretic.
17
 
 
Antilipemic medications 
According to the NCEP ATP III guidelines, the recommended antilipemic 
medication classes include statins, fibrates, bile acid sequestrants, and nicotinic acid.
18
 
 
Medication prescribing pattern 
The medication prescribing pattern includes antihypertensive and antilipemic 
medication class and number of medications used in patients with concomitant 
hypertension and dyslipidemia stratified by BMI. 
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Antihypertensive medication prescribing pattern was determined by first-line 
antihypertensive drug class and number of prescribed medications during the baseline 
and follow-up period.  The medication prescribing pattern was also analyzed for 
complicated and uncomplicated hypertension based on the presence of co-morbidities 
(diabetes, CVD, and renal disease).  Complicated hypertension defined as stage 1 or stage 
2 hypertension without co-morbidities and uncomplicated hypertension is defined as 
presence of co-morbidities in patients with elevated BP.
17
  It is based on the JNC 7 
guidelines as shown in Table 8.  For the purpose of analysis, for both uncomplicated and 
complicated hypertension, number of medications prescribed was analyzed. 
Antilipemic medication prescribing pattern was based on type of medication class 
and number of medications used.  NCEP ATP III guidelines recommend use of statins, 
nicotinic acid, fibrates or bile acid sequestrant.  Moreover, medication prescribed pattern 
was separately analyzed for patients with high/or very high cardiovascular risk (patients 
having at least two risk factors or co-morbidities such as diabetes and CVD). 
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Table 8: Antihypertensive medication prescribing pattern
17
 
Indication Medication therapy 
No compelling indication 
Stage 1 hypertension Thiazide-type diuretics.  May consider ACEI, ARB, BB, CCB, or 
combination. 
Stage 2 hypertension Two-drug combination for most (usually thiazide type diuretic and ACEI, 
or ARB, or BB, or CCB) 
Compelling indications 
Heart failure ≥2 drugs, ACEIs or BBs or ARBs or aldosterone blockers in combination 
with diuretics 
Stable angina pectoris  ≥2 drugs, BBs or CCBs 
Unstable angina ≥2 drugs, BBs or ACEIs 
Post-myocardial infarction ≥2 drugs, ACEIs or BBs or aldosterone antagonists 
Diabetes Combinations of ≥ 2 drugs with thiazide-type diuretics, BBs, ACEIs, 
ARBs, and CCBs 
Chronic kidney disease ≥3 drugs, ACEIs or ARBs in a combination with diuretics or BBs 
Cerebrovascular disease ≥2 drugs, Combination of an ACEI and thiazide-type diuretic 
ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; BB: Beta-blocker; 
CCB: Calcium channel blocker 
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Statistical analysis 
Microsoft SQL and Statistical Package for Social Sciences (SPSS version 20.0) 
were used for analytical purposes.  Most of the variables as discussed in this section were 
measured on categorical scale.  However, age, systolic and diastolic BP, LDL-C, HDL-C, 
triglyceride, and total cholesterol levels were also evaluated on continuous scale for 
purpose of statistical analysis.  All analyses were evaluated at a priori p < 0.05.  The data 
were prescreened for missing values and required assumptions were evaluated for 
univariate and multivariate statistical techniques used for analyses. 
 
Objective 1: To examine distribution of patient-related and clinical factors in patients 
with concomitant hypertension and dyslipidemia stratified by body mass index. 
For purpose of analysis, patients were classified into three cohorts based on their 
BMI: normal-weight, overweight, and obese individuals.  Descriptive analyses were 
conducted to assess the baseline patient-related and clinical factors among normal-
weight, overweight, and obese individuals and were compared using two-way 
contingency analysis for categorical variables and one-way ANOVA for continuous 
variables.  Distribution of post-index BP and lipid measurements were also compared 
among three cohorts using one-way ANOVA. 
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Objective 2: To examine variation in BP and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia stratified by body mass index. 
Descriptive analyses were conducted to assess the BP and/or lipid goal attainment 
among normal-weight, overweight, and obese individuals and were compared using two-
way contingency analysis for categorical variables. 
 
Objective 3: To examine variations in antihypertensive and antilipemic medication 
utilization pattern based on JNC 7 and NCEP ATP III guidelines, respectively in patients 
with concomitant hypertension and dyslipidemia stratified by body mass index. 
Descriptive analyses were conducted to assess treatment pattern (antihypertensive 
or antilipemic medication class used and number of medications) among normal-weight, 
overweight and obese individuals and were compared using two-way contingency 
analysis. 
 
Objective 4: To examine predictors of BP or/and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia. 
Statistical analysis techniques, such as one-way ANOVA and two-way 
contingency analysis, do not adjust for confounding variables.  Thus, multivariate 
analyses using logistic regression were conducted to evaluate effect of BMI on goal 
attainment while controlling for all other patient-related, clinical, and medication-related 
variables.  For the purpose of analyses, dummy variables (a binary indicator that explains 
the absence or presence of a categorical effect) for each category were created for 
variables with more than two categories.  The standard logistic regression was used in 
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which all the selected variables were entered into the multivariate logistic regression 
model simultaneously to evaluate association of BMI with inadequate goal attainment, 
while controlling for all other factors.  In addition, the association of other factors with 
inadequate goal attainment was also evaluated in patients with concomitant hypertension 
and dyslipidemia.  The significant predictors were then entered into stepwise regression 
model using Forward LR method to evaluate the contribution of these predictors. 
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CHAPTER FOUR 
RESULTS 
 
Obesity is highly prevalent in US population and is an independent risk factor for 
high BP, high blood cholesterol, type 2 diabetes, and CHD.
1, 2
  Presence of multiple risk 
factors (hypertension and dyslipidemia) in obese patients negatively affects therapeutic 
(BP and lipid) goal attainment, thereby increasing cardiovascular risk.  Thus, the overall 
objective of this study was to evaluate variations in therapeutic (BP and lipid) goal 
attainment and medication utilization pattern in obese versus non-obese patients having 
concomitant hypertension and dyslipidemia.  In this chapter, results for the study 
objectives are presented. 
 
 
Objective 1: To examine distribution of patient-related and clinical factors in patients 
with concomitant hypertension and dyslipidemia stratified by body mass index. 
Patients with concomitant hypertension and dyslipidemia were classified into 
three cohorts based on their BMI:  normal weight (≤24.9 kg/m2), overweight (25.0-29.9 
kg/m
2), and obese (≥30.0 kg/m2) individuals.  Using descriptive analyses, frequencies 
were reported for categorical variables and mean was reported for continuous variables.  
Moreover, these three cohorts were compared using two-way contingency table analysis 
for categorical variables and one-way ANOVA for continuous variables.  Patient 
variables included age, gender, race, marital status, primary payer, and patient location.  
Clinical variables included cardiovascular conditions, smoking status, DBP, SBP, 
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hypertension stage, cardiovascular risk, LDL-C, HDL-C, total cholesterol, and 
triglyceride.  For BP and lipid measurements, distributions of both baseline and post-
index measurements were compared among three cohorts using one-way ANOVA. 
 
Patient-related variables 
 In total population with concomitant hypertension and dyslipidemia (N = 9,086), 
0.6% had a BMI ≤18.49 (underweight), 13.2% had BMI 18.5-24.9kg/m2 (normal-weight), 
33% had BMI 25.0-29.9 kg/m
2
 (overweight), 28.6% had BMI 30.0-34.9 kg/m
2
 
(moderately obese), 13.6% had BMI
  
35.0-39.9 kg/m
2 
(severely obese), and 10.4% had 
BMI ≥40.0 kg/m2 (very severely obese).  For the purpose of analysis, patients were 
classified into three groups:
 normal weight (≤24.9 kg/m2), overweight (25.0-29.9 kg/m2), 
and obese (≥30.0 kg/m2).  For the total population, mean age was 60.03±13.21 years with 
a mean BMI of 31.46±7.04 kg/m
2
.  For each BMI category, the mean BMI was 
22.66±2.12 kg/m
2
 (normal-weight), 27.65±1.41 kg/m
2
 (overweight), 36.21±6.30 kg/m
2
 
(obese).  Patients who had normal-weight were older (70.16±12.49 years) compared to 
patients who were overweight (mean age: 65.22±12.80 years) or obese (mean age: 
60.03±12.68 years). 
 A two-way contingency table analysis (Table 9) indicated that age, gender, race, 
marital status, and primary payer showed significant (P<0.05) variation across BMI 
whereas patient location did not vary significantly across BMI.  For total population, 
most of the patients were in the age group  of 56-64 years (24.6%) followed by 65-74 
years (23.4%), ≥75 years (22.7%), and 45-55 years (21.3%) compared to age group 18-44 
years (7.9%).  For each of the age groups, most of the patients were either overweight or 
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obese, except for age group ≥ 75 years of age (43.2%) who were more likely to have 
normal weight.  The total population included more females (51.9%) compared to males 
(48.1%).  Males were more likely to be overweight (50.9%) or obese (50.0%) compared 
to females who were more likely to have normal-weight (66.2%).  Race was reported for 
about 89% of population and majority comprised of Caucasians (76.9%).  Similarly, 
marital status was reported for about 34.8% of the population and majority of them were 
married (34.8%).  Regarding primary payer, most of the patients were having private 
insurance (60.5%) followed by Medicare (27.9%).  Patients who were obese (64.8%) 
were more likely to have private insurance versus patients who were normal-weight 
(49.1%) or overweight (58.5%) and patients who were normal-weight were more likely to 
have Medicare (38.6%) versus patients who were overweight (31.6%) and obese (22.7%).  
Majority of the patients were residing in urban areas (62.3%) compared to those residing 
in rural areas (37.7%).  The significant difference in patient location based on BMI was 
not observed.   
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Table 9: Distribution of bio-demographic characteristics by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
b
 
≤24.9 kg/m2 
(N = 1,256)
b
 
25.0-29.9 kg/m
2
 
(N = 3,058)
b
 
≥30.0 kg/m2 
(N = 4,772)
b
 
P value
c
 
Age (years)     <0.001 
18-44 718 (7.9%) 34 (2.7%) 170 (5.6%) 514 (10.8%)  
45-55 1936 (21.3%) 147 (11.7%) 531 (17.4%) 1258 (26.4%)  
56-64 2235 (24.6%) 227 (18.1%) 717 (23.4%) 1291 (27.1%)  
65-74 2130 (23.4%) 306 (24.4%) 814 (26.6%) 1010 (21.2%)  
≥75 2067 (22.7%) 542 (43.2%) 826 (27.0%) 699 (14.6%)  
      
Gender     <0.001 
Male 4367 (48.1%) 424 (33.8%) 1556 (50.9%) 2387 (50.0%)  
Female 4719 (51.9%) 832 (66.2%) 1502 (49.1%) 2385 (50.0%)  
      
Race     0.019 
Caucasians 6977 (76.9%) 947 (75.5%) 2337 (76.5%) 3693 (77.5%)  
African-Americans 15 (0.2%) 5 (0.4%) 6 (0.2%) 4 (0.1%)  
Others 172 (1.9% ) 17 (1.4%) 51 (1.7%) 104 (2.2%)  
Undetermined 1909 (21.0%) 285 (22.7%) 659 (21.6%) 965 (20.2%)  
      
Marital status      
Married 3160 (34.8%) 363 (28.9%) 1031 (33.7%) 1766 (37.0%) <0.001 
Divorced/Widowed/ Separated 786 (8.7%) 157 (12.5%) 253 (8.3%) 376 (7.9%)  
Single 528 (5.8%) 70 (5.6%) 146 (4.8%) 312 (6.5%)  
Undetermined 4612 (50.8%) 666 (53.0%) 1628 (53.2%) 2318 (48.6%)  
      
Primary payer      
Medicare 2536 (27.9%) 485 (38.6%) 967 (31.6%) 1084 (22.7%) <0.001 
Medicaid 385 (4.2%) 46 (3.7%) 93 (3.0%) 246 (5.2%)  
Private 5500 (60.5%) 617 (49.1%) 1789 (58.5%) 3094(64.8%)  
Self-pay 576 (6.3%) 90 (7.2%) 184 (6.0%) 302 (6.3%)  
Other 89 (1.0%) 18 (1.4%) 25 (0.8%) 46 (1.0%)  
      
Patient location     0.077 
Urban 5657 (62.3%) 810 (64.5%) 1923 (62.9%) 2924 (61.3%)  
Rural 3429 (37.7%) 446 (35.5%) 1135 (37.1%) 1848 (38.7%)  
aTwo-way contingency analysis was utilized for analysis.  bColumn percentages are reported unless otherwise specified. Data is presented as N (%). 
cSignificance tested at P<0.05 
 74 
 
Clinical variables 
A two-way contingency table analysis (Table 10) indicated that presence of some 
cardiovascular conditions such as diabetes, CAD, peripheral vascular disease, and 
cerebrovascular disease showed significant (P<0.05) variation across BMI, whereas other 
cardiovascular conditions such as heart failure, myocardial infarction, angina pectoris, 
and kidney disease did not show any significant variation across BMI.  Other clinical 
factors that showed significant (P<0.05) variation across BMI categories included 
number of cardiovascular conditions, smoking status, and cardiovascular risk.  
Hypertension stage did not show significant variation across BMI. 
Each cardiovascular condition was grouped into two categories: cardiovascular 
condition present and cardiovascular condition absent.  For the total population, most 
patients (37.3%) had diabetes.    Among cardiovascular conditions significantly 
associated with BMI, diabetes rates were higher among obese patients (47.4%) compared 
to patients who had either normal-weight (21.7%) or overweight (27.9%).  However, 
rates of CAD were higher among normal-weight patients (19.7%) versus overweight 
(19.0%) and obese (16.0%) patients.  Similarly, the rates of peripheral vascular disease 
were also higher among normal-weight patients (12.8%) versus overweight (9.5%) or 
obese (7.2%) patients and the rates of cerebrovascular disease were higher among 
normal-weight patients (16.4%) compared to overweight (12.4%) or obese (8.9%) 
patients. 
For the total population, majority of the patients (42.8%) had no cardiovascular 
condition followed by patients with one cardiovascular condition (35.8%).    Majority of 
overweight patients (46.5%) did not have any CV condition followed by patients who had 
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normal-weight (46.5%) compared to obese patients (38.4%).  Majority of the obese 
patients had one (39.7%) or two (14.4%) CV conditions when compared to normal-
weight or overweight patients.  Cardiovascular risk was categorized based on the CV 
conditions and CV risk factors.  Majority of the patients had high CV risk (57.2%) 
followed by intermediate risk (38.2%).  Majority of the obese patients were in high risk 
category (61.6%) compared to normal-weight (53.5%) or overweight (51.8%) patients.  
For high risk category, most of the patients were overweight (44.0%) followed by 
normal-weight (43.6%) versus obese patients (33.1%).  For hypertension stage, most of 
the patients were in prehypertension category (54.3%) followed by stage 1 (35.3%) and 
stage 2 (10.4%).  However, no differences were observed across BMI for each 
hypertension stage.  Most of the patients were non-smokers (54.6%) and significant 
variations were also observed for each category of smoking status across BMI.  For non-
smoker category, most of the patients had normal-weight (56.2%) compared to 
overweight (54.6%) and obese (5.1%) patients.  Similarly, for current smoker category, 
most of the patients had normal-weight (14.3%) compared to overweight (10.7%) and 
obese (11.5%) patients.  However, for former-smoker category, most of the patients were 
obese (34.4%) or overweight (34.7%) compared to patients with normal-weight (29.5%). 
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Table 10: Distribution of clinical characteristics by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
b
 
≤24.9 kg/m2 
(N = 1,256)
b
  
25.0-29.9 kg/m
2
 
(N = 3,058)
b
 
≥30.0 kg/m2 
(N = 4,772)
b
 
P value
d
 
CV conditions (present)c      
Diabetes 3387 (37.3%) 273 (21.7%) 853 (27.9%) 2261 (47.4%) <0.001 
Heart failure 440 (4.8%) 65 (5.2%) 132 (4.3%) 243 (5.1%) 0.249 
Myocardial infarction 275 (3.0%) 45 (3.6%) 101 (3.3%) 129 (2.7%) 0.148 
Angina pectoris 132 (1.5%) 26 (2.1%) 34 (1.1%) 72 (1.5%) 0.052 
Coronary artery disease 1593 (17.5%) 248 (19.7%) 582 (19.0%) 763 (16.0%) <0.001 
Peripheral vascular disease 795 (8.7%) 161 (12.8%) 290 (9.5%) 344 (7.2%) <0.001 
Cerebrovascular disease 1011 (11.1%)  206 (16.4%) 380 (12.4%) 425 (8.9%) <0.001 
Kidney disease 477 (5.2%) 69 (5.5%) 163 (5.3%) 245 (5.1%) 0.853 
      
No. of CV conditions     <0.001 
0 3889 (42.8%) 584 (46.5%) 1474 (48.2%) 1831 (38.4%)  
1 3249 (35.8%) 402 (32.0%) 954 (31.2%) 1893 (39.7%)  
2 1245 (13.7%) 162 (12.9%) 396 (12.9%) 687 (14.4%)  
≥3 703 (7.7%) 108 (8.6%) 234 (7.7%) 361 (7.6%)  
      
Cardiovascular risk     <0.001 
Low 416 (4.6%) 36 (2.9%) 129 (4.2%) 251 (5.3%)  
Intermediate 3473 (38.2%) 548 (43.6%) 1345 (44.0%) 1580 (33.1%)  
High 5197 (57.2%) 672 (53.5%) 1584 (51.8%) 2941 (61.6%)  
      
Hypertension stage     0.671 
Prehypertension 4931 (54.3%) 688 (54.8%) 1643 (53.7%) 2600 (54.5%)  
Stage 1 3210 (35.3%) 437 (34.8%) 1110 (36.3%) 663 (34.8%)  
Stage 2 945 (10.4%) 131 (10.4%) 305 (10.0%) 509 (10.7%)  
      
Smoking status     0.001 
Non-smoker 4704 (54.6%) 662 (56.2%) 1571 (54.6%) 2471 (54.1%)  
Current 1001 (11.6%) 169 (14.3%) 309 (10.7%) 523 (11.5%)  
Former-smoker 2917 (33.8%) 347 (29.5%) 998 (34.7%) 1572 (34.4%)  
CV: Cardiovascular 
aTwo-way contingency analysis was utilized for analysis. 
b
Column percentages are reported unless otherwise specified. Data presented as N (%). 
cN (%) represents percentage of patients having above mentioned CV conditions.  Comparison group is absence of CV condition. 
dSignificance tested at P<0.05 
 77 
 
One-way ANOVA (Table 11) indicated that DBP, LDL-C, HDL-C, total 
cholesterol, and triglyceride measurements both at baseline and post-index showed 
significant (P<0.05) variation across BMI.  Systolic blood pressure did not show 
significant variation across BMI. 
On average, the total population with concomitant hypertension and dyslipidemia 
did not have optimum BP (mean SBP = 138.80 ± 30.09 mm Hg and mean DBP = 84.49 ± 
29.33 mm Hg) and lipid levels (mean LDL-C = 142.94 ± 29.51 mg/dL, mean total 
cholesterol = 217. 23 ± 40.15 mg/dL, and mean triglyceride = 174.61 ± 104.79mg/dL) at 
baseline.  However, on average, patients had optimum HDL-C levels (50.90 ± 14.14 
mg/dL).  Mean DBP was higher for patients who were obese (M = 84.34, SD = 33.30 mm 
Hg).  Regarding lipid levels, mean LDL-C (mg/dL) was higher for patients who were 
overweight (M = 144.80, SD = 30.63).  Mean triglyceride levels were higher (M = 
188.47, SD = 113.41 mg/dL) and mean HDL-C was lower (M = 47.86, SD = 12.44 
mg/dL) for patients who were obese.  Interestingly, mean total cholesterol was higher for 
normal-weight patients (M = 220.30, SD = 37.82 mg/dL). 
On average, the total population did not have optimum BP (mean SBP = 134.79 ± 
25.59 mmHg and mean DBP = 81.25 ± 14.27 mmHg) and lipid levels (mean LDL-C = 
123.20 ± 31.69 mg/dL, mean total cholesterol = 202.66 ± 38.31 mg/dL, and mean 
triglyceride = 163.58 ± 87.50 mg/dL) at post-index.  However, on average, patients had 
optimum HDL-C levels (50.50 ± 14.28 mg/dL).  Mean DBP was higher for patients who 
were obese (M = 82.22, SD = 14.31 mm Hg).  Mean triglyceride levels were higher (M = 
176.24, SD = 91.82 mg/dL) and mean HDL-C was lower (M = 47.34, SD = 12.53 mg/dL) 
for patients who were obese.  Interestingly, mean LDL-C (M = 125.04, SD = 
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31.31mg/dL) and mean total cholesterol (M = 208.41, SD = 37.53 mg/dL) was higher for 
patients with normal-weight. 
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Table 11: Distribution of baseline and post-index BP and lipid levels by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
b
 
≤24.9 kg/m2 
(N = 1,256)
b
  
25.0-29.9 kg/m
2
 
(N = 3,058)
b
 
≥30.0 kg/m2 
(N = 4,772)
b
 
P value
c
 
Baseline      
SBP (mm Hg) 138.80 ± 30.09 138.78 ± 13.81 138.60 ± 12.60 138.94 ± 39.65  0.889 
DBP (mm Hg) 84.49 ± 29.33 82.19 ± 25.02 84.34 ± 33.30 85.19 ± 27.59 0.005 
LDL-C (mg/dL) 142.94 ± 29.51 143.48 ± 28.69 144.80 ± 30.63 141.62 ± 28.93 <0.001 
HDL-C (mg/dL) 50.90 ± 14.14 59.76 ± 16.80 52.08 ± 13.78 47.86 ± 12.44 <0.001 
Total cholesterol (mg/dL) 217. 23 ± 40.15 220.30 ± 37.82 218.45 ± 39.89 215.64 ± 40.83 <0.001 
Triglyceride (mg/dL) 174.61 ± 104.79 140.19 ± 76.94 166.79 ± 96.15 188.47 ± 113.41 <0.001 
      
Post-index      
SBP (mm Hg) 134.79 ± 25.59 134.26 ± 13.1 134.64 ± 11.91 135.02 ± 33.33 0.601 
DBP (mm Hg) 81.25 ± 14.27 78.50 ± 13.08 80.87 ± 14.52 82.22 ± 14.31 <0.001 
LDL-C (mg/dL) 123.20 ± 31.69 125.04 ± 31.31 123.76 ± 32.15 122.35 ± 31.47 0.013 
HDL-C (mg/dL) 50.50 ± 14.28 59.76 ± 17.14 51.68 ± 13.75 47.34 ± 12.53 <0.001 
Total cholesterol (mg/dL) 202.66 ± 38.31 208.41 ± 37.53 203.45 ± 38.67 200.65 ± 38.11 <0.001 
Triglyceride (mg/dL) 163.58 ± 87.50 133.58 ±74.15 155.84 ± 81.49 176.24 ± 91.82 <0.001 
DBP: Diastolic blood pressure; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; SBP: Systolic blood pressure 
aOne-way ANOVA was utilized for analyses 
bResults are presented as Mean ± SD 
cSignificance tested at P<0.05
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Objective 2: To examine variations in BP and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia stratified by BMI. 
For BP and LDL-C, patients were classified into two categories: those at goal (BP 
or LDL-C) and not at goal (BP or LDL-C).  These goals were based on the JNC 7 and the 
NCEP ATP III guidelines.  Using descriptive analyses, frequencies were reported for 
categorical variables across the three BMI categories and the cohorts were compared 
using two-way contingency table analysis.  In addition to the evaluation of variations in 
attainment of post-index LDL-C goals, variations in other lipids (HDL-C, total 
cholesterol, and triglycerides) were evaluated across the three BMI categories. 
 
Variations in BP goal attainment by BMI 
 Two-way contingency table analysis (Figure 10) indicated a significant difference 
(P<0.001) in BP goal attainment across BMI.  Overall, 15% of patients attained BP goals 
and 85% did not attain BP goals.  Among patients who attained BP goals, higher 
proportion of patients had normal-weight (19.6%) followed by those who were 
overweight (16.1%) or obese (13.2%).  Among patients who did no attain BP goals, 
higher proportion of patients were obese (86.8%) followed by those who were 
overweight (83.9%) or normal-weight (80.4%).  Clearly, BP goal attainment was lower 
among patients who were obese. 
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Figure 10: Variations in BP goal attainment by body mass index
a
 (N = 9,086). 
 
BP: Blood pressure 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
 
P < 0.001 
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Variations in LDL-C goal attainment by BMI 
 Two-way contingency table analysis (Figure 11) indicated a significant difference 
(P<0.05) in LDL-C goal attainment across BMI.  Overall, 26% of patients attained LDL-
C goals and 74% did not attain LDL-C goals.  Among patients who attained LDL-C 
goals, higher proportion of patients were overweight (27.6%) followed by normal-weight 
(26.0%) and obese (25.0%).  Among patients who did not attain LDL-C goals, higher 
proportion of patients were obese (75.0%) followed by normal-weight (74.0%) and 
overweight (72.4%) patients.  Similar to results seen in BP control, LDL-C goal 
attainment was lower among obese patients. 
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Figure 11: Variations in LDL-C goal attainment by body mass index
a
 (N = 9,086). 
 
LDL-C: Low-density lipoprotein cholesterol 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
 
P = 0.038 
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Variations in combined BP and LDL-C goals by BMI 
 Two-way contingency table analysis (Figure 12) indicated a significant difference 
(P<0.001) in combined BP and LDL-C goal attainment across BMI.  Overall, most of the 
patients (64.1%) did not attain combined BP and LDL-C goals compared to 33.1% of 
patients who attained either one or both of these goals.  Among patients, who did not 
attain combined BP and LDL-C goals, most of them were obese (66.3%) compared to 
normal-weight (60.4%) or overweight (62.0%).  For patients attaining one or both of 
these goals, most of them had normal-weight (39.6%) followed by overweight (38.0%) 
compared to obese patients (33.7%).  Again, higher proportions of patients who were 
obese were not at combined BP and LDL-C goals. 
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Figure 12: Variations in combined BP and LDL-C goals by body mass index
a
 (N = 
9,086). 
 
BP: Blood pressure; LDL-C: Low-density lipoprotein cholesterol 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
P < 0.001 
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Variations in HDL-C levels by BMI 
 Two-way contingency table analysis (Figure 13) indicated a significant difference 
(P<0.05) in HDL-C levels across BMI.  As per the NCEP ATP III guidelines, HDL-C 
levels ≥ 40 mg/dL are considered desirable.  Overall, 75.7% of patients had HDL-C < 40 
mg/dL and 24.3% had HDL-C ≥ 40 mg/dL.  Among patients who had HDL-C < 40 
mg/dL, higher proportion of patients were obese (77.1%) followed by overweight 
(74.0%) and normal-weight (66.0%).  Among patients who had HDL-C ≥ 40 mg/dL, 
higher proportion of patients had normal-weight (34.0%) followed by overweight 
(26.0%) and obese (22.9%) patients.  Thus, higher proportion of patients who were obese 
had less than the desirable HDL-C levels. 
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Figure 13: Variations in HDL-C levels by body mass index
a
 (N = 1,852). 
 
HDL-C: High density lipoprotein cholesterol 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
P = 0.026 
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Variations in total cholesterol levels by BMI 
Two-way contingency table analysis (Figure 14) indicated a significant difference 
(P<0.001) in total cholesterol levels across BMI.  As per the NCEP ATP III guidelines, 
total cholesterol levels < 200 mg/dL are considered desirable.  Overall, 33.7% of patients 
had total cholesterol levels < 200 mg/dL and 66.3% had total cholesterol levels ≥ 200 
mg/dL.  Among patients with total cholesterol levels < 200 mg/dL, higher proportion of 
patients were obese (36.2%) followed by overweight (33.1%) and normal-weight (26.2%) 
patients.  Among patients with total cholesterol levels ≥ 200 mg/dL, higher proportion of 
patients were normal-weight (73.8%) followed by overweight (66.9%) and obese (63.8%) 
patients.  Interestingly, higher proportion of obese patients had desirable total cholesterol 
levels compared to patients who had normal-weight or were overweight. 
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Figure 14: Variations in total cholesterol levels by body mass index
a
 (N = 4,852). 
 
a
Two-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
 
P < 0.001 
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Variations in triglyceride levels by BMI 
Two-way contingency table analysis (Figure 15) indicated a significant difference 
(P<0.001) in triglyceride levels across BMI.  According to the NCEP ATP III guideline, 
triglyceride levels < 150 mg/dL are considered desirable.  Overall, 25.4% of patients had 
triglyceride levels < 150 mg/dL and 74.6% had triglyceride levels ≥ 150 mg/dL.  Among 
patients with triglyceride levels < 150 mg/dL, higher proportion of patients had normal-
weight (35.2%) followed by overweight (28.6%) and obese (22.3%) patients.  Among 
patients with triglyceride levels ≥ 150 mg/dL, higher proportion of patients were obese 
(77.7%) followed by overweight (71.4%) and normal-weight (64.8%) patients.  Thus, 
higher proportion of patients who were obese did not have desirable triglyceride levels. 
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Figure 15: Variations in triglyceride levels by body mass index
a
 (N = 4,267). 
 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
 
P < 0.001 
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Objective 3: To examine variations in hypertension and dyslipidemia medication 
utilization pattern based on JNC 7 and NCEP ATP III guidelines, respectively in 
patients with concomitant hypertension and dyslipidemia stratified by BMI. 
 Using descriptive analyses, frequencies were reported for categorical variables 
across the three BMI categories and the cohorts were compared using two-way 
contingency table analysis.  Medication utilization pattern comprises of type of 
medication (antihypertensive or antilipemic), medication class, and number of 
medications.  Medication prescribing pattern for anti-hypertensive and antilipemic 
medication was evaluated for both baseline and follow-up. 
 
Variation in antihypertensive and/or antilipemic medications use at baseline and during 
follow-up by BMI 
Two-way contingency table analysis (Figure 16) indicated that there was a 
significant (P<0.05) relationship between medication type (antihypertensive or 
antilipemic) and BMI at baseline as well as during follow-up.  Regarding medication 
prescribing pattern at baseline and during follow-up, 36.1% and 30.1% of total 
population was prescribed both antihypertensive and antilipemic medications; 37.2% and 
30.2% were prescribed only antihypertensives; 9.1% and 15.7% were prescribed only 
antilipemics; and 17.6% and 24.1% were not prescribed any medication.  Patients who 
were obese were more likely to be prescribed both antihypertensive and antilipemic; 
baseline (37.3%) as well as during follow-up (31.6%).  In addition, patients who were 
obese had less likelihood of not being prescribed any medication; baseline (16.8%) and 
follow-up (22.8%).  However, patients who had normal-weight were more likely to be 
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prescribed only antihypertensive medication both at baseline (39.4%) and follow-up 
(32.8%).  Patients who were overweight were more likely to be prescribed only 
antilipemic medication both at baseline (10.1%) and follow-up (16.8%). 
 
Variations in total number of medications (combining both antihypertensive and 
antilipemic) at baseline and during follow-up by BMI 
Two-way contingency table analysis (Figure 17) indicated that there was a 
significant (P<0.05) relationship between total number of medications (combining both 
antihypertensive and antilipemic) and BMI at baseline.  Most of the patients were 
prescribed one medication both at baseline (26.2%) and during follow-up (31.5%).  
Patients who were obese were less likely to be not prescribed any medication; baseline 
(16.8%) and follow-up (22.8%).  However, patients who were obese were more likely to 
be prescribed at least four medications; baseline (19.7%) and follow-up (11.1%).   
For patients who were prescribed one, two or three medications, a different pattern was 
observed at baseline and during follow-up across BMI.  At baseline, patients with 
normal-weight (28.3%) were more likely to be prescribed one medication whereas during 
follow-up, patients who were overweight (32.5%) were more likely to be prescribed one 
medication.  At baseline, patients who were overweight were more likely to be prescribed 
two (23.6%) or three (16.0%) medications.  However, during follow-up, obese patients 
were more likely to be prescribed two (22.4%) or three (12.7%) medications. 
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Figure 16: Variations in medication type (antihypertensive or antilipemic) at baseline and post-index by body mass index
a
 (N = 
9,086). 
 
AH: Antihypertensives; AL: Antilipemics 
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
Baseline Post-index 
P = 0.001 P < 0.001 
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Figure 17: Variations in total number of medications (combining both antihypertensive and antilipemic) at baseline by BMI
a
 
(N = 9,086). 
 
AH: Antihypertensives; AL: Antilipemics 
aTwo-way contingency analysis was utilized for analysis.  
Significance tested at P<0.05. 
 
 
Baseline Post-index 
P = 0.001 P = 0.004 
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Variations in antihypertensive medication utilization at baseline and during follow-up by 
BMI 
Two-way contingency table analysis (Table 12 and Table 13) was conducted to 
evaluate baseline antihypertensive medication prescribing pattern across three BMI 
categories.  The baseline medication-related factors that showed significant variation 
(P<0.05) across BMI included antihypertensive medication class such as ACEI, thiazide 
diuretics, and other diuretics, combination therapy (ACEIs and diuretics), and number of 
medications.  The follow-up medication-related factors that showed significant (P<0.05) 
variation across BMI included antihypertensive medication class such as ACEI, CCB, 
and other diuretics.  Among total population, most patients were prescribed ACEI both at 
baseline (30.0%) and during follow-up (23.4%) followed by BBs (baseline, 29.0% and 
follow-up, 18.5%). 
 ACEIs were more likely to be prescribed to patients who were obese; baseline 
(32.1%) and during follow-up (25.3%).  At baseline, thiazide diuretics were significantly 
more likely to be prescribed to patients who were obese (17.8%), but during follow-up, 
no significant difference was observed across BMI.  At baseline, ACEI-diuretic 
combination was significantly more likely to be prescribed to patients who were 
overweight (5.5%), but no significant difference was observed across BMI. 
 At baseline, most patients (36.1%) were prescribed one antihypertensive 
medication followed by 26.7% who were not prescribed any medication.  However, 
during follow-up, most patients were not prescribed any medication (39.8%).  Patients 
who were obese were significantly less likely to be not prescribed any medication 
(25.1%), but significantly were more likely to be prescribed at least four medications 
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(11.4%) at baseline.  However, during follow-up, no significant difference regarding 
number of medications was observed across BMI. 
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Table 12: Variations in antihypertensive medication utilization at baseline by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
c
 
≤24.9 kg/m2 
(N = 1,256)
c
  
25.0-29.9 kg/m
2
 
(N = 3,058)
c
 
≥30.0 kg/m2 
(N = 4,772)
c
 
P value
b
 
Medication class-Monotherapy (Prescribed)d 
ACEI 2726 (30.0%) 342 (27.2%) 851 (27.8%) 1533 (32.1%) <0.001 
ARB 1150 (12.7%) 152 (12.1%) 368 (12.0%) 630 (13.2%) 0.258 
BB 2636 (29.0%) 375 (29.9%) 904 (29.6%) 1357 (28.4%) 0.438 
CCB 1861 (20.5%) 283 (22.5%) 602 (19.7%) 976 (20.5%) 0.321 
Combined alpha- & BBs 271 (3.0%) 37 (2.9%) 86 (2.8%) 148 (3.1%) 0.761 
Alpha 1 blockers 472 (5.2%) 48 (3.8%) 166 (5.4%) 258 (5.4%) 0.061 
Thiazide diuretics 1519 (16.7%) 181 (14.4%) 490 (16.0%) 848 (17.8%) 0.008 
Other diuretics 839 (9.2%) 100 (8.0%) 189 (6.2%) 550 (11.5%) <0.001 
Other antihypertensives 578 (6.4%) 80 (6.4%) 176 (5.8%) 322 (6.7%) 0.214 
      
Medication class-Combination therapy (Prescribed)d 
ACEIs and CCBs 313 (3.4%) 45 (3.6%) 94 (3.1%) 174 (3.6%) 0.383 
ACEIs and diuretics 439 (4.8%) 39 (3.1%) 138 (5.5%) 229 (4.8%) 0.001 
ARBs and diuretics 742 (8.2%) 89 (7.1%) 254 (8.3%) 399 (8.4%) 0.320 
BBs and diuretics 102 (1.1%) 14 (1.1%) 32 (1.0%) 56 (1.2%) 0.873 
Diuretic and diuretic 466 (5.1%) 58 (4.6%) 161 (5.3%) 247 (5.2%) 0.666 
      
No. of medications     0.002 
0 2424 (26.7%) 362 (28.8%) 862 (28.2%) 1200 (25.1%)  
1 2777 (30.6%) 385 (30.7%) 953 (31.2%) 1439 (30.2%)  
2 1893 (20.8%) 247 (19.7%) 628 (20.5%) 1018 (21.3%)  
3 1057 (11.6%) 148 (11.8%) 339 (11.1%) 570 (11.9%)  
≥4 935 (10.3%) 114 (9.1%) 276 (9.0%) 545 (11.4%)  
ACEI: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin II receptor blocker; BB: Beta blocker; CCB: Calcium channel blocker 
Combination therapy: Fixed-dose combination of antihypertensive medications 
aTwo-way contingency analysis was utilized; bSignificance tested at P<0.05 
cColumn percentages are reported unless otherwise specified. Data presented as N (%). 
dN (%) represents percentage of patients prescribed above mentioned antihypertensives.  Comparison group is the above mentioned specific antihypertensive not 
prescribed. 
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Table 13: Variations in antihypertensive medication utilization at follow-up by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
c
 
≤24.9 kg/m2 
(N = 1,256)
c
  
25.0-29.9 kg/m
2
 
(N = 3,058)
c
 
≥30.0 kg/m2 
(N = 4,772)
c
 
P value
b
 
Medication class-Monotherapy (Prescribed)d 
ACEI 2126 (23.4%) 277 (22.1%) 644 (21.1%) 1205 (25.3%) <0.001 
ARB 844 (9.3%) 98 (7.8%) 301 (9.8%) 445 (9.3%) 0.110 
BB 1678 (18.5%) 251 (20.0%) 571 (18.7%) 856 (17.9%) 0.235 
CCB 1268 (14.0%) 204 (16.2%) 425 (13.9%) 639 (13.4%) 0.034 
Combined alpha- & BBs 303 (3.3%) 37 (2.9%) 94 (3.1%) 172 (3.6%) 0.315 
Alpha 1 blockers 349 (3.8%) 47 (3.7%) 111 (3.6%) 191 (4.0%) 0.691 
Thiazide diuretics 1016 (11.2%) 129 (10.3%) 337 (11.0%) 550 (11.5%) 0.428 
Other diuretics 712 (7.8%) 90 (7.2%) 183 (6.0%) 439 (9.2%) <0.001 
Other antihypertensives 465 (5.1%) 64 (5.1%) 152 (5.0%) 249 (5.2%) 0.889 
      
Medication class-Combination therapy (Prescribed)d 
ACEIs and CCBs 197 (2.2%) 32 (2.5%) 61 (2.0%) 104 (2.2%) 0.525 
ACEIs and diuretics 422 (4.6%) 45 (3.6%) 141 (4.6%) 236 (4.9%) 0.124 
ARBs and diuretics 485 (5.3%) 68 (5.4%) 162 (5.3%) 255 (5.3%) 0.988 
BBs and diuretics 62 (0.7%) 9 (0.7%) 22 (0.7%) 31 (0.6%) 0.924 
Diuretic and diuretic 206 (2.3%) 36 (2.9%) 68 (2.2%) 102 (2.1%) 0.298 
      
No. of medications     0.110 
0 3615 (39.8%) 500 (39.8%) 1278 (41.8%) 1837 (38.5%)  
1 2806 (30.9%) 397 (31.6%) 940 (30.7%) 1469 (30.8%)  
2 1470 (16.2%) 201 (16.0%) 455 (14.9%) 814 (17.1%)  
3 702 (7.7%) 91 (7.2%) 224 (7.3%) 387 (8.1%)  
≥4 493 (5.4%) 67 (5.3%) 161 (5.3%) 265 (5.6%)  
ACEI: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin II receptor blocker; BB: Beta blocker; CCB: Calcium channel blocker 
Combination therapy: Fixed-dose combination of antihypertensive medications 
aTwo-way contingency analysis was utilized; bSignificance tested at P<0.05 
cColumn percentages are reported unless otherwise specified. Data presented as N (%). 
dN (%) represents percentage of patients prescribed above mentioned antihypertensives.  Comparison group is the above mentioned specific antihypertensive not 
prescribed. 
 
 
 100 
 
Variations in antilipemic medication utilization at baseline and during follow-up by BMI 
Two-way contingency table analysis (Table 14 and Table 15) was conducted to 
evaluate baseline antilipemic medication prescribing pattern across the three BMI 
categories.  At baseline and during follow-up, significant difference (P<0.05) was 
observed for the antilipemic medication class such as statins and fibrates as well as 
number of medications across BMI.  Overall, most patients were prescribed statins both 
at baseline (39.6%) and during follow-up (42.4%).  At baseline, patients who were 
overweight were more likely to be prescribed statins (41.3%) whereas during follow-up, 
patients who were obese were more likely to be prescribed statins (43.6%).  Patients who 
were obese were more likely to be prescribed fibrates both at baseline (6.2%) and during 
follow-up (4.3%). 
Regarding number of antilipemic medications, most patients were not prescribed 
any antilipemic medication both at baseline (54.7%) and follow-up (54.3%) followed by 
one medication (baseline, 40.8% and follow-up, 42.2%).  Patients with normal-weight 
were more likely to be not prescribed any antilipemic medication both at baseline 
(58.6%) and follow-up (54.3%).  Patients who were overweight (41.5%) or obese 
(41.0%) were more likely to be prescribed one medications at baseline.  However, during 
follow-up, patients who were obese (43.5%) were more likely to be prescribed one 
medication.  In addition, patients who were overweight (baseline, 4.8% and follow-up, 
3.7%) or obese (baseline, 4.7% and follow-up, 3.8%) were more likely to be prescribed at 
least two medications. 
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Table 14: Variations in antilipemic medication utilization at baseline by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
b
 
≤24.9 kg/m2 
(N = 1,256)
c
  
25.0-29.9 kg/m
2
 
(N = 3,058)
c
 
≥30.0 kg/m2 
(N = 4,772)
c
 
P value
b
 
Medication class (Prescribed)d 
Statins 3602 (39.6%) 454 (36.1%) 1262 (41.3%) 1886 (39.5%) 0.007 
Fibrates 473 (5.2%) 31 (2.5%) 148 (4.8%) 294 (6.2%) <0.001 
Nicotinic acid 348 (3.8%) 59 (4.7%) 119 (3.9%) 170 (3.6%) 0.172 
Bile acid sequestrants 121 (1.3%) 20 (1.6%) 40 (1.3%) 61 (1.3%) 0.682 
      
No. of medications     0.020 
0 4974 (54.7%) 736 (58.6%) 1644 (53.8%) 2594 (54.4%)  
1 3703 (40.8%) 479 (38.1%) 1268 (41.5%) 1956 (41.0%)  
≥2 409 (4.5%) 41 (3.3%) 146 (4.8%) 222 (4.7%)  
aTwo-way contingency analysis was utilized; bSignificance tested at P<0.05 
cColumn percentages are reported unless otherwise specified. Data presented as N (%). 
dN (%) represents percentage of patients prescribed above mentioned antilipemic.  Comparison group is the above mentioned specific antilipemic not prescribed. 
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Table 15: Variations in antilipemic medication utilization during follow-up by BMI
a
 (N = 9,086) 
Variables All patients 
(N = 9,086)
c
 
≤24.9 kg/m2 
(N = 1,256)
c
  
25.0-29.9 kg/m
2
 
(N = 3,058)
c
 
≥30.0 kg/m2 
(N = 4,772)
c
 
P value
b
 
Medication class (Prescribed)d 
Statins 3850 (42.4%) 468 (37.3%) 1301 (42.5%) 2081 (43.6%) <0.001 
Fibrates 326 (3.6%) 25 (2.0%) 96 (3.1%) 205 (4.3%) <0.001 
Nicotinic acid 193 (2.1%) 23 (1.8%) 70 (2.3%) 100 (92.1%) 0.626 
Bile acid sequestrants 121 (1.3%) 22 (1.8%) 39 (1.3%) 60 (1.3%) 0.375 
      
No. of medications     <0.001 
0 4934 (54.3%) 750 (59.7%) 1669 (54.6%) 2515 (52.7%)  
1 3832 (42.2%) 477 (38.0%) 1277 (41.8%) 2078 (43.5%)  
≥2 320 (3.5%) 29 (2.3%) 112 (3.7%) 179 (3.8%)  
aTwo-way contingency analysis was utilized; bSignificance tested at P<0.05 
cColumn percentages are reported unless otherwise specified. Data presented as N (%). 
dN (%) represents percentage of patients prescribed above mentioned antilipemic.  Comparison group is the above mentioned specific antilipemic not prescribed. 
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Variations in antihypertensive medication prescribing pattern in patients with 
complicated/uncomplicated hypertension stratified by BMI 
 According to JNC7 guidelines hypertension can be classified into complicated 
(presence of diabetes and CVD) and uncomplicated hypertension (stage 1 and stage 2).  
Patients with these conditions are recommended at least two medications for treatment 
comprising of combination of different antihypertensive medication class.  For the 
purpose of analysis, patients were grouped into three categories based on number of 
medications: 0, 1 and ≥2.  These groups were compared across three BMI categories 
using two-way contingency table analysis (Figure 18). 
 For uncomplicated hypertension, there was a significant difference (P<0.05) in 
number of medications prescribed across BMI.  Overall, majority of patients (57.5%) 
were prescribed at least two mediations compared to patients who were prescribed one 
(27.6%) or no (14.7%) medication.  Among patients who were prescribed at least two 
medications, most of them were obese (60.5%) compared to the normal-weight (57.7%) 
or overweight (53.7%) patients. 
 For complicated hypertension, there was no significant difference (P>0.05) in 
number of medications prescribed across BMI.  However, most of the patients were 
prescribed at least two medications (67.1%) and included higher proportion of obese 
patients (68.4%). 
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Figure 18: Variations in antihypertensive medication prescribing pattern in patients with uncomplicated/complicated 
hypertension stratified by BMI
a
. 
 
HTN: Hypertension               
aTwo-way contingency analysis was utilized for analysis. 
Significance tested at P<0.05. 
 
P = 0.010 P = 0.193 
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Variations in antilipemic medication prescribing pattern in patients with high or very 
high cardiovascular risk stratified by BMI 
 NCEP ATP III guidelines recommend use of antilipemic medications in patients 
with high cardiovascular risk (presence of at least two risk factors) or very high 
cardiovascular risk (co-morbid conditions such as diabetes or cardiovascular conditions).  
Two-way contingency table analysis (Figure 19) indicated that there was a significant 
difference (P<0.05) in the patients who were prescribed/not prescribed any antilipemic 
medications across BMI.   
  Regarding patients with high cardiovascular risk, majority of them (69.6%) were 
prescribed medication and 30.4% were not prescribed any medication.  Among patients 
who were prescribed medication, most of them were obese (73.1%) followed by 
overweight (68.8%) or normal-weight (60.4%) patients.  Among patients who were not 
prescribed any medication, majority of them had normal-weight (39.6%) compared to 
overweight (31.2%) or obese (26.9%) patients. 
 Regarding patients with very high cardiovascular risk, majority of them (71.1%) 
were prescribed medication and 28.9% were not prescribed any medication.  Among 
patients who were prescribed medication, most of them were obese (72.2%) or 
overweight (72.4%) compared to normal-weight patients (63.2%).  Among patients who 
were not prescribed any medication, most of them had normal-weight (36.8%) compared 
to overweight (27.6%) or obese (27.8%) patients. 
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Figure 19: Variations in antilipemic medication prescribing pattern in patients with high cardiovascular risk stratified by 
BMI
a
. 
 
CV: Cardiovascular               
 
a
Two-way contingency analysis was utilized for analysis. 
 Significance tested at P<0.05. 
P = 0.009 P = 0.004 
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Objective 4: To examine predictors of BP or/and lipid goal attainment in patients with 
concomitant hypertension and dyslipidemia.   
 Logistic regression was conducted to examine whether BMI was a predictor of BP 
or/and lipid goal attainment in patients with concomitant hypertension and dyslipidemia.  
BP and LDL-C are the primary targets for treatment of hypertension and dyslipidemia, 
respectively.  For BP and/ or LDL-C, the specific goals for successful treatment of these 
conditions are provided in JNC7 and NCEP ATP III guidelines, respectively.  The 
outcome variable was goal attainment categorized as ―at goal‖ and ―not at goal‖.  The 
focus of the study was to determine predictors of inadequate goal attainment, thus ―at 
goal‖ was used as the reference category.  Moreover, other lipids (total cholesterol, 
triglyceride, and HDL-C) were also evaluated.  For these lipids, there are no specific 
goals in the guidelines, thus the outcome variable was classified into two categories based 
on the optimum levels of these lipids.  The predictor variables included age, gender, 
primary payer, patient location, BMI, presence/absence of each cardiovascular condition 
(diabetes, heart failure, myocardial infarction, angina pectoris, CAD, peripheral vascular 
disease, cerebrovascular disease, and kidney disease), hypertension stage, cardiovascular 
risk, smoking status, baseline clinical measurements (DBP, SBP, LDL-C, total 
cholesterol, HDL-C, and triglycerides), and number of antihypertensive medication and 
number of antilipemic medications used at follow-up. 
The standard logistic regression was used in which all the selected variables were 
entered into the multivariate logistic regression model simultaneously to evaluate 
association of BMI with inadequate goal attainment, while controlling for all other 
factors.  For assessing the appropriateness, adequacy, and usefulness of the model, test 
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statistics such as goodness of fit of the model, the Hosmer-Lemeshow test, and 
Nagelkerke R
2
 were evaluated (these statistics for these tests are reported under each 
table).  The goodness of fit model includes a test of the full model with all predictors 
against a constant only model and a statistically significant test (P<0.05) indicates that 
the predictors, as a set, reliably distinguishes between the categories of outcome variable.  
The goodness of fit of a model is also indicated by the Hosmer-Lemeshow test and non-
significant test (P>0.05) indicates that the observed values are not significantly different 
from those predicted by the model and that the overall model fit is good.  Nagelkerke R
2
 
indicates the usefulness of the explanatory variables in the model in predicting the 
response variable and can be referred to as measure of effect size.  For each of the 
predictors included in the model, Wald statistics, odds ratio, P value, and 95% confidence 
intervals were reported.  The significant predictors were then entered into stepwise 
regression model using Forward LR method to evaluate the contribution of each of these 
predictors.  
 
Predictors of inadequate BP goal attainment 
The results of standard logistic regression are presented in Table 16.  In 
multivariate logistic regression analysis, BMI was significantly associated with BP goal 
attainment in patients with concomitant hypertension and dyslipidemia (P<0.001).  
Increase in BMI increased the likelihood of not attaining BP goal: overweight 
(OR=1.345, P=0.003) and obese (OR=1.562, P<0.001) each versus normal-weight 
patients. 
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Age was also significantly associated with BP goal attainment (P=0.001).  
Increase in age was more likely to be associated with not attaining BP goals: 56-64 year 
old (OR=1.494, P=0.003), 65-74 year old (OR=1.433, P=0.002), and ≥75 (OR=2.131, 
P<0.001) each versus 18-44 year old.  However, no significant difference was observed 
in age group 45-55 year olds when compared to 18-44 year olds.  Females were more 
likely to be associated with not attaining goals (OR=1.214, P=0.007) compared to males. 
Increased likelihood of not attaining BP goals was also associated in patients with 
diabetes (OR=3.803, P<0.001) versus those not having diabetes and patients with kidney 
disease (OR=2.302, P=0.001) versus those not having kidney disease.  However, patients 
with CAD (OR=0.702, P=0.004) were less likely to have inadequate goal attainment 
versus patients who did not have CAD.  Regarding hypertension stage, patients with 
stage 1 (OR=1.888, P<0.001) and stage 2 hypertension (OR=2.244, P<0.001) were more 
likely to have inadequate BP goals compared with patients with prehypertension and 
likelihood of not attaining goals increased with higher BP levels.  Moreover, BP goals 
were not attained in patients with high (≥240 mg/dL) total cholesterol levels (OR=1.397, 
P=0.006). 
Number of antihypertensive medications used at follow-up were also associated 
with BP goal attainment.  Increase in the number of medications resulted in increased 
likelihood of not attaining BP goals: one medication (OR=1.495, P<0.001), two 
medications (OR=2.222, P<0.001), three medications (OR=2.981, P<0.001), and at least 
four medications (OR=5.410, P<0.001) each versus no medication. 
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Table 16: Multivariate analysis of factors associated with inadequate BP goal 
attainment
a
 (N = 9,086) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories 20.094  .000   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 8.984 1.345 .003 1.108 1.632 
≥30.0 kg/m2 19.985 1.562 .000 1.285 1.900 
      
Age (years) 26.887  .000   
18-44 Reference     
45-55 1.278 1.149 .258 .903 1.462 
56-64 8.787 1.494 .003 1.146 1.948 
65-74 9.763 1.601 .002 1.192 2.151 
≥75 20.859 2.131 .000 1.540 2.948 
      
Gender      
Male Reference     
Female 7.202 1.214 .007 1.054 1.399 
      
Primary payer 8.416  .077   
Medicare Reference     
Medicaid .064 .952 .800 .648 1.397 
Private  3.354 .837 .067 .692 1.013 
Self-pay 1.441 1.220 .230 .882 1.688 
Other .744 .765 .388 .415 1.407 
      
Patient location      
Urban  Reference     
Rural 3.461 1.137 .063 .993 1.303 
      
CV conditions (present)c      
Diabetes 111.141 3.803 .000 2.967 4.876 
Heart failure .781 .840 .377 .572 1.236 
Myocardial infarction 2.530 .738 .112 .507 1.073 
Angina pectoris 1.075 .763 .300 .457 1.272 
Coronary artery disease 8.162 .702 .004 .550 .895 
Peripheral vascular disease .212 1.068 .645 .807 1.415 
Cerebrovascular disease 1.350 1.178 .245 .894 1.552 
Kidney disease 11.663 2.302 .001 1.427 3.715 
      
Hypertension stage (baseline) 92.190  .000   
Prehypertension Reference     
Stage 1 72.930 1.888 .000 1.632 2.185 
Stage 2 35.158 2.244 .000 1.718 2.931 
      
LDL-C (baseline) 5.542  .063   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) .015 .986 .903 .781 1.243 
High/very high (≥160 mg/dL) 2.668 .791 .102 .598 1.048 
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Table 16 (continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline) 7.652  .022   
Desirable (<200 mg/dL) Reference     
Borderline high (200-239 mg/dL) 2.557 1.154 .110 .968 1.376 
High (≥240 mg/dL) 7.649 1.397 .006 1.102 1.770 
      
Triglyceride (baseline) 2.304  .316   
Desirable (<150 mg/dL) Reference     
Borderline high (150-199 mg/dL) 1.124 1.094 .289 .926 1.292 
High/very high (≥200 mg/dL) 1.927 1.128 .165 .951 1.338 
      
HDL-C (baseline)      
Low (<40 mg/dL) Reference     
Desirable (≥40 mg/dL) 2.570 1.157 .109 .968 1.382 
      
Smoking status 1.823  .610   
Non-smoker Reference     
Current .596 .920 .440 .745 1.137 
Former-smoker 1.577 .911 .209 .787 1.054 
      
Cardiovascular risk 1.156  .561   
Low Reference     
Intermediate .700 1.132 .403 .847 1.513 
High 1.141 1.224 .285 .844 1.775 
      
No. of antihypertensive medications 113.186  .000   
0 Reference     
1 29.691 1.495 .000 1.294 1.728 
2 54.796 2.222 .000 1.798 2.744 
3 39.169 2.981 .000 2.117 4.196 
≥4 33.385 5.410 .000 3.051 9.591 
      
No. of antilipemic medications 3.110  .211   
0 Reference     
1 .647 .946 .421 .826 1.083 
≥2 2.008 1.341 .156 .894 2.013 
CV: Cardiovascular; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein 
cholesterol 
aStandard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 845.085, P<0.001. 
Hosmer-Lemeshow test: P = 0.314. 
Variance in BP goal attainment (Nagelkerke R square test): 16.9%.   
Percentage of cases correctly classified by the model: 84.7%. 
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Stepwise logistic regression (Table 17) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 15) accounted for 
16.5% of the variance in BP goal attainment.  Presence/absence of diabetes accounted for 
7.4% of the variance.  Presence/absence of diabetes and hypertension stage 1 together 
accounted for 9.1% of variance.   
The other significant predictors were added in the model in the following 
sequence: hypertension stage 2, age group ≥75 years, number of antihypertensive 
medications = 2, number of antihypertensive medications ≥4, number of antihypertensive 
medications = 3, number of antihypertensive medications = 1, gender (female), 
presence/absence of kidney disease, age group 56-64 years, presence/absence of CAD, 
age group 45-55 years, BMI ≥30.0 kg/m2, and BMI 25.0-29.9 kg/m2.   
BMI 25.0-29.9 kg/m
2 
added at Step 14 and BMI ≥30.0 kg/m2 added at Step 15 
together with other variables (Presence/absence of diabetes, hypertension stage 1, 
hypertension stage 2, age group ≥75 years, number of antihypertensive medications = 2, 
number of antihypertensive medications ≥4, number of antihypertensive medications = 3, 
number of antihypertensive medications = 1, gender (female), presence/absence of kidney 
disease, age group 56-64 years, presence/absence of CAD, age group 45-55 years) 
accounted for 16.5% of variance. 
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Table 17: Stepwise logistic regression for BP goal attainment 
Steps Variables R
2
 
Step1 DM 0.074 
   
Step2 DM; hypertension stage 1 0.091 
   
Step3 DM; hypertension stage 1; hypertension stage 2 0.108 
   
Step4 DM; hypertension stage 1; hypertension stage 2; age ≥75 years 0.119 
   
Step5 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2 
0.125 
   
Step6 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2, ≥4 
0.134 
   
Step7 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2, ≥4, 3 
0.140 
   
Step8 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2, ≥4, 3, 1 
0.146 
   
Step9 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2, ≥4, 3, 1; gender 
0.150 
   
Step10 DM; hypertension stage 1; hypertension stage 2; age ≥75 years; number of 
antihypertensive medications = 2, ≥4, 3, 1; gender; kidney disease 
0.153 
   
Step11 DM; hypertension stage 1; hypertension stage 2; age ≥75 years, 65-74 years; kidney 
disease; number of antihypertensive medications = 2, ≥4, 3, 1; gender 
0.155 
   
Step12 DM; hypertension stage 1; hypertension stage 2; age ≥75 years, 65-74 years; kidney 
disease; number of antihypertensive medications = 2, ≥4, 3, 1; gender; CAD 
0.158 
   
Step13 DM; hypertension stage 1; hypertension stage 2; age ≥75 years, 65-74 years, 45-55 
years; kidney disease; number of antihypertensive medications = 2, ≥4, 3, 1; gender; 
CAD 
0.161 
   
Step14 DM; hypertension stage 1; hypertension stage 2; age ≥75 years, 65-74 years, 45-55 
years; kidney disease; number of antihypertensive medications = 2, ≥4, 3, 1; gender; 
CAD; BMI ≥30.0 kg/m2 
0.162 
   
Step15 DM; hypertension stage 1; hypertension stage 2; age ≥75 years, 65-74 years, 45-55 
years; kidney disease; number of antihypertensive medications = 2, ≥4, 3, 1; gender; 
CAD; BMI ≥30.0 kg/m2; BMI 25.0-29.9 kg/m2 
0.165 
BMI: Body mass index; BP: Blood pressure; DM: Diabetes mellitus; CAD: Coronary artery disease 
R2 reported is Nagelkerke R square 
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Predictors of LDL-C goal attainment 
The results of standard logistic regression are presented in Table 18.  In 
multivariate logistic regression analysis, BMI was not a significant predictor of LDL-C 
goal attainment (P=0.845) in patients with concomitant hypertension and dyslipidemia.  
Regarding gender, females (OR=1.137, P=0.026) were more likely to be associated with 
not attaining LDL-C goals. 
Patients with diabetes (OR=1.630, P<0.001) were more likely to be associated 
with not attaining LDL-C goals compared with patients not having diabetes.  However, 
patients with angina pectoris versus not having angina pectoris (OR=0.504, P=0.001) and 
patients with kidney disease versus not having kidney disease (OR=0.655, P<0.001) were 
less likely to be associated with not attaining LDL-C goals.  The likelihood of not 
attaining LDL-C goal increased with increase in cardiovascular risk: patients at 
intermediate cardiovascular risk (OR=1.885, P<0.001) and patients at high 
cardiovascular risk (OR=3.550, P<0.001) each versus patients at low cardiovascular risk. 
Regarding baseline clinical measurements, patients with borderline high 
(OR=1.233, P=0.017) or high/very high (OR=1.253, P=0.047) LDL-C had increased 
likelihood of not attaining LDL-C goals.  Similarly, patients with borderline high 
(OR=2.005, P<0.001) or high (OR=3.523, P<0.001) total cholesterol were more likely to 
fail to attain LDL-C goals.  However, patients with high/very high triglycerides 
(OR=0.861, P=0.031) were less likely to fail to attain LLD-C goals.  Patients prescribed 
one antihypertensive medication had increased likelihood of not attaining BP goals 
(OR=1.139, P=0.037).  However, patients prescribed one antilipemic medication were 
less likely to fail to attain LDL-C goals (OR=0.666, P<0.001). 
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Table 18: Multivariate analysis of factors associated with inadequate LDL-C goal 
attainment
a
 (N = 9,086) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories .336  .845   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 .302 .955 .582 .809 1.126 
≥30.0 kg/m2 .086 .976 .769 .827 1.151 
      
Age (years) 5.948  .203   
18-44 Reference     
45-55 .097 .965 .755 .773 1.206 
56-64 .329 .933 .567 .736 1.183 
65-74 2.363 .819 .124 .636 1.056 
≥75 3.087 .786 .079 .602 1.028 
      
Gender      
Male Reference     
Female 4.985 1.137 .026 1.016 1.273 
      
Primary payer 2.431  .657   
Medicare Reference     
Medicaid .672 1.135 .412 .839 1.536 
Private  .016 .991 .899 .861 1.140 
Self-pay .931 1.121 .335 .889 1.415 
Other .455 1.202 .500 .705 2.048 
      
Patient location      
Urban  Reference     
Rural .122 1.019 .727 .915 1.136 
      
CV conditions (present)c      
Diabetes 30.642 1.630 .000 1.371 1.937 
Heart failure .976 .880 .323 .684 1.133 
Myocardial infarction 1.524 .829 .217 .616 1.116 
Angina pectoris 11.001 .504 .001 .337 .756 
Coronary artery disease .355 1.054 .551 .887 1.252 
Peripheral vascular disease 1.335 1.127 .248 .920 1.380 
Cerebrovascular disease .826 .917 .363 .762 1.105 
Kidney disease 12.773 .655 .000 .519 .826 
      
Hypertension stage (baseline) .566  .754   
Prehypertension Reference     
Stage 1 .000 .999 .985 .893 1.117 
Stage 2 .517 1.070 .472 .889 1.288 
      
LDL-C (baseline) 5.964  .051   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) 5.741 1.233 .017 1.039 1.464 
High/very high (≥160 mg/dL) 3.948 1.253 .047 1.003 1.565 
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Table 18 (Continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline) 166.981  .000   
Desirable (<200 mg/dL) Reference     
Borderline high (200-239 mg/dL) 98.698 2.005 .000 1.748 2.300 
High (≥240 mg/dL) 151.827 3.523 .000 2.883 4.304 
      
Triglyceride (baseline) 5.239  .073   
Desirable (<150 mg/dL) Reference     
Borderline high (150-199 mg/dL) .006 .995 .939 .872 1.135 
High/very high (≥200 mg/dL) 4.667 .861 .031 .752 .986 
      
HDL-C (baseline)      
Low (<40 mg/dL) Reference     
Desirable (≥40 mg/dL) .403 .955 .525 .830 1.100 
      
Smoking status 3.996  .262   
Non-smoker Reference     
Current 2.335 1.154 .126 .960 1.387 
Former-smoker .188 .975 .665 .868 1.095 
      
Cardiovascular risk 69.051  .000   
Low Reference     
Intermediate 22.350 1.885 .000 1.449 2.451 
High 63.941 3.550 .000 2.602 4.842 
      
No. of antihypertensive medications 5.395  .249   
0 Reference     
1 4.339 1.139 .037 1.008 1.288 
2 1.206 1.089 .272 .935 1.269 
3 .052 .976 .820 .795 1.200 
≥4 .019 1.018 .890 .792 1.308 
      
No. of antilipemic medications 60.222  .000   
0 Reference     
1 54.562 .666 .000 .598 .742 
≥2 .991 1.171 .320 .858 1.597 
CV: Cardiovascular; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein 
cholesterol 
aStandard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 554.993, P<0.001. 
Hosmer-Lemeshow test: P = 0.055. 
Variance in LDL-C goal attainment (Nagelkerke R square test): 11.9%.   
Percentage of cases correctly classified by the model: 73.4%. 
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Stepwise logistic regression (Table 19) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 11) accounted for 
8.3% of the variance in LDL-C goal attainment.  Baseline high total cholesterol 
accounted for 1.9% of the variance.  Baseline total cholesterol and diabetes together 
accounted for 3.9% of variance. 
The other significant predictors were added in the model in the following 
sequence: borderline high total cholesterol at baseline, number of antilipemic medications 
= 1, high cardiovascular risk, intermediate cardiovascular risk, kidney disease, angina 
pectoris, gender, high/very high LDL-C, borderline high LDL-C at baseline. 
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Table 19: Stepwise logistic regression for LDL-C goal attainment 
Steps Variables R
2
 
Step1 High total cholesterol at baseline 0.019 
   
Step2 High total cholesterol at baseline; DM 0.039 
   
Step3 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline 0.056 
   
Step4 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1 
0.065 
   
Step5 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk 
0.072 
   
Step6 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk 
0.076 
   
Step7 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk; KD 
0.078 
   
Step8 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk; KD; 
angina pectoris 
0.080 
   
Step9 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk; KD; 
angina pectoris; gender 
0.081 
   
Step10 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk; KD; 
angina pectoris; gender; high/very high LDL-C at baseline 
0.081 
   
Step11 High total cholesterol at baseline; DM; borderline high total cholesterol at baseline; 
number of antilipemic medications = 1; high CV risk; intermediate CV risk; KD; 
angina pectoris; gender; high/very high LDL-C; borderline high LDL-C at baseline 
0.083 
DM: Diabetes mellitus; CV: cardiovascular risk; KD: Kidney disease; LDL-C: Low-density lipoprotein 
cholesterol 
R2 reported is Nagelkerke R square 
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Predictors of inadequate BP and LDL-C (combined) goal attainment 
The results of standard logistic regression are presented in Table 20.  In 
multivariate logistic regression analysis, patients who were obese had increased 
likelihood of failure to attain dual BP and LDL-C goal (OR=1.193, P=0.023).  Regarding 
gender, females (OR=1.197, P=0.001) were more likely to be associated with not 
attaining combined goals. 
Patients with diabetes versus not having diabetes (OR=2.241, P<0.001) were 
more likely to be associated with not attaining combined goal whereas patients with 
angina pectoris versus not having angina pectoris (OR=0.586, P=0.008) were less likely 
to be associated with not attaining combined goals.  Patients with stage 1 (OR=1.320, 
P<0.001) and stage 2 hypertension (OR=1.456, P<0.001), each versus prehypertension 
were more likely to be associated with not attaining combined BP and LDL-C goals.  
Increased cardiovascular risk increased the likelihood of not attaining combined goals: 
intermediate cardiovascular risk (OR=1.668, P<0.001) and high cardiovascular risk 
(OR=2.718, P<0.001) each versus low cardiovascular risk.  Patients with borderline high 
LDL-C were more likely to be associated with not attaining combined BP/LDL-C goals 
(OR=1.209, P=0.019).  In addition presence of borderline high total cholesterol 
(OR=1.676, P<0.001) or high/very high total cholesterol (OR=2.765, P<0.001) increased 
the likelihood of not attaining combined goals. 
Patients prescribed one antilipemic medication were less likely to be associated 
with not attaining combined goals (OR=0.720, P<0.001) versus patients prescribed no 
medication.  Increased likelihood of not attaining combined goals was associated with 
increase in number of prescribed antihypertensive medications: one medication 
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(OR=1.320, P<0.001), two medications (OR=1.382, P<0.001), three medications 
(OR=1.390, P=0.001), at least four medications (OR=1.415, P=0.005) each versus no 
medication. 
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Table 20: Multivariate analysis of factors associated with inadequate combined BP 
and LDL-C goal attainment
a
 (N = 9,086) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories 5.408  .067   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 1.945          1.114 .163 .957 1.297 
≥30.0 kg/m2 5.194   1.193 .023 1.025 1.388 
      
Age (years) 3.672  .452   
18-44 Reference     
45-55 .273 1.055 .601 .863 1.289 
56-64 2.429 1.185 .119 .957 1.466 
65-74 .634 1.098 .426 .872 1.383 
≥75 1.084 1.139 .298 .892 1.454 
      
Gender      
Male Reference     
Female 11.346 1.197 .001 1.078 1.329 
      
Primary payer 8.579  .073   
Medicare Reference     
Medicaid .823 1.137 .364 .862 1.499 
Private  1.684 .916 .194 .803 1.046 
Self-pay 2.249 1.182 .134 .950 1.470 
Other .056 1.060 .813 .654 1.718 
      
Patient location      
Urban  Reference     
Rural 2.248 1.080 .134 .977 1.194 
      
CV conditions (present)c      
Diabetes 96.953 2.241 .000 1.908 2.631 
Heart failure 1.631 .855 .202 .673 1.087 
Myocardial infarction 3.573 .764 .059 .579 1.010 
Angina pectoris 7.071 .586 .008 .395 .869 
Coronary artery disease 1.095 .919 .295 .784 1.077 
Peripheral vascular disease 1.130 1.107 .288 .918 1.336 
Cerebrovascular disease .031 .984 .859 .826 1.173 
Kidney disease 3.684 .801 .055 .639 1.005 
      
Hypertension stage (baseline) 36.193  .000   
Prehypertension Reference     
Stage 1 27.055 1.320 .000 1.189 1.465 
Stage 2 18.216 1.456 .000 1.225 1.730 
      
LDL-C (baseline) 7.377  .025   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) 5.512 1.209 .019 1.032 1.416 
High/very high (≥160 mg/dL) .395 1.067 .530 .871 1.308 
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Table 20 (Continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline) 121.228  .000   
Desirable (<200 mg/dL) Reference     
Borderline high (200-239 mg/dL) 60.061 1.676 .000 1.470 1.909 
High (≥240 mg/dL) 117.687 2.765 .000 2.301 3.322 
      
Triglyceride (baseline) 1.202  .548   
Desirable (<150 mg/dL) Reference     
Borderline high (150-199 mg/dL) .018 1.009 .892 .892 1.140 
High/very high (≥200 mg/dL) .926 .940 .336 .829 1.066 
      
HDL-C (baseline)      
Low (<40 mg/dL) Reference     
Desirable (≥40 mg/dL) .707 1.058 .400 .928 1.205 
      
Smoking status 3.022  .388   
Non-smoker Reference     
Current .330 1.049 .566 .891 1.236 
Former-smoker 1.413 .936 .235 .840 1.044 
      
Cardiovascular risk 49.975  .000   
Low Reference     
Intermediate 16.201 1.668 .000 1.300 2.141 
High 45.741 2.718 .000 2.034 3.631 
      
No. of antihypertensive medications 36.431  .000   
0 Reference     
1 23.322 1.320 .000 1.179 1.477 
2 19.692 1.382 .000 1.198 1.594 
3 10.735 1.390 .001 1.141 1.692 
≥4 7.960 1.415 .005 1.112 1.801 
      
No. of antilipemic medications 49.604  .000   
0 Reference     
1 40.932 .720 .000 .652 .797 
≥2 3.023 1.285 .082 .969 1.705 
CV: Cardiovascular; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein 
cholesterol 
aStandard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 773.965, P<0.001. 
Hosmer-Lemeshow test: P = 0.833. 
Variance in combined BP and LDL-C goal attainment (Nagelkerke R square test): 12.3%.   
Percentage of cases correctly classified by the model: 66.3%. 
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Stepwise logistic regression (Table 21) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 15) accounted for 
11.1% of the variance in combined BP and LDL-C goal attainment.  Presence/absence of 
diabetes accounted for 6.3% of the variance.  Presence/absence of diabetes and high total 
cholesterol at baseline accounted for 7.4% of variance.   
The other significant predictors were added in the model in the following 
sequence: borderline high total cholesterol at baseline, number of antilipemic medication 
= 1, high cardiovascular risk, intermediate cardiovascular risk, hypertension stage 1, 
hypertension stage 2, gender, number of antihypertensive medications = 1, 2, ≥4, 3, 
angina pectoris, and borderline high LDL-C at baseline. 
 124 
 
Table 21: Stepwise logistic regression for combined BP and LDL-C goal attainment 
Steps Variables R
2
 
Step1 DM 0.047 
   
Step2 DM; high total cholesterol at baseline 0.086 
   
Step3 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline 0.094 
   
Step4 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1 
0.101 
   
Step5 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk 
0.107 
   
Step6 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk 
0.120 
   
Step7 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1 
0.122 
   
Step8 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2 
0.124 
   
Step9 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender 
0.126 
   
Step10 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 2 
0.129 
   
Step11 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 1, 2 
0.130 
   
Step12 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 1, 2; angina pectoris 
0.131 
   
Step13 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 1, 2, ≥4; angina pectoris 
0.133 
   
Step14 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 1, 2, ≥4, 3; angina pectoris 
0.134 
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Table 21 (Continued) 
Steps Variables R
2
 
Step15 DM; high total cholesterol at baseline; borderline high total cholesterol at baseline; 
number of antilipemic medication = 1; high CV risk; intermediate CV risk; 
hypertension stage 1; hypertension stage 2; gender; number of antihypertensive 
medications = 1, 2, ≥4, 3; angina pectoris; borderline high LDL-C at baseline 
0.135 
DM: Diabetes mellitus; CV: cardiovascular risk; LDL-C: Low-density lipoprotein cholesterol 
R2 reported is Nagelkerke R square 
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Predictors of not attaining optimum total cholesterol levels 
The results for standard logistic regression are presented in Tale 22.  According to 
NCEP ATP III guidelines, cholesterol level < 200 is defined as optimum total cholesterol 
level.  In multivariate logistic regression analysis, patients who were overweight 
(OR=0.809, P=0.047) or obese (OR=0.774, P=0.016) were less likely to be associated 
with failure to attain optimum total cholesterol levels.  Regarding gender, females 
(OR=1.547, P<0.001) were more likely to be associated with not attaining optimum total 
cholesterol levels. 
Presence of diabetes versus absence of diabetes (OR=0.740, P=0.008) and 
presence of CAD versus absence of CAD (OR=0.731, P=0.007) were less likely to be 
associated with not attaining optimum total cholesterol levels.  Regarding baseline 
clinical measurements, borderline high LDL-C (OR=1.519, P<0.001) or high/very high 
LDL-C (OR=1.594, P<0.001), high total cholesterol (OR=2.349, P<0.001), and 
high/very high triglyceride (OR=1.225, P=0.015) were more likely to be associated with 
not attaining optimum total cholesterol levels.  Interestingly, patients with higher HDL-C 
levels (desirable) were also more likely to be associated with failure to attain optimum 
total cholesterol levels (OR=1.492, P<0.001).   
Patients prescribed antilipemic medications were less likely to be associated with 
not attaining optimum total cholesterol levels: one medication (OR=0.320, P<0.001) and 
at least two medications (OR=0.586, P=0.002) each versus no medication.  Patients 
prescribed at least four antihypertensive medications were also less likely to be associated 
with not attaining optimum cholesterol levels (OR=0.721, P=0.034). 
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Table 22: Multivariate analysis of factors associated with not attaining optimum 
total cholesterol levels
a
 (N = 4,852) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories 5.865  .053   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 3.958 .809 .047 .657 .997 
≥30.0 kg/m2 5.819 .774 .016 .629 .953 
      
Age (years) 12.164  .016   
18-44 Reference     
45-55 .584 1.100 .445 .861 1.406 
56-64 .011 1.014 .916 .780 1.319 
65-74 2.349 .796 .125 .594 1.066 
≥75 .088 1.049 .767 .763 1.442 
      
Gender      
Male Reference     
Female 38.315 1.547 .000 1.347 1.776 
      
Primary payer 5.007  .287   
Medicare Reference     
Medicaid 1.450 .809 .228 .574 1.142 
Private  .059 .978 .808 .815 1.173 
Self-pay .383 1.094 .536 .823 1.453 
Other 2.784 .588 .095 .315 1.097 
      
Patient location      
Urban  Reference     
Rural .709 .945 .400 .827 1.079 
      
CV conditions (present)c      
Diabetes 6.960 .740 .008 .592 .925 
Heart failure .017 1.025 .895 .709 1.481 
Myocardial infarction .032 .962 .859 .629 1.471 
Angina pectoris 2.335 .628 .126 .346 1.140 
Coronary artery disease 7.192 .731 .007 .582 .919 
Peripheral vascular disease .054 1.032 .816 .792 1.345 
Cerebrovascular disease .415 1.085 .519 .847 1.389 
Kidney disease .000 1.002 .988 .724 1.388 
      
Hypertension stage (baseline) .792  .673   
Prehypertension Reference     
Stage 1 .002 1.003 .966 .875 1.150 
Stage 2 .686 .918 .407 .749 1.124 
      
LDL-C (baseline) 16.132  .000   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) 14.985 1.519 .000 1.229 1.876 
High/very high (≥160 mg/dL) 13.037 1.594 .000 1.238 2.054 
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Table 22 (Continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline)      
Borderline high (200-239 mg/dL) Reference     
High (≥240 mg/dL) 98.185 2.349 .000 1.984 2.782 
      
Triglyceride (baseline) 15.775  .000   
Desirable (<150 mg/dL) Reference     
Borderline high (150-199 mg/dL) 3.321 .860 .068 .731 1.011 
High/very high (≥200 mg/dL) 5.976 1.225 .015 1.041 1.442 
      
HDL-C (baseline)      
Low (<40 mg/dL) Reference     
Desirable (≥40 mg/dL) 18.904 1.492 .000 1.246 1.787 
      
Smoking status 1.097  .778   
Non-smoker Reference     
Current .922 1.109 .337 .898 1.371 
Former-smoker .018 .990 .893 .859 1.142 
      
Cardiovascular risk 2.405  .300   
Low Reference     
Intermediate .135 1.060 .714 .775 1.451 
High .487 .875 .485 .602 1.272 
      
No. of antihypertensive medications 9.229  .056   
0 Reference     
1 2.136 1.118 .144 .963 1.298 
2 .249 .953 .618 .791 1.150 
3 .111 1.044 .739 .811 1.343 
≥4 4.495 .721 .034 .533 .976 
      
No. of antilipemic medications 277.082  .000   
0 Reference     
1 276.662 .320 .000 .280 .366 
≥2 9.818 .586 .002 .419 .818 
CV: Cardiovascular; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein 
cholesterol 
aStandard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 757.727, P<0.001. 
Hosmer-Lemeshow test: P = 0.363. 
Variance in total cholesterol levels (Nagelkerke R square test): 18.7%.   
Percentage of cases correctly classified by the model: 70.6%. 
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Stepwise logistic regression (Table 23) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 9) accounted for 
17.1% of the variance in total cholesterol levels.  Number of antilipemic medications = 1 
accounted for 6.4% of the variance.  Number of antilipemic medications = 1 and high 
total cholesterol at baseline accounted for 12.3% of variance. 
The other significant predictors were added in the model in the following 
sequence: DM, gender, CAD, HDL-C at baseline, number of antilipemic medications ≥2, 
number of antihypertensive medications ≥4, and high/very high triglyceride at baseline. 
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Table 23: Stepwise logistic regression for total cholesterol levels 
Steps Variables R
2
 
Step1 Number of antilipemic medications = 1 0.064 
   
Step2 Number of antilipemic medications = 1; high total cholesterol at baseline 0.123 
   
Step3 Number of antilipemic medications = 1; high total cholesterol at baseline; DM 0.142 
   
Step4 Number of antilipemic medications = 1; baseline total cholesterol; DM; gender 0.156 
   
Step5 Number of antilipemic medications = 1; baseline total cholesterol; DM; gender; CAD 0.163 
   
Step6 Number of antilipemic medications = 1; baseline total cholesterol; DM; gender; CAD; 
HDL-C at baseline 
0.166 
   
Step7 Number of antilipemic medications = 1, ≥2; baseline total cholesterol; DM; gender; 
CAD; HDL-C at baseline 
0.168 
   
Step8 Number of antilipemic medications = 1, ≥2; baseline total cholesterol; DM; gender; 
CAD; HDL-C at baseline, number of antihypertensive medications ≥4 
0.170 
   
Step9 Number of antilipemic medications = 1, ≥2; baseline total cholesterol; DM; gender; 
CAD; HDL-C at baseline; number of antihypertensive medications ≥4; high/very 
high triglyceride at baseline 
0.171 
DM: Diabetes mellitus; CAD: Coronary artery disease; HDL-C: High-density lipoprotein cholesterol 
R2 reported is Nagelkerke R square 
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Predictors of not attaining optimum triglyceride levels  
The results from standard logistic regression are reported in Table 24.  According 
to the NCEP ATP III guidelines, triglyceride level < 150 is defined as optimum 
triglyceride level.  In multivariate logistic regression analysis, BMI was a significant 
predictor of combined BP and LDL-C goal attainment (P<0.001) in patients with 
concomitant hypertension and dyslipidemia and likelihood of failure to attain optimum 
triglyceride levels increased with increase in BMI: overweight (OR=1.332, P=0.042) and 
obese (OR=1.864, P<0.001).  Regarding gender, females (OR=1.543, P<0.001) were 
more likely to be associated with not attaining optimum triglyceride levels. 
Presence of high/very high triglyceride levels at baseline versus borderline high 
triglyceride (OR=4.448, P<0.001) was more likely to be associated with not attaining 
optimum triglyceride levels.  In addition, presence of higher HDL-C levels (desirable) at 
baseline (OR=0.771, P=0.007) was less likely to be associated with not attaining 
optimum triglyceride levels. 
Patients prescribed one antilipemic medication versus no medication (OR=0.795, 
P=0.004) were less likely to be associated with not attaining optimum triglyceride levels 
whereas patients prescribed two antihypertensive medications versus no medication 
(OR=1.998, P=0.002) were more likely to be associated with not attaining optimum 
triglyceride levels. 
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Table 24: Multivariate analysis of factors associated with not attaining optimum 
triglyceride levels
a
 (N = 4,267) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories 26.726  .000   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 4.137 1.332 .042 1.010 1.755 
≥30.0 kg/m2 19.914 1.864 .000 1.418 2.451 
      
Age (years) 2.028  .731   
18-44 Reference     
45-55 .222 1.074 .637 .798 1.447 
56-64 1.504 1.220 .220 .888 1.677 
65-74 .467 1.131 .494 .795 1.608 
≥75 .264 1.103 .608 .759 1.604 
      
Gender      
Male Reference     
Female 24.084 1.543 .000 1.298 1.835 
      
Primary payer .876  .928   
Medicare Reference     
Medicaid .263 1.118 .608 .730 1.711 
Private  .052 .975 .820 .787 1.209 
Self-pay .132 1.070 .716 .742 1.542 
Other .181 .849 .670 .399 1.805 
      
Patient location      
Urban  Reference     
Rural .718 .933 .397 .795 1.095 
      
CV conditions (present)c      
Diabetes .291 1.071 .589 .834 1.377 
Heart failure 1.907 .777 .167 .544 1.111 
Myocardial infarction 1.973 1.392 .160 .878 2.207 
Angina pectoris .413 .818 .520 .443 1.509 
Coronary artery disease .023 .981 .880 .768 1.254 
Peripheral vascular disease .696 1.133 .404 .845 1.520 
Cerebrovascular disease 1.327 1.181 .249 .890 1.568 
Kidney disease 1.248 1.228 .264 .857 1.760 
      
Hypertension stage (baseline) .278  .870   
Prehypertension Reference     
Stage 1 .274 .956 .601 .809 1.130 
Stage 2 .008 .988 .929 .760 1.285 
      
LDL-C (baseline) 2.147  .342   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) 2.145 1.200 .143 .940 1.532 
High/very high (≥160 mg/dL) .933 1.168 .334 .852 1.601 
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Table 24 (Continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline) 3.188  .203   
Desirable (<200 mg/dL) Reference     
Borderline high (200-239 mg/dL) 1.155 .887 .283 .713 1.104 
High (≥240 mg/dL) 3.188 .766 .074 .571 1.026 
      
Triglyceride (baseline)      
Borderline high (150-199 mg/dL) Reference     
High/very high (≥200 mg/dL) 314.219 4.448 .000 3.771 5.246 
      
HDL-C (baseline)      
Low (<40 mg/dL) Reference     
Desirable (≥40 mg/dL) 7.396 .771 .007 .639 .930 
      
Smoking status 3.104  .376   
Non-smoker Reference     
Current 2.651 1.241 .103 .957 1.610 
Former-smoker .018 1.012 .892 .850 1.205 
      
Cardiovascular risk 2.559  .278   
Low Reference     
Intermediate 1.508 .770 .220 .508 1.168 
High 2.554 .681 .110 .425 1.091 
      
No. of antihypertensive medications 7.850  .097   
0 Reference     
1 2.240 1.148 .134 .958 1.377 
2 6.564 1.351 .010 1.073 1.701 
3 .065 1.041 .799 .764 1.417 
≥4 1.863 1.298 .172 .892 1.889 
      
No. of antilipemic medications 21.231  .000   
0 Reference     
1 8.075 .795 .004 .678 .931 
≥2 9.246 1.998 .002 1.279 3.121 
CV: Cardiovascular; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein 
cholesterol 
aStandard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 484.218, P<0.001. 
Hosmer-Lemeshow test: P = 0.670. 
Variance in triglyceride levels (Nagelkerke R square test): 16.6%.   
Percentage of cases correctly classified by the model: 75.0%. 
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Stepwise logistic regression (Table 25) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 8) accounted for 
16.1% of the variance in triglyceride levels.  Baseline high/very high triglyceride levels 
accounted for 13.3% of the variance.  Baseline high/very high triglyceride levels and 
BMI ≥30.0 kg/m2 together accounted for 14.1% of variance in attaining optimum 
triglyceride levels. 
The other significant predictors were added in the model in the following 
sequence: gender, number of antilipemic medications ≥2, number of antilipemic 
medications = 1, HDL-C at baseline, number of antihypertensive medications = 2; and 
BMI = 25.0-29.9 kg/m
2
. 
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Table 25: Stepwise logistic regression for triglyceride levels 
Steps Variables R
2
 
Step1 High/very high triglyceride at baseline 0.133 
   
Step2 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2 0.141 
   
Step3 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender 0.147 
   
Step4 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender; number of 
antilipemic medications ≥2 
0.153 
   
Step5 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender; number of 
antilipemic medications ≥2, 1 
0.156 
   
Step 6 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender; number of 
antilipemic medications ≥2, 1; HDL-C at baseline 
0.158 
   
Step 7 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender; number of 
antilipemic medications ≥2, 1; HDL-C at baseline; number of antihypertensive 
medications = 2 
0.160 
   
Step 8 High/very high triglyceride at baseline; BMI ≥30.0 kg/m2; gender; number of 
antilipemic medications ≥2, 1; HDL-C at baseline; number of antihypertensive 
medications = 2; BMI = 25.0-29.9 kg/m2 
0.161 
BMI: Body mass index; HDL-C: High-density lipoprotein cholesterol 
R2 reported is Nagelkerke R square 
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Predictors of not attaining optimum HDL-C levels  
The results for standard logistic regression are presented in Table 26.  According 
to NCEP ATP III guidelines, HDL-C ≥ 40 is defined as optimum HDL-C level.  In 
multivariate logistic regression analysis, patients who were obese were more likely to be 
associated with not attaining optimum levels of HDL-C (OR=1.933, P=0.009).  
Regarding gender, females were less likely to be associated with not attaining optimum 
HDL-C levels (OR=0.591, P<0.001). 
Presence of borderline high total cholesterol (OR=0.801, P=0.027) or high total 
cholesterol (OR=0.529, P=0.008) at baseline was less likely to be associated with not 
attaining optimum HDL-C levels whereas presence of borderline high (OR=1.507, 
P=0.013) or high/very high (OR=2.187, P<0.001) triglyceride levels were more likely to 
be associated with failure to attain optimum HDL-C levels.  Patients who were current 
smokers were also more likely to fail to attain optimum HDL-C levels (OR=1.626, 
P=0.009).  Patients prescribed two antihypertensive medications were less likely to fail to 
attain optimum HDL-C levels (OR=0.713, P=0.045). 
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Table 26: Multivariate analysis of factors associated with not attaining optimum 
HDL-C levels
a
 (N = 1,852) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
BMI categories 8.194  .017   
≤24.9 kg/m2 Reference     
25.0-29.9 kg/m2 2.733 1.536 .098 .923 2.554 
≥30.0 kg/m2 6.923 1.933 .009 1.183 3.159 
      
Age (years) 3.776  .437   
18-44 Reference     
45-55 1.924 .765 .165 .524 1.117 
56-64 1.638 .771 .201 .518 1.148 
65-74 .297 .876 .586 .544 1.411 
≥75 .022 1.041 .883 .613 1.766 
      
Gender      
Male Reference     
Female 15.469 .591 .000 .455 .768 
      
Primary payer 13.168  .051   
Medicare Reference     
Medicaid .424 1.219 .515 .672 2.211 
Private  2.498 1.324 .114 .935 1.876 
Self-pay .174 1.125 .676 .648 1.954 
Other 7.460 .236 .066 .084 .665 
      
Patient location      
Urban  Reference     
Rural 2.850 1.228 .091 .967 1.559 
      
CV conditions (present)c      
Diabetes 3.339 .692 .068 .467 1.027 
Heart failure .147 1.119 .702 .629 1.989 
Myocardial infarction 1.154 .716 .283 .389 1.317 
Angina pectoris 1.016 1.699 .314 .606 4.760 
Coronary artery disease .559 1.147 .455 .801 1.642 
Peripheral vascular disease 1.612 1.360 .204 .846 2.186 
Cerebrovascular disease .168 .909 .682 .577 1.433 
Kidney disease .260 1.156 .610 .662 2.017 
      
Hypertension stage (baseline) 1.453  .484   
Prehypertension Reference     
Stage 1 .883 1.134 .347 .872 1.474 
Stage 2 .235 .910 .628 .621 1.333 
      
LDL-C (baseline) 2.146  .342   
Near/above optimal (100-129 mg/dL) Reference     
Borderline high (130-159 mg/dL) .935 .845 .334 .601 1.188 
High/very high (≥160 mg/dL) .082 1.075 .775 .656 1.762 
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Table 26 (Continued) 
Variables Wald Odds ratio P value
b
 95% CI 
    Lower Upper 
Total cholesterol (baseline) 7.830  .020   
Desirable (<200 mg/dL) Reference     
Borderline high (200-239 mg/dL) 4.919 .701 .027 .511 .959 
High (≥240 mg/dL) 6.928 .529 .008 .329 .850 
      
Triglyceride (baseline) 25.118  .000   
Desirable (<150 mg/dL) Reference     
Borderline high (150-199 mg/dL) 6.144 1.507 .013 1.090 2.084 
High/very high (≥200 mg/dL) 25.009 2.187 .000 1.610 2.973 
      
Smoking status 8.988  .029   
Non-smoker Reference     
Current 6.743 1.626 .009 1.127 2.346 
Former-smoker .401 .919 .527 .706 1.195 
      
Cardiovascular risk      
Low Reference     
High .192 .902 .661 .567 1.433 
      
No. of antihypertensive medications 8.435  .077   
0 Reference     
1 1.649 .833 .199 .631 1.101 
2 4.007 .713 .045 .512 .993 
3 1.840 1.442 .175 .850 2.447 
≥4 .047 .937 .828 .523 1.681 
      
No. of antilipemic medications 2.535  .282   
0 Reference     
1 1.699 .849 .192 .664 1.086 
≥2 1.524 .729 .217 .442 1.204 
Constant 3.192 2.100 .074   
CV: Cardiovascular; LDL-C: Low-density lipoprotein cholesterol 
a
Standard logistic regression was utilized. 
bSignificance level:P<0.05 
cReference category for each of the CV condition: absence of that specific CV condition. 
A test of the full model with all the predictors against a constant only model: χ2 = 99.516, P<0.001. 
Hosmer-Lemeshow test: P = 0.897. 
Variance in HDL-C levels (Nagelkerke R square test): 24.1%.   
Percentage of cases correctly classified by the model: 75.9%. 
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Stepwise logistic regression (Table 27) was conducted in which only significant 
variables (P<0.05) entered the model and final step in the model (Step 7) accounted for 
21.2% of the variance in HDL-C levels.  Gender and high/very high triglycerides at 
baseline accounted for 20.1% of the variance.   
The other significant predictors were added in the model in the following 
sequence: current smoker, high total cholesterol at baseline, borderline high total 
cholesterol at baseline, borderline high triglyceride levels at baseline, and BMI ≥30.0 
kg/m
2
. 
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Table 27: Stepwise logistic regression for HDL-C levels 
Steps Variables R
2
 
Step1 Gender  0.198 
   
Step2 Gender; High/very high triglyceride levels at baseline 0.201 
   
Step3 Gender; High/very high triglyceride levels at baseline; current smoker 0.204 
   
Step4 Gender; High/very high triglyceride levels at baseline; current smoker; high total 
cholesterol at baseline 
0.206 
   
Step5 Gender; High/very high triglyceride levels at baseline; current smoker; high total 
cholesterol at baseline; borderline high total cholesterol at baseline 
0.208 
   
Step6 Gender; High/very high triglyceride levels at baseline; current smoker; high total 
cholesterol at baseline; borderline high total cholesterol at baseline; borderline high 
triglyceride levels at baseline 
0.210 
   
Step7 Gender; High/very high triglyceride levels at baseline; current smoker; high total 
cholesterol at baseline; borderline high total cholesterol at baseline; borderline high 
triglyceride levels at baseline; BMI ≥30.0 kg/m2 
0.212 
BMI: Body mass index; DM: Diabetes mellitus 
R2 reported is Nagelkerke R square 
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Assumptions underlying statistical tests 
Prior to analysis, data were subjected to the assumptions for different statistical 
tests used for the study objectives.   
 
Assumptions underlying two-way contingency table analysis 
Assumption 1: The observations for a two-way contingency table analysis are 
independent of each other. 
According to this assumption, each observation should be independent of another 
observation.  The study design included observations that were independent of each 
other, thus meeting this assumption.  The study was designed such that each patient was 
selected based on the unique patient ID and there was no overlapping of data for each 
patient. 
 
Assumption 2: Two-way contingency analyses yield a statistic that is approximately 
distributed as a chi-square when the sample size is relatively large. 
Overall, this study has a sample size of N = 9,086.  Moreover, to meet this 
assumption, the data  were grouped into categories such that the expected frequencies for 
each cell were greater than or equal to 5.  This assumption was tested using two-way 
contingency analysis. 
 
Assumptions underlying one-way ANOVA 
Assumption 1: The dependent variable is normally distributed for each of the populations 
as defined by the different levels of the factor. 
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This study has large sample size and according to the central limit theorem, the 
sample size of 30 cases per group is sufficiently large to yield accurate p values.  Thus, 
the DV was assumed to be normally distributed.  
 
Assumption 2: The variances of the dependent variable are the same for all populations. 
Levene‘s test was used to assess this assumption of homogeneity of variance 
(Table 28).  The homogeneity of variances is assumed when the p value for Levene‘s test 
is not significant (P>0.05).  For the variables in which this assumption was violated, the 
statistics (Browne-Forsythe or Welch) that do not assume equality of population 
variances were used as a replacement for F-test. 
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Table 28: Levene’s test for homogeneity of variance assumption underlying one-way 
ANOVA (BMI as the independent variable) 
Variable F statistic P value 
Baseline   
SBP (mm Hg) 0.502 0.606 
DBP (mm Hg) 0.505 0.603 
LDL-C (mg/dL) 2.075 0.126 
HDL-C (mg/dL)* 73.87 0.000 
Total cholesterol (mg/dL) 2.298 0.101 
Triglyceride (mg/dL)* 34.9 0.000 
   
Post-index   
SBP (mm Hg) 0.748 0.474 
DBP (mm Hg) 0.062 0.940 
LDL-C (mg/dL) 1.937 0.144 
HDL-C (mg/dL)* 95.47 0.000 
Total cholesterol (mg/dL) 1.857 0.156 
Triglyceride (mg/dL)* 33.05 0.000 
*For variables HDL-C and triglyceride (both baseline and post-index), Levene‘s test was significant 
(P<0.05) and thus this assumption was violated.  For HDL-C and triglyceride measurements, Welch test 
(that does not assume homogeneity of variances) was used for analysis. 
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Assumption 3: The observations for a one-way ANOVA and scores on test variable are 
independent of each other. 
The study was designed such that the observations and scores on test variables 
were independent of each other.  Each clinical measure (BP, lipid level) were measured at 
a different period of time.  Thus, for each patient, the clinical measures assessed at 
baseline were independent of clinical measures assessed at follow-up. 
 
Assumptions underlying logistic regression 
 For objective 4, the analysis includes dichotomous outcome variable and mix set 
of predictors (discrete, and dichotomous).  Thus, logistic regression technique is 
appropriate for complex and varied data sets and does not require normality, linearity, 
and homoscedasticity assumptions. 
 
Assumption 1: Ratio of cases to variables is adequate. 
According to this assumption, there should be adequate number of cases for each 
discrete category of predictor.  In other words, the combinations of discrete variables 
should not result in cells with no cases.  There should be at least five times the cases as 
cells in the study design.  The data  were grouped such that there was adequate number of 
cases in each discrete category of predictors used and no cell had zero cases.  Also, the 
presence of large sample size was useful in meeting this assumption. 
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Assumption 2: Adequacy of expected frequencies. 
 According to this assumption, all expected frequencies are greater than 1 and no 
more than 20% are less than five.  This assumption was met because of the large sample 
size and proper grouping of variables.  Further, the data  were also screened using SPSS 
crosstabs and desired expected frequencies were confirmed.  
 
Assumption 3: Absence of multicollinearity. 
Logistic regression is highly sensitive to extremely high correlation among 
predictor variables.  Multicollinearity is examined using tolerance statistics or variance 
inflation factor (VIF) statistics.  If tolerance statistic is > 0.1 or VIF is < 10, then there is 
no problem for multicollinearity.  For the predictor variables with more than two 
categories, dummy variables were created and were examined for multicollinearity. The 
redundant variables (number of cardiovascular conditions, type of antihypertensive or 
antilipemic medication) were identified in the initial examination of multicollinearity and 
were not included for analysis.  Table 29 shows the tolerance statistics and VIF statistics 
for the predictor variables that were included in the model. 
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Table 29: Absence of multicollinearity assumption underlying logistic regression  
Variables Collinearity statistics 
 Tolerance VIF 
Age: 45-55 years  .322 3.107 
Age: 56-64 years  .265 3.775 
Age: 65-74 years  .237 4.220 
Age: ≥75years  .220 4.551 
Medicaid .797 1.255 
Private  .540 1.851 
Self-pay .835 1.197 
Other .958 1.044 
25.0-29.9 kg/m2 .409 2.448 
≥30.0 kg/m2 .368 2.719 
CV risk: Intermediate .414 2.414 
CV risk: High .377 2.651 
Hypertension stage 1 .894 1.118 
Hypertension stage 2 .880 1.136 
Current .867 1.154 
Former-smoker .881 1.135 
No. of antihypertensives = 1 .804 1.244 
No. of antihypertensives = 2 .815 1.226 
No. of antihypertensives = 3 .851 1.176 
No. of antihypertensives  ≥4 .849 1.178 
No. of antilipemics = 1 .902 1.109 
No. of antilipemics  ≥2 .928 1.078 
Gender  .813 1.230 
Presence/absence of diabetes .394 2.541 
Presence/absence of heart failure .908 1.101 
Presence/absence of myocardial infarction .916 1.092 
Presence/absence of angina pectoris .970 1.031 
Presence/absence of coronary artery disease .648 1.544 
Presence/absence peripheral vascular disease .864 1.157 
Presence/absence cerebrovascular disease .810 1.235 
Presence/absence kidney disease .914 1.094 
LDL-C (borderline high) at baseline .399 2.506 
LDL-C (high/very high) at baseline .323 3.095 
Total cholesterol (borderline high) at baseline .560 1.786 
Total cholesterol (high) at baseline .395 2.531 
Triglyceride (borderline high) at baseline .861 1.162 
Triglyceride at (high/very high) at baseline .725 1.380 
HDL-C at baseline .779 1.283 
Patient location .971 1.029 
Reference categories: 
Age: 18-44 years; Insurance type: Medicare; BMI: ≤24.9 kg/m2; CV risk: low; Hypertension stage: 
Prehypertension; Smoking status: Non-smoker; No. of antihypertensives = 0; No. of antilipemics = 0; LDL-
C: optimal/above optimal; Total cholesterol: optimal; Triglyceride: optimal; HDL-C: <40 mg/dL 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
This chapter includes discussion, conclusions, study limitations, study implications, and 
opportunities for future research. 
 
DISCUSSION 
Obesity is associated with increased risk of hypertension, dyslipidemia, diabetes, 
metabolic syndrome, and CVD.
1
  Most of the obesity-related cardiovascular morbidity is 
linked to the increased prevalence of cardiovascular risk factors, such as hypertension, 
dyslipidemia, or glucose intolerance.
1,2
  All these factors predispose or increase the 
probability of developing CVD.  Hypertension and dyslipidemia are highly prevalent risk 
factors and their prevalence substantially increases with increase in BMI.  Further, it has 
been suggested that concomitant presence of increased BP, elevated lipid levels, and 
higher BMI decreases the probability of attaining optimum BP and lipid levels, thereby 
increasing the risk of CVD.
18, 23, 24
  However, these risk factors are modifiable if managed 
appropriately and in a timely manner.  Current obesity treatment guidelines have strongly 
emphasized the control of BP and lipid levels in patients who are obese by implementing 
lifestyle modifications and pharmacological treatment.  Further, JNC7 and NCEP ATP III 
guidelines recommend simultaneous management of risk factors (hypertension and 
dyslipidemia).
12, 18
  Although disease management guidelines have been established, 
previous research suggests that more than 50% of patients do not attain recommended BP 
and lipid goals.  Further, to the best of our knowledge, no studies to date have examined 
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obesity in relation to the attainment of recommended BP and lipid goals in patients with 
concomitant hypertension and dyslipidemia. 
To achieve the study objective, GE Centricity EMR database was utilized since it 
is rich in clinical data and reflects a real-world clinical practice.  The other advantage of 
EMR data is that it can be analyzed longitudinally and in a real-time basis for the entire 
population under care and provides large sample sizes.  The ability of EMR data to 
provide clinical information (e.g., BMI, BP, lipid levels) is by far the most important 
advantage over commonly used administrative claims databases.   EMR also provides a 
quick, less expensive, and more comprehensive approach to conducting outcomes 
research and facilitates accurate assessment of the proportion of patients with 
hypertension or dyslipidemia in whom BP or lipid levels are not controlled.  The 
information regarding medication type and number of medications prescribed is also 
available in the EMR data.  Such outcome studies using EMR data can assist physicians 
in quickly identifying all the patients with multiple risk factors and can specifically target 
those who are not at goal. 
Thus, this study was conducted using EMR database to examine the variations in 
therapeutic (BP and lipid) goal attainment and medication utilization pattern in patients 
with concomitant hypertension and dyslipidemia, specifically comparing obese versus 
non-obese patients.  Using EMR database, this study provides information regarding 
therapeutic goal attainment and medication prescribing pattern in context of real world 
medical practice.  
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Patient and clinical profile of patients with concomitant hypertension and dyslipidemia 
Overall, 19,190 adult patients (≥18 years) had concomitant hypertension and 
dyslipidemia, which accounts for about 12.3% of total EMR patient population.  Johnson 
et al. (2006) reported 23.8% of population with concomitant hypertension and 
dyslipidemia in a Veteran Affairs population.
33
  This variation in prevalence might be due 
to different population and setting.  For overall US population, information available 
from NHANES III (1988-1994) suggests that 15% of US adults have concomitant 
hypertension and dyslipidemia.
20
 
Among patients with concomitant hypertension and dyslipidemia, majority of 
them were middle-aged (mean = 60.03 years), had private insurance, were either obese or 
overweight, had diabetes and were at high cardiovascular risk.  A multitude of research 
studies have shown similar trend for age, BMI, and prevalence of diabetes.
23, 24, 33, 34, 63
  In 
the study by Johnson et al., most patients with concomitant hypertension and 
dyslipidemia were middle-aged (mean = 60.3 years).
33
  Other studies have shown that 
prevalence of hypertension or dyslipidemia increased with BMI or patients with higher 
BMI were more likely to have hypertension or dyslipidemia.
23, 24
  Similarly, it has been 
suggested that there is an association between diabetes, hypertension, and dyslipidemia.
33, 
34, 63 
The reason for higher proportion of patients having private insurance can be 
attributed to the majority of our study population consisting of patients less than 65 years 
of age.  Further, more than one-half of population was at high cardiovascular risk which 
can be attributed to the higher proportion of patients having diabetes or other 
cardiovascular conditions.  
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Our study results showed that 51.9% of females had concomitant hypertension 
and dyslipidemia.  Similar results have been shown by Selby et al. (2004); 49.5% of 
females had concomitant hypertension and dyslipidemia in a Kaiser Permanente 
population.
63
 
 
Patient and clinical profile of obese versus non-obese patients with concomitant 
hypertension and dyslipidemia 
Most of the patients who were overweight or obese were less than 65 years of age 
and comprised of males and this was consistent with NHANES and Centers for Disease 
Control and Prevention (CDC) 2008-2010 statistics.
7, 8, 64
  The 2008-2010 statistics 
indicate higher prevalence of obesity in younger population (< 65 years of age ) and 
higher rate of obesity among males (30.0%) compared to females (27.1%) in 
Pennsylvania (PA).
64
  Since our population represents the Southwestern region of PA; 
higher proportion of males compared to females were either overweight (35.6% vs. 
31.8%) or obese (54.7% vs. 50.5%).  
Regarding clinical characteristics, patients who were obese or overweight were 
more likely to have higher diastolic BP, elevated levels of triglycerides, and lower levels 
of HDL-C.  Surprisingly, they were less likely to have higher levels of LDL-C and total 
cholesterol levels.  Patients who were obese or overweight were more likely to have 
diabetes and had at least one cardiovascular condition.  The results for BP, triglyceride, 
HDL-C, diabetes, and cardiovascular risk are consistent with previous research.  
However, contradictory results were seen with LDL-C and total cholesterol levels.  It has 
been shown that BP increases with weight gain and decreases with weight loss.
23, 24, 63
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Obesity has the most profound effect on hypertension and risk estimates from population 
studies suggest that about 75% of hypertension can be attributed to obesity alone.
63
  
Evidence suggests that the neuroendocrine mechanisms and the factors derived from 
adipose tissues could play a major role
65, 66
;  however, the exact mechanisms relating 
obesity to hypertension remains unclear.  Obesity also has a strong effect on lipoprotein 
metabolism and an increase in weight is shown to be associated with higher levels of 
triglycerides, elevated LDL-C, and low HDL-C.  However, normal-weight patients were 
observed to have higher levels of LDL-C and total cholesterol compared to overweight 
and obese patients.  A possible explanation could be that LDL-C and total cholesterol 
concentrations are generally associated with visceral obesity which can be more 
appropriately determined using waist circumference.  Although, BMI is highly correlated 
with adiposity, it measures lean mass as well as fat mass.
65
  The association between 
obesity and LDL-C is complex and the exact mechanism has not been fully elucidated. 
Obesity-related hypertension is associated with additional factors of metabolic 
syndrome (insulin resistance and glucose intolerance) resulting in increased risk of 
diabetes.  Studies have suggested that obesity accounts for about 50% of change in 
insulin sensitivity, but it is difficult to define the precise contribution of obesity to insulin 
resistance.
65, 66
  Obesity is an independent risk factor for CVD, i.e., obese patients are at 
increased cardiovascular risk, especially the risk of developing diabetes or metabolic 
syndrome.
1, 12
 
 Regarding all other cardiovascular conditions (heart failure, myocardial 
infarction, CAD, peripheral vascular disease, and cerebrovascular disease), either there 
was no significant difference across BMI or prevalence was higher among non-obese 
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patients.  In our study, patients who were obese were more likely to be younger or 
middle-aged population compared to non-obese patients who were older (≥65 years).  
Similarly, for cardiovascular conditions, younger and middle-aged patients were less 
likely to have these cardiovascular conditions compared to older patients.  Obesity 
undoubtedly increases the risk for developing CVD, but age is one of the non-modifiable 
risk factor for CVD, i.e., proper management of cardiovascular factors decreases with 
increase in age and cardiovascular conditions increase with increase in age. 
 
Therapeutic (BP and lipid) goal attainment in patients with concomitant hypertension 
and dyslipidemia  
In patients with concomitant hypertension and dyslipidemia, higher proportion of 
patients failed to attain BP (85.0%), LDL-C (74.0%), and dual BP/LDL-C (64.1%) goals.  
These findings are consistent with the results of Johnson et al. (2006)
33
 study which 
assessed goal attainment in patients with concomitant hypertension and dyslipidemia in 
Veteran Affairs population.  Johnson et al. evaluated different population subgroups 
(patients with diabetes, without diabetes, with CVD, and without CVD) and reported that 
a higher proportion of patient population did not attain BP and LDL-C goals; not at BP 
goal (55.9% - 75.7%), not at LDL-C goal (52% - 69%), and not at dual BP and LDL-C 
goals (75.6% - 87%).
33
  Previous research suggests that the presence of multiple risk 
factors can result in decreased control of BP and LDL-C levels.  Additionally, our study 
indicated that at least one-third of the patients were not receiving any antihypertensive 
medication and at least one-half of patients were not receiving any antilipemic 
medication.  For patients receiving medications and yet showing poor control lack of 
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adherence to the medications has been suggested as one the potential reasons for 
inadequate attainment of LDL-C goals.
31,
 
33
  Statin dose needs to be titrated to the level 
required for maximum reduction of lipids and lack of proper dosage has also been 
suggested as one of the reasons for failure of LDL-C goal attainment.
31
 
In addition, higher proportion of patients failed to attain optimum total cholesterol 
(66.3%), triglyceride (74.6%), and HDL-C (75.7%) levels.  Failure to attain non LDL-C 
lipid levels (total cholesterol, triglyceride, and HDL-C) could largely be due to the lack of 
clinical attention as they are not recommended by the disease management guidelines
18
 
for specific treatment targets.  This is primarily because of insufficient evidence to 
support recommendations.  However, research is being conducted for the role of these 
lipids in reducing cardiovascular risk. 
Further, to identify factors associated with therapeutic goal attainment and 
quantify the role of obesity in therapeutic goal attainment in patients with concomitant 
hypertension and dyslipidemia, multivariate analysis was conducted.  These results have 
been grouped into four categories based on the type of factors associated with therapeutic 
goal attainment: BMI, patient-related factors, clinical factors, and medication-related 
factors. 
 
BMI and therapeutic goal attainment 
Higher proportion of obese and overweight failed to attain BP, LDL-C, and dual 
BP/LDL-C targets as well as optimum HDL-C and triglyceride levels compared to those 
with normal-weight.  After adjusting for confounders such as age, gender, cardiovascular 
conditions, hypertension stage at baseline, smoking status, cardiovascular risk, baseline 
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lipid levels, and number of antihypertensive and antilipemic medications, obese patients 
remained less likely to attain BP goals, dual BP/LDL-C goals, optimum HDL-C, and 
triglyceride levels compared to normal-weight patients.  However, after adjusting for 
confounders, no significant difference in obese versus non-obese was observed for LDL-
C goal attainment.  Similar to obese patients, overweight patients were less likely to 
attain BP goals and optimum triglyceride levels, after adjusting for confounding factors.  
Previous research has shown similar trends for BP or LDL-C goal attainment with respect 
to BMI.  
Obesity has consistently been associated with the failure of BP goal attainment.
37, 
39, 43
  Blood pressure increases with increase in BMI
65
, thus weight loss has been 
recommended in achieving optimum BP levels.  Our study results indicated that obese 
patients were more likely to be prescribed antihypertensives, and yet, few obese patients 
attained BP goal.  As suggested by the disease management guidelines, the probable 
reason for higher proportion of obese patients not attaining BP targets could be that 
patients with multiple risk factors might be more resistant to therapy, thereby making it 
difficult to manage risk factors in these patients.
12, 18
  In such patients, combination 
therapy comprising of pharmacological treatment and lifestyle interventions have been 
recommended for attaining adequate BP goals. 
Significantly higher proportion of obese patients did not attain LDL-C goals, 
however, this difference was not significant after adjusting for other patient-related and 
clinical factors.  According to the NCEP ATP III guidelines, there is a strong relationship 
between obesity and risk for CHD, but it is not classified among the risk factors that 
modify LDL-C treatment goals.
18
  Majority of BMI associated risk on LDL-C goals are 
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mediated by other risk factors such as high BP and elevated lipid levels.  This is 
consistent with our study results.  Nichols et al. (2009) studied patients with dyslipidemia 
who had initiated antilipemic therapy and were on therapy for at least one year.
50
  Obesity 
was not a significant predictor of LDL-C goal attainment, suggesting that managing 
obesity might be a better approach than lowering LDL-C in patients who are either 
overweight or mildly obese.  Even NCEP ATP III guidelines recommend considering 
obesity as a direct target for clinical intervention rather than an indicator for lipid-
modifying treatment.  
Optimum levels of other lipid levels such as triglycerides and HDL-C were less 
likely to be attained in obese patients.  Unlike LDL-C, in which the effect of obesity is 
mediated by other factors, the study results suggest that the effect of obesity has a direct 
effect on attaining optimum triglycerides and HDL-C levels.  This is an interesting 
finding and needs further research to determine the relation between obesity and different 
lipid types.  Another interesting finding was that overweight or obese patients were more 
likely to attain optimum total cholesterol levels compared to patients with normal weight.  
 
Patient-related factors associated with therapeutic goal attainment 
Patient‘s age was associated with BP goal attainment only and no differences 
were observed for LDL-C goal or dual BP/LDL-C goals.  Those above 55 years of age 
were less likely to attain BP goal and with increase in age, the likelihood of failure to 
attain BP goal also increased.  Further, females were less likely to attain BP, LDL-C, dual 
BP/LDL-C goals as well as optimum total cholesterol and triglyceride levels.  Females 
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were more likely to attain only optimum levels of HDL-C and these findings are 
consistent with other published research
51,
 
68
. 
Evidence indicate that number of co-morbid conditions and high cardiovascular 
risk in the elderly result in inadequate goal attainment.
37
  McDonald et al. (2009) utilized 
NHANES data from 1999-2004 and concluded that age was not a significant predictor of 
LDL-C goal attainment.
56
  Wong et al. (2003) showed that  the estimated attributable risk 
percent is higher in women resulting in lower rates of BP goal attainment.
67
 
Previous studies have also shown that males are more likely to attain LDL-C 
levels and optimum triglyceride levels.
45, 46, 50, 51, 52
  In addition, our study population 
comprised of more older-aged (≥65 years) women (55.6%) compared to older-aged men 
(36.1%), suggesting that increased likelihood of failure to attain lipid goals/optimum 
levels in women might result from increase in cardiovascular risk and co-morbidities with 
age.  However, the exact reason for variation in LDL-C goal attainment by gender is not 
known and needs further research.  The probable reason for the finding that females were 
more likely to attain optimum levels of HDL-C could be that women in general tend to 
have higher HDL-C levels than men.
51,
 
68
 
 
Clinical factors associated with therapeutic goal attainment 
Presence of diabetes was associated with a decreased likelihood of attaining BP, 
LDL-C, and dual BP/LDL-C goals.  Diabetes has been consistently associated with 
failure to attain BP and/or LDL-C goals.
38, 41, 43
  The probable reason, based on the 
previous research, could be that patients are not receiving adequate therapy for 
hypertension (at least two antihypertensive medications) or for dyslipidemia (statin 
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therapy).
 38, 41, 43
  For patients who were prescribed recommended medications, disease 
management guidelines suggest that various factors, such as patient-related factors 
(adherence to complex medical regimen), provider-related factors (attitude, experience, 
and practice patterns), and treatment-related costs, might result in patients not taking their 
prescribed medication
12
, thereby resulting in decreased attainment of goals in patients 
with concomitant hypertension and dyslipidemia.  However, patients with diabetes were 
more likely to attain optimum total cholesterol levels.  The overview of anti-diabetic 
medications by Keiden et al. (2002) indicated that some of these anti-diabetic 
medications such as metformin and insulin decrease cholesterol levels.
69
 
 Presence of CAD was more likely to be associated with BP goal attainment and 
total cholesterol levels whereas presence of angina pectoris was more likely to be 
associated with attainment of LDL-C goals.  The attainment of recommended goals in 
patients could be due to better monitoring of BP and lipid levels in these patients to avoid 
any further disease-related complications.  Presence of kidney disease increased the 
likelihood of not attaining BP goals.  The evidence shows that the presence of renal 
dysfunction plays a key role in increasing BP.
70
  However, patients with kidney disease 
were more likely to attain LDL-C goals.  The reason for attainment of LDL-C goals in 
patients with kidney disease is not known. 
 Patients with stage 1 and stage 2 hypertension were less likely to attain BP and 
dual BP/LDL-C goals compared to patients with prehypertension.  Similarly, patients at 
intermediate or high cardiovascular risk were less likely to attain LDL-C or dual 
BP/LDL-C goals.  A number of reasons have been cited in the literature for the failure to 
achieve recommended goals.  First, for effective control of BP, JNC 7 recommends 
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combination of two or more lifestyle modifications such as Dietary Approaches to Stop 
Hypertension (DASH) eating plan, dietary sodium reduction, physical activity, and 
weight reduction in overweight or obese as well as recommended anti-hypertensive 
medications.
12
  Lack of compliance to this behavioral modifications coupled with 
complex treatment regimen might result in lower likelihood of attaining BP goals.  
Second, it has also been shown that only 36% of patients are adherent to both 
antihypertensive and antilipemic medications after one year of treatment
71
 which can 
further explain the lack of goal attainment in most patients.  Finally, results from a meta-
analysis study
72
 indicated that a patient‘s health belief played an important role in 
adherence.  The Health Belief Model (HBM) was one of the first models and is one of the 
most widely recognized conceptual frameworks of heath behavior.  HBM adapted theory 
from behavioral sciences to health problems and comprised of four components 
(perceived susceptibility, perceived severity, perceived benefits, and perceived barriers) 
which indicated individual‘s ―readiness to act‖.  These HBM components, specifically 
―perceived severity‖ have been studied as predictors of patients‘ adherence to treatment.  
Further, actual disease severity (health status) has also been suggested as a factor in 
adherence to treatment.  Thus, based on HBM, it has been suggested that patients with 
lower disease severity have increased likelihood of not being adherent to treatment 
regimen.  Similarly, poor adherence has been indicated for patients with more serious 
health conditions and this reduced adherence results from physical and emotional 
challenges of adhering to complex treatment regimens. 
Patients with higher LDL-C levels and higher total cholesterol at baseline were 
less likely to attain LDL-C and dual BP/LDL-C goals as well as optimum total 
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cholesterol levels.  In our study population with concomitant hypertension and 
dyslipidemia, most of the patients were at intermediate (38.2%) or high (57.2%) 
cardiovascular risk, which might be the reason for lower likelihood of LDL-C control in 
patients who had higher LDL-C levels at baseline.  Lack of appropriate control of LDL-C 
levels might further have negative effect on attaining BP goals.  However, the exact 
relation between LDL-C goal attainment and BP goal attainment is not known.  There 
might be some link between different lipids as well as lipids and cardiovascular risk 
factors.  However, the exact reason for the effect of total cholesterol on BP and LDL-C 
goals is not known. 
Patients with higher triglyceride levels were more likely to attain LDL-C goals.  
The probable reason could be that triglycerides are considered secondary target of 
treatment and it could be that triglyceride levels are monitored especially in patients with 
diabetes, atherogenic dyslipidemia, and metabolic syndrome to further reduce 
cardiovascular risk.
18
  However, optimum total cholesterol, triglyceride, and HDL-C 
levels were not attained in patients with higher triglyceride levels at baseline.  The exact 
reason for association between non-LDL lipids and triglyceride levels is not known and 
needs further research.  Higher HDL-C levels at baseline were associated with increased 
likelihood of attaining optimum triglyceride levels.  Higher HDL-C levels, especially ≥60 
is considered a protective factor and decreases cardiovascular risk and might also have 
some effect on overall lipid profile. 
 Increased likelihood of not attaining optimum HDL-C levels was observed in 
patients who were current smokers.  This finding is consistent with previous research that 
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suggests that cigarette smoking depresses HDL-C level in the blood and this result in 
excessive buildup of cholesterol levels.
73, 74
  
 
Medication-related factors associated with therapeutic goal attainment  
 Patients prescribed at least one antihypertensive medication were less likely to 
attain BP and dual BP/lipid goals compared to patients not prescribed any medication.  
Further, the likelihood of attaining BP goals decreased with increase in number of 
antihypertensive medications prescribed.  This is an interesting but a counterintuitive 
finding since anti-hypertensive medications have shown to be effective for BP control.  
Physicians suggest that BP is more difficult to control than lipid levels and is even harder 
with very high BP {Dr. Louis Civitarese (Preferred Primary Care Physician Group), 
personal conversation, June 21, 2012}.  Our study results showed that most of the 
patients were at prehypertension stage (borderline high BP).  So, it is possible that 
patients who had borderline high BP were not prescribed any medication, but were still 
able to achieve recommended BP target by lifestyle modifications (e.g., DASH diet plan, 
reduced dietary sodium intake, exercise, and weight reduction).  As discussed earlier, two 
or more lifestyle modifications are recommended by JNC 7 for effective BP control.  
Further, guidelines recommend that for the therapy to be effective, patient should be 
motivated to take the medication.  Lack of patient compliance to the prescribed 
medication regimen as well as recommended dosage might be associated with increased 
likelihood of not attaining BP goals.  Several factors such as physician-related 
(experience, attitude), physician-patient communication, cost of medication, complexity 
of care
18
 might contribute to lack of patient compliance to prescribed medications.  
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Optimum triglyceride levels were not attained in patients prescribed two 
antihypertensive medications and optimum total cholesterol levels were more likely to be 
attained in patients prescribed at least four medications.  The reason for this finding is not 
known and needs further research. 
Patients prescribed one antilipemic medication were more likely to achieve LDL-
C and dual BP/LDL-C goals.  Most of the patients were prescribed statins, which are 
effective in lowering LDL-C levels and other lipid levels.  In addition, use of statins is 
recommended in patients at high or very high cardiovascular risk.  Similarly, optimum 
total cholesterol and triglyceride levels were attained in patients prescribed at least one 
antilipemic medication.  
 
Medication prescribing pattern 
 Patients with multiple risk factors such as hypertension, dyslipidemia, and obesity 
are considered to be at high cardiovascular risk.  Further, patients with cardiovascular 
conditions such as diabetes, heart disease, stroke, and kidney disease are considered to be 
at very high cardiovascular risk.  The JNC 7 and NCEP ATP III guidelines recommend 
simultaneous control of factors, especially modifiable risk factors (hypertension, 
dyslipidemia, and obesity) by implementing both lifestyle modifications and 
pharmacological treatment.  As discussed previously in the Methods section, aggressive 
treatment is also recommended for these patients for attaining recommended BP and lipid 
goals.  For example, patients with complicated hypertension are recommended at least 
two antihypertensive medications.  Further, the information regarding type of medication 
and number of medications prescribed is available in EMR.  It is important to evaluate 
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whether the guideline recommended pharmacological treatment is being implemented 
appropriately for attaining optimum BP and lipid levels.  Thus, both antihypertensive and 
antilipemic medications and prescribing pattern was analyzed in patients with 
concomitant hypertension and dyslipidemia and differences in medication prescribing 
pattern were also evaluated for obese versus non-obese patients. 
 
Medication prescribing pattern in patients with concomitant hypertension and 
dyslipidemia 
About 60% of patients were prescribed antihypertensive medications either alone 
or in combination with antilipemic medication.  The JNC7 guidelines recommend at least 
two antihypertensive medications be prescribed to these patients; 57.5% or 67.1% of 
patients with uncomplicated or complicated hypertension, respectively, were prescribed 
the recommended number of medications.  Only 39% patients were prescribed 
antilipemic medication either alone or in combination with antihypertensive medications.  
NCEP ATP III guidelines recommend at least one antilipemic medication for patients at 
high or very high cardiovascular risk and lifestyle intervention for patients at low or 
intermediate risk.  Among patients at high or very high risk, about 70% of population was 
prescribed at least one antilipemic medication.   
An analysis of the 1999-2000 NHANES demonstrated that only 58.4% of patients 
were treated for hypertension
29
 and only 12% of patients with dyslipidemia were 
prescribed antilipemic medication
32
.  Beaton et al. (2004) study of diabetic patients 
(population at high cardiovascular risk) in managed care plan showed that 64% patients 
were prescribed antihypertensive medications and 28% were prescribed antilipemic 
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medications.
75
  Welch et al. (2005) study results showed that antilipemic medications 
were prescribed to 55.3% of patients at high cardiovascular risk.
57
  Our study shows 
improved treatment rates and this might be due to physicians adhering to treatment 
guidelines.  Another reason for higher proportion of patients being prescribed could be 
that most of the patients in our study have multiple conditions (hypertension, 
dyslipidemia, diabetes, and obesity).  Still, about one-third of patients with complicated 
hypertension or at high cardiovascular risk were not receiving at least two anti-
hypertensives or at least one antilipemic, respectively.  The probable reason could be less 
number of physician office visits which might result from complexity of care
12
 
(transportation, difficulty in scheduling appointments, and life‘s competing demands). 
In patients with concomitant hypertension and dyslipidemia, ACEI was the most 
common antihypertensive medication class prescribed followed by beta blockers, calcium 
channel blockers, thiazide diuretics and ARBs.  Among combination therapy (both fixed 
dose and other combinations), ACEI and diuretics combination was the most commonly 
used followed by ARBs and diuretics combination.  Among antilipemic medications, 
higher proportions of patients were using statins.  All of these medication classes have 
shown beneficial effect in clinical controlled outcome trials and thus are recommended 
by JNC7 and NCEP ATP III guidelines.  In addition, results are consistent with other 
studies which have reported ACEI (mono-therapy) and ACEI-diuretics (combination 
therapy) to be used more commonly compared to other antihypertensive medications
36, 37, 
39
 and statins being the most commonly prescribed antilipemic medications
49, 53
. 
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Medication prescribing pattern in obese versus non-obese patients with concomitant 
hypertension and dyslipidemia  
 Most of the obese patients were prescribed both antihypertensive and antilipemic 
medication.  Higher proportion of obese patients were prescribed at least two 
antihypertensives medications compared with normal-weight and overweight patients.  In 
addition, higher proportion of obese patients were also prescribed at least one antilipemic 
medication compared with normal-weight and overweight patients.  The probable reason 
could be that higher proportion of obese patients had co-morbid conditions like diabetes 
and were at high cardiovascular risk, as shown by our study results.  Having multiple risk 
factors like hypertension, dyslipidemia, obesity, and diabetes can further increase the 
cardiovascular risk, thus making it necessary to control these risk factors. 
 Regarding antihypertensive medication class, significantly higher proportion of 
obese patients were prescribed ACEI and/or diuretics as well as other diuretics at 
baseline.  Thiazide diuretics or in combination with ACEIs are the most commonly used 
in different populations and are shown to be effective for treating hypertension.  Thus, for 
achieving recommended BP targets in this population, ACEI and diuretics were 
commonly prescribed.  However, significant difference for thiazide diuretics was not 
observed at follow-up because these drugs are most commonly recommended for initial 
therapy. 
Regarding antilipemic medications prescribed at baseline, statins were prescribed 
to higher proportion of overweight patients followed by obese patients.  However, at 
follow-up higher proportion of obese patients were prescribed statins.  Statins are the 
most effective treatment for elevated LDL-C.  Obese patients were at high cardiovascular 
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risk followed by overweight patients and thus, statins were prescribed to these patients 
for effective control of LDL-C levels. 
 
 
CONCLUSIONS 
In conclusion, substantial proportion of patients with concomitant hypertension 
and dyslipidemia failed to attain BP and lipid goals.  The study results also demonstrated 
that in patients with concomitant hypertension and dyslipidemia, obesity appears to be an 
independent risk factor for the failure to attain BP goal as well as optimum levels of 
triglycerides and HDL-C.  Further, patients who were overweight or obese failed to attain 
BP goals, despite being prescribed higher number of antihypertensive medications.  
Higher likelihood of failure to attain BP or LDL-C goals was also observed for women 
and patients who also had diabetes.  Inadequate goal attainment observed in this study are 
consistent with findings in other populations, suggesting that further work is required to 
determine the underlying reasons for these differences to improve the management of 
patients with hypertension, dyslipidemia, and obesity.  Patients who are obese might 
inherently have more severe hypertension and dyslipidemia that are more difficult to 
control.  The potential reasons for these differences could not be assessed in our 
observational study, but it appears that a combination of pharmacologic and lifestyle 
therapies might be the best approach to narrow this treatment gap.  Our results suggest 
that quality improvement projects should be directed at patients with high cardiovascular 
risk, particularly those who are obese, to eliminate the existing treatment gap, thereby 
improving the control of blood pressure and lipid levels.  
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STUDY IMPLICATIONS 
The study results provide insight into the variations in therapeutic goal attainment 
(BP and lipid) and medication prescribing pattern in patients with concomitant 
hypertension and dyslipidemia, with a primary focus on obese versus non-obese patients.  
It is evident from the study findings that there is inadequate BP or/and LDL-C goal 
attainment in patients with concomitant hypertension and dyslipidemia, especially in 
obese patients.  The study results can be interpreted in the context of real-world medical 
practice and can be useful in the following aspects. 
First, the study results have identified population at increased cardiovascular risk, 
i.e. patients with multiple risk factors.  The physician group using this EMR database can 
identify and follow-up these patients and immediately implement appropriate strategies, 
tailored specifically for each patient based on their cardiovascular risk profile For 
example, our study identified patients in whom BP and/or LDL-C goals were not 
attained.  Based on this information, physicians can review the patient information in the 
EMR and can specifically intervene on patients not attaining recommended BP or LDL-C 
goals.  Moreover, the EMR provides advantage of having complete clinical information 
and the data available from EMR can be analyzed in an ongoing and real-time basis for 
the entire populations under care, which can be useful for physicians in monitoring health 
status of patients regularly and in a timely manner. 
Second, the study results will also help physicians in making clinical decisions on 
the intensity of preventive interventions.  This includes dietary advice which can be strict 
and specific based on the patient‘s risk factors, suggestions for physical activity along 
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with duration and intensity, and prescribing the recommended medications, all tailored 
individually based on the patient‘s overall predicted risk. 
Lastly, the use of EMR for outcomes research may be used to help improve the 
overall process of care, especially in primary care practice.  EMR provides a patient-
centered data and patients with multiple conditions can be identified easily.  Thus, 
physicians can treat patients taking all the multiple conditions into account.  For example, 
our study showed that some patients had concomitant hypertension, dyslipidemia, 
diabetes, and obesity, while others had only concomitant hypertension and dyslipidemia.  
This information plays a vital role in designing a patient-centered approach, i.e., 
treatment strategies tailored specifically based on the health status of each patient.  EMR 
provides both pre- and post-diagnosis information which can be helpful for improving 
follow-up of test results and overall health status.  For example, physicians can monitor 
patients not at BP or LDL-C goals from time to time. 
 
 
LIMITATIONS 
Although this study provides insight into the factors associated with BP and lipid 
goal attainment as well as medication utilization pattern in a real-world practice using 
EMR database, but there are some limitations.  First, the study results are based on a 
specific patient population and may not be generalizable to other populations.  Second, 
the EMR database used contains data from one physician group from a limited 
geographical area and results may not be generalizable to other physician practices.  
Moreover, the differences in the evaluation of patient by different providers within the 
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practice itself might result in variations in management of hypertension and dyslipidemia.  
Third, EMR does not provide information related to lifestyle modifications (diet and 
physical activity), an important factor for management of hypertension and dyslipidemia.  
Fourth, race/ethnicity being another important variable associated with hypertension or 
dyslipidemia was excluded from the multivariate analysis because there were about 21% 
of missing or undetermined cases.  Fifth, BMI was used as the indicator of obesity for 
this study.  Recent studies have suggested that the use of waist circumference or waist/hip 
ratio might be a more accurate measure of visceral obesity, specifically for determining 
cardiovascular risk.  EMR does not contain information on waist circumference, thus this 
measure was not used along with BMI.  However, BMI is still an accepted measure of 
obesity and was an appropriate for this study as main focus was on attainment of 
therapeutic goals and medication prescribing pattern.  Lastly, EMR database provides 
information regarding medications prescribed to patients, but information related to 
actual utilization of medications (proportions of prescriptions filled, proportions of 
prescriptions not filled, patient compliance) is not available.  The information regarding 
medication dosage is also not available, which might affect BP or lipid goal attainment. 
 
 
OPPORTUNITIES FOR FUTURE RESEARCH 
 Based on the study findings, it is evident that variations in therapeutic goal 
attainment and medication prescribing pattern do exist among patients with concomitant 
hypertension and dyslipidemia, especially in obese versus non-obese patients.  Further 
research needs to be conducted to better understand these differences.  Additional studies 
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should evaluate the mechanistic link between obesity and failure to achieve 
recommended therapeutic goals.   
The lifestyle modification (diet and physical activity) is recommended by 
guidelines for treatment of hypertension and dyslipidemia.  Studies focusing on effect of 
both non-pharmacological or/and pharmacological treatment approach might be useful in 
designing appropriate interventions for attaining recommended therapeutic goals. 
Adherence to treatment (pharmacological or non-pharmacological) is important 
for managing hypertension, dyslipidemia, and obesity.  Studies have suggested that 
patient motivation to take prescribed medications and to maintain a health-promoting 
lifestyle play an important role in the management of hypertension.  Patient attitudes are 
influenced by cultural differences, beliefs, and previous experiences with healthcare 
system.  To understand these differences, healthcare professionals should have increased 
communication with the patients.  Thus, studies should explore the role of physician-
patient communication on attainment of recommended therapeutic goals.  Further studies 
focusing on role of pharmacist-physician collaboration in management of BP and lipid 
goals in patients at-risk might be useful in designing interventions with improved patient 
adherence.  Studies should also focus on relationship between physician-related factors 
(physician‘s experience, knowledge, and attitude) and attainment of therapeutic goals.  
Time needed to attain BP and lipid goals is also an important aspect of managing 
hypertension and dyslipidemia.  Studies evaluating the time needed to attain goals and 
identifying factors that are associated with time taken to attain goals might provide useful 
information for designing patient-centered strategy for managing cardiovascular risk 
factors appropriately. 
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